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Chapter 1: Abstract 
 
Pharmacological interventions for pain relief during orthodontic treatment. 
Aoife Monk 
Background: Pain is a common and unwanted side effect of orthodontic treatment, 
caused by a reduction in blood flow during tooth movement using orthodontic 
appliances. Pain has been shown to be the most common reason for patients 
wanting to discontinue treatment. Pharmacological methods of pain relief have been 
investigated in the literature showing promising results, although there remains some 
uncertainty among orthodontists as to which painkillers are most suitable and 
whether pre-emptive analgesia is beneficial and therefore present as a simple 
intervention to prevent this unwanted side effect of treatment. Therefore a Cochrane 
review is warranted to assess and summarise the international evidence.1 
Objectives: To determine the most effective drug intervention for pain relief during 
orthodontic treatment.1 
Search methods: We searched the following databases up to August 2016: 
Cochrane Oral Health Group Trials Register, Cochrane Pain, Palliative and 
Supportive Care Group Trials Register, Cochrane Central Register of Controlled 
Trials (CENTRAL), MEDLINE via Ovid, EMBASE via Ovid and CINAHL via EBSCO. 
We searched the US National Institutes of Health Trials Registry, and the WHO 
Clinical Trials Registry Platform for ongoing trials. No restrictions were placed on 
language or date of publication when searching databases.1 
Selection criteria: We included randomized controlled trials (RCTs) relating to pain 
control during orthodontic treatment measured on a visual analogue scale (VAS), 
numerical rating scale (NRS) or any categorical scale. 
Data collection and analysis: Two reviewers independently extracted information 
regarding methods, participants, interventions, outcomes, harms and results, 
independently and in duplicate. The Cochrane risk of bias tool was used to assess 
the methodological quality of the studies.1 
Main results: 22 RCTs were identified which included 2110 participants. A meta-
analysis was carried out on twelve papers that compared analgesics versus control, 
nine that compared NSAIDs versus paracetamol and two comparing pre-emptive 
versus post-treatment ibuprofen for pain control following orthodontic treatment. 
Analgesics were found to effectively reduce pain at 2, 6 and 24 hours following 
orthodontic treatment (mean difference -24.48, 95% CI -30.54 to -18.43, 
P=<0.00001). No difference was found between the efficacy of NSAIDs and 
paracetamol, except low quality evidence that paracetamol is more effective at 
reducing pain associated with initial archwire placement at 2 hours (MD 14.63, 95% 
CI 0.77 to 28.50, P=0.04). Pre-emptive ibuprofen gives better pain relief at 2 hours 
(MD -11.33, 95% CI -16.09 to -6.58, P=<0.00001) however the effect reduces over 
time. No difference was found between the use of topical NSAIDs and local 
anaesthetic. However overall quality of evidence was poor and levels of 
heterogeneity were variable (I2 results varied from 0% to 87%). 
Authors' conclusions: Analgesics are effective at reducing pain following orthodontic 
treatment. There is no difference between the efficacy of systemic NSAIDs and 
paracetamol, or topical NSAID and local anaesthetic. Pre-emptive ibuprofen gives 
better pain relief at 2 hours however the effect reduces over time. More high quality 
research is needed to investigate the effect of NSAID and paracetamol and the effect 
of pre-emptive and post-treatment administration of analgesics for orthodontic pain.  
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Chapter 2: Introduction 
 
Orthodontic treatment plays a vital role in the correction of malocclusions for both 
children and adults. However, orthodontic movement of teeth is often associated with 
discomfort or pain, of varying intensity and duration which can be a major concern 
for patients, guardians, and clinicians.2 The effect that this has on patients’ decision 
making regarding treatment can differ; from having little or no effect to resulting in 
patients discontinuing or even not commencing treatment.3 Management of the pain 
associated with orthodontic treatment is therefore fundamental to the successful 
management of orthodontic patients.4,5 Pharmacological and non-pharmacological 
managements of acute dental pain have been discussed in the literature since the 
late nineteenth and early twentieth centuries.6 Advances in our knowledge and 
understanding of both the cause of orthodontic pain and the pharmacology of 
analgesic drugs, has led to improvements in the management of pain pre-, peri- and 
post-operatively over the past four decades.7 Orthodontic treatment, in its various 
forms and with appropriate pain management, has therefore assumed an important 
role in the modern day management of malocclusions in order to provide functional 
and aesthetic changes to patients who may have otherwise refused treatment for 
fear of the associated pain. 
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Chapter 2: Literature Review 
 
2.1: The Role of Orthodontics 
Orthodontics is the branch of dentistry concerned with the growth and development 
of the face and jaws and the treatment of irregularities of the teeth.8 It also involves 
the treatment of the teeth and jaws when they are irregular in their alignment, 
morphology and/or function. Orthodontics is typically carried out to improve the 
functioning and appearance of the teeth. This may involve moving teeth by applying 
a force via fixed appliances (braces where the components are attached to the teeth 
for the duration of the treatment); removable appliances (braces which, although 
normally worn full-time during treatment, can be removed from the mouth for 
cleaning during treatment); and/or functional appliances (braces that aim to move the 
teeth and modify the direction of growth of the jaws to induce an orthopaedic 
change. These functional appliances can either be removable from the mouth or 
fixed to the teeth during treatment).8 
Orthodontic treatment may also involve the extraction of teeth in order to provide 
space to allow the teeth to be aligned, surgery to expose unerupted or impacted 
teeth in an attempt to guide them into alignment, and occasionally jaw surgery to 
correct the underlying position of the jaws.9,10,11 
Most patients undergoing orthodontic treatment are children or adolescents although 
an increasing number of adults are seeking treatment.12 
Treatment typically begins with the construction and placement of the orthodontic 
appliance; whether fixed, removable or functional; usually over two thirty to forty-five 
minute visits. Routine adjustments are then carried out every four to six weeks over 
the course of treatment, which normally lasts approximately twelve to twenty-four 
months. Following treatment, the removal of fixed appliances takes approximately 
thirty to forty-five minutes and retainers are then provided to maintain the teeth in 
their newly aligned position.9 
2.2: Pain associated with orthodontics 
2.2.1: Definition of pain 
Pain is a complex experience and therefore difficult to define. The International 
Association for the Study of Pain (IASP) defines pain as: 
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“An unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage.”13 
 
Pain can also be subcategorised depending on its characteristics and/or the stimulus 
that has elicited the emotional experience. Examples include allodynia, where pain 
occurs as a result of a stimulus which would normally not provoke pain, 
hyperalgesia, where pain is increased to beyond the normal threshold from a 
stimulus which normally provokes pain, and hypoalgesia, which is a diminished 
response from a normally painful stimulus. 
 
In addition, pain may be categorised by duration. Acute pain is a biological process, 
provoked by a normal stimulus and is self-limiting. Chronic pain, however, serves no 
biological process and outlasts the normal times of healing.14 The appropriate pain 
management regime can differ significantly for acute and chronic pain; as too can 
the management of pain of varying characteristics. It is therefore important to 
understand the physiology of pain and identify the nature of the pain being 
experienced so as to treat the patient appropriately. Conversely, experiences which 
resemble pain but are not unpleasant; pricking for example; should not be called 
pain. They may be categorised as discomfort.  
 
It is also important to note that pain is described as always being subjective. Each 
individual learns the application of the word pain through previous experiences 
related to injury and therefore large individual variations are seen.15 For example, 
patients may report pain in the absence of any tissue damage or likely 
pathophysiological cause. There is usually no way to distinguish their experience 
from that of one caused by tissue damage due to the subjective nature of pain 
experience and therefore its reporting. If a patient regards their experience as pain, 
and if they report it in the same ways as pain caused by tissue damage, it should be 
accepted as pain. It is, therefore, important to remember that pain is a highly 
personal experience, with the degree of pain and suffering reported not always 
related to the amount of tissue injury.16 
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2.2.2: Factors which influence pain perception 
A number of factors have been identified throughout the literature which are thought 
to influence a patient’s perception of pain. However, evidence is varying and often 
contradictory. These factors include age, gender, race, individual pain threshold, 
expectations, treatment received, the magnitude of the force applied, time since the 
force was applied, present emotional state and stress, cultural differences, and 
previous pain experiences.13,14,15 A summary of a selection of evidence which has 
been presented to demonstrate the effect of some of these factors on a patient 
perception of pain is shown in Table 1. 
Firestone et al.16 investigated fifty adolescent orthodontic patients who had 
undergone recent placement of initial archwires. Patients were given questionnaires 
pre-treatment to assess their expectations regarding pain and how they expect it will 
influence their daily lives. When compared with reported levels of pain following 
bond-up and placement of initial aligning archwires, a positive correlation was 
identified between the level of anticipated pain and the level of experienced pain. 
Conversely, a study in 2012 by Kafle and Rajbhandari,17 of 45 orthodontic patients 
undergoing treatment, found a significant difference between the anticipated pain 
before orthodontic treatment and the pain experienced following treatment. They 
also found that perception of pain between males and females was significantly 
different however, anticipated pain among males and females did not differ. When 
comparing the same procedure, female patients had experienced more pain than 
male patients. 
Brown and Moerenhout18 carried out a longitudinal study to assess age-related 
changes in psychological measurement of pain in patients undergoing orthodontic 
treatment. They found a significant difference in reported pain experienced during 
banding and archwire adjustments in an adolescent group (aged fourteen to 
seventeen years), compared to a pre-adolescent group (aged eleven to thirteen 
years) and an adult group (aged eighteen and above), with the adolescent group 
reporting significantly more pain than the pre-adolescent and adult groups. As a 
result, the authors hypothesise that adolescents may be more vulnerable to 
undesirable psychological effects of orthodontic treatment. 
Jones and Chan,19 when comparing different aligning archwires, noted similar 
associations between age and pain experienced. However, contrary to the finding of 
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previous researchers, they did not find a relationship between pain experienced and 
gender, social class or crowding.  
It would therefore appear, from the evidence, that pain response is highly variable 
and consistently subjective. 
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Table 1. A summary of literature exploring factors that influence patients’ perception of pain following orthodontic treatment. 
 
Study Participants Method Comparison Outcomes Results 
          
Firestone, 
Scheurer, 
Burgin. 
1999.16 
 
 N = 50 consecutively 
treated patients.  
 28 females, 22 males.  
 Age range 8.9-39.3 
years. Mean = 15.5 
years. 
Pre-treatment 
oral and written 
VAS 
questionnaire. 
A second questionnaire was 
completed 1 week after 
initial archwire placement. 
 Patient expectations of 
pain as a result of 
orthodontic treatment. 
 Anticipated effects of pain 
on lives. 
 True experienced pain and 
effect of pain on lives. 
 No difference between anticipated and 
reported pain. 
 Patients significantly underestimated the 
changes they would have to make to diet as 
a result of pain. 
 Patients who anticipated greater pain, 
experienced greater pain and disruption to 
their daily lives. 
Kafle and 
Rajbhandari. 
2012.17 
 N = 45 patients. Pre-treatment 
VAS scale for 
anticipated pain. 
Post-treatment VAS scale 
for pain experienced 
following orthodontic 
procedure. 
 Anticipated pain before 
treatment. 
 Intensity of pain 
experienced following 
orthodontic treatment. 
 Significant difference between anticipated 
pain and actual pain experienced during 
orthodontic treatment. 
 For the same procedure, females 
experienced significantly more pain than 
males. 
Brown and 
Moerenhout. 
1991.18 
 N = 76. 
 Aged 11 years and 
above. 
Longitudinal 
series of 4 pain 
questionnaires. 
 T1: 1 day after separation. 
 T2: 1 day after banding. 
 T3: 1 day after adjustment 
3-4weeks in treatment. 
 T4:1 day after adjustment 
3-4 months in treatment. 
 Pain intensity and duration 
in relation to treatment 
stage. 
 Pain intensity and duration 
in relation to patient age. 
 Significant differences in the response 
profiles of the adolescent age group (14 to 
17 years) compared to the preadolescent 
(11 to 13 years) and adult groups (18 years 
and older). 
Jones and 
Chan. 
1992.19 
 N = 43 patients. Pre and post-
treatment pain 
questionnaires 
and VAS. 
 Randomisation to: 
- Superelastic archwire. 
- Multistrand stainless steel 
archwire. 
 Nature, prevalence, 
duration and intensity of 
pain experienced. 
 Analgesic consumption. 
 No difference in prevalence, intensity, and 
duration of pain after insertion of archwire. 
 Pain more severe than post-extraction. 
 Pain peaked the morning after arch wire 
placement, typically lasting 5-6 days. 
Ngan, Kess, 
Wilson. 
1989.20 
 Control = 29 patients 
(19 female, 10male). 
 Intervention = 65 
patients (42 female, 23 
male). 
 Age range 10.5-38 
years. 
Discomfort index 
and visual 
analogue scale 
(VAS) 
questionnaires. 
 Placement of separators 
for 7 days. 
 Removal of separators, 
placement of Begg 
appliances and initial arch 
wires. 
 Pain intensity. 
 Pain duration. 
 Significant increase in discomfort after 
insertion of separators/arch wires at 4 hours 
and 24 hours, but not at 7 days. 
 No significant difference in pain for patients 
over 16 years of age compared with those 
16 years and under. 
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2.2.3: Neural pathways of pain 
In order to appreciate the effect of analgesics on orthodontic pain, it is important to 
understand the biology and neural pathways behind the production of pain 
sensation.  
The neural pathway for pain consists of four processes; these are transduction, 
transmission, modulation and perception.21 Transduction is where noxious stimuli 
cause electrical stimulation in specific free nerve endings called nociceptors. These 
are the peripheral receptors in the face and mouth which respond to noxious, pain-
causing orofacial stimuli.22 The noxious input is then transmitted, via the neural 
system, to the CNS for processing. The neural system, which processes the noxious 
input, consists of three parts; the peripheral sensory nerve primary afferent neuron 
carries the nociceptive input via the dorsal root, to the dorsal horn in the spinal cord. 
All cell bodies of primary neurons are located in the dorsal root ganglion; followed by 
the second order neuron, which can involve more than one neuron and carries the 
input across the spinal cord, and via the anterolateral spinothalamic pathway, to the 
thalamus; the final part of the system involves neural interactions between the 
thalamus, cortex and limbic system. This is where modulation occurs, as the cortex 
and brainstem can control the pain-transmitting neurons. This is known as the gate 
control theory, where the signal can be blocked, transmitted, or modified to enhance 
or reduce the arriving input at different central regions.23 
Finally, perception is achieved when nociceptive input reaches the cortex and a 
complex interaction of neurons between the higher centres of the brain occurs and 
pain behaviours begin.24 
2.2.4: The Trigeminal System 
Orofacial sensory input enters the spinal cord via the fifth cranial nerve, the 
trigeminal nerve.25 The trigeminal nerve is made up of three sensory branches: the 
ophthalmic division (V1), the maxillary division (V2) and the mandibular division (V3); 
as illustrated in Figure 1.  
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Figure 1. Sensory fields of the trigeminal nerve branches26 
 
The trigeminal spinal pathway also receives and transmits input from the 
glossopharyngeal (ninth cranial nerve) and the vagus nerve (tenth cranial nerve).27 
Furthermore, the trigeminal system transmits motor impulses, from the muscles of 
mastication for example. Transmission cells exist in three types in the trigeminal 
system.22 However, it the small-diameter polymodal nociceptive fibres which are 
responsible for transmission of orthodontic pain. They are each responsible for an 
area known as a receptive field. They are activated by high-intensity orofacial 
stimulus applied to their localised receptive field.28 Two types of nociceptors have 
been identified. The first is the C-fibre, which is the most common fibre found in the 
dental pulp. It is sensitive to mechanical, chemical and heat stimuli29 and conveys a 
burning or dull aching pain sensation. They have a receptive field of 10cm, a 
diameter of 0.5-1µm and are unmyelinated, making them slower at conducting 
impulses. The second type of nociceptor is the A-delta (A-δ) fibre, which elicits a 
pricking, sharp pain and is sensitive to mechanical and heat stimuli.29 A-δ-fibres are 
myelinated, and therefore they have faster signal transduction. 
2.2.5: Biology of orthodontic pain 
The pressure-tension theory is the classic theory behind our understanding of 
orthodontic tooth movement. The theory suggests that, when force is applied to a 
tooth, areas of pressure and tension are generated within the periodontal ligament 
(PDL). Early histological studies, carried out at tissue level by Standstedt30,31,32 in the 
early 20th century, demonstrate the chemical signalling and cellular changes that 
occur on the pressure and tension sides when force was applied to maxillary incisors 
in dogs. In areas of tension, bone is deposited with both light and heavy forces. 
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Whilst in areas of pressure/compression, light forces result in resorption of bone 
directly by multinucleate osteoclasts in the Howship’s lacunae. However, when 
forces are heavy and exceed capillary blood pressure, the PDL is compressed and 
cell death occurs resulting in the development of a localised cell-free area, termed 
“hyalinisation”. This is due to its glass-like appearance under light microscopy similar 
to that of hyaline cartilage.33 Resorption in these areas is termed “undermining 
resorption” and occurs at a delayed rate due to delayed migration of osteoclasts from 
adjacent tissues. This results in slower tooth movement and more pain for the 
patient.33 Continuous forces, as light as 30g, can cause hyalinisation; particularly 
when tipping teeth, because forces are more concentrated compared to evenly and 
uniformly distributed force exerted during bodily movement.32 
When pressure is delivered to a tooth by orthodontic appliances, ischemia, 
inflammation, and oedema will occur immediately in the area of compression of the 
periodontal ligament.34 The tooth will be displaced within the periodontal ligament 
space, loading the alveolar bone. The mechanical strain produced alters blood flow 
within the periodontal ligament, stimulating the synthesis and release of algogens 
such as histamine, prostaglandin PGE2, and leukotrienes, thus activating an 
inflammatory reaction.31 This will result in pain for the patient, usually commencing 
about two hours after application of orthodontic force, reaching a peak level at 24 
hours, and lasting approximately five days.16 In addition to the mechanically-induced 
inflammatory response, pain is transmitted directly from periodontal nerve ending. 
Nerve endings in the periodontal ligament consist of low-threshold mechano-
receptors and nociceptors. Pain is initiated via compression and stretch of the low-
threshold mechano-receptors, whilst nociceptors are activated by tissue injury or 
heavy forces.35 
2.2.6: Sources of orthodontic pain 
It is generally understood by patients that pain and discomfort are common clinical 
symptoms, especially in the period immediately following fixed appliance 
placement.36 
Literature shows that the pain experience during treatment begins with initial 
discomfort when orthodontic force is applied, but this disappears immediately. The 
second response appears much later, with peak intensity on day one and lasts a few 
days.19 However, the source of this pain varies and therefore the ultimate discomfort 
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experienced by the patient will depend on the appliances, auxiliaries and order of 
treatment used by their clinician. A summary of a selection of evidence exploring 
common sources of orthodontic pain is shown in Table 2.  
Different forms of orthodontic appliances or auxiliaries will have a varying effect on 
the intensity of pain experienced. Literature has shown that patients wearing fixed or 
functional appliances have a significantly higher level of pain than those who are 
undergoing treatment with removal upper and/or lower appliances.37 
Pain experienced during the placement of separators has been shown in the 
literature to be of particular significance.  A study by Bergius et al. in 200238 
investigated fifty-five adolescent patients who had bilateral molar elastic separators 
placed. The vast majority (87%) of patients reported pain the first evening. The 
highest intensity of pain was reached the day after placement of separators whilst at 
day 7, 42% of the patients still reported pain. Although pain experience varied 
substantially, their findings reflect those of other researchers.39 
Pain, during the initial alignment stage of treatment, can be expected. In the 
literature, the severity of this pain has been compared to that of premolar extractions 
when they have been carried out to aide correction of the malocclusion. This has 
shown that patients who underwent both premolar extractions and orthodontic tooth 
movement experienced more pain 24 hours after initial arch wire placement than 
they did 24 hours after tooth extraction.19 
In addition to the pain experience at the beginning of treatment; with both separation 
and placement of initial aligning archwires, patients may also experience pain for 1 to 
2 days following each adjustment appointment. This can be experienced acutely or 
continuously in between adjustment visits.  
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Table 2. A summary of literature exploring sources of orthodontic pain. 
Study Participants Method Outcomes Results 
Sergl, Klages, 
Zentner. 
1998.37 
 N = 84 patients 
undergoing orthodontic 
treatment. 
 45 female: 39 male. 
 Mean age: 12.8 years. 
 Questionnaires and rating scale 
at 1, 2, 6 weeks and 3, 6months 
after appliance insertion. 
 Patients had either: 
- 1 removable plate (25) 
- 2 removable plates (31) 
- Functional appliances (14) 
- Fixed appliances (14) 
 Pain experience. 
 Patient attitude towards 
treatment. 
 Compliance at 1, 2, 6 weeks 
and 3, 6months. 
 Adaptation to pain occurred in the first 3-5 days after 
appliance placement. 
 Severity of pain wearing functional or fixed appliances 
was significantly higher than by those treated with upper 
and/or lower removable plates. 
 Patients who had higher perception of the severity of 
their malocclusion seemed to adapt faster and have less 
pain. 
Bergius, 
Berggren, 
Kiliaridis. 
2002.38 
 N =55 patients. 
 12-18 years old. 
 Treatment due to 
crowding. 
 
 Bilateral molar separators. 
 Telephone interviews for 7 days. 
 Pain intensity on a VAS 
scale. 
 Pain medication required. 
 87% reported pain in the first evening. 
 Highest intensity of pain one day after separator 
placement. 
 42% still had pain at day 7. 
 Analgesics taken by 27% within 2 days. 
 No patients took analgesics after 2 days. 
 Females had higher pain ratings at day 3-7. 
Mangnall, 
Dietrich, 
Scholey. 
2013.39 
 N = 90 patients. 
 45 control: 45 
intervention). 
 Multicentre RCT. 
 Control: No intervention during 
debond. 
 Intervention: Soft acrylic wafer in 
situ during debond. 
 Pain experience during 
treatment. 
 Expectations of pain during 
debond. 
 Pain experienced during 
debond. 
 Biting on an acrylic wafer significantly reduced pain 
during debond of posterior teeth. 
 39% found debond of lower anteriors most painful. 
 Expected pain was significantly greater than pain 
experienced. 
 Greater pain during treatment correlated with increased 
expectations and increased pain experienced at debond. 
Stewart, Kerr, 
Taylor. 
1997.40 
 N = 52 Caucasian 
patients. 
 35 female: 17 male. 
 Consecutively enrolled. 
 31 fixed, 21 removable. 
 Questionnaires at 7, 14 and 90 
days after appliance insertion. 
 Treatment with either: 
- two-arch fixed appliances 
- upper removable appliance 
 Pain following insertion of 
appliances. 
 Convenience of appliance. 
 Self-comfort of appliance. 
 Fixed appliances are more painful for the first 7 days. 
 Removable appliances cause more disturbance to 
speech and swallowing. Even after 3 months, influence on 
speech remains. 
 Fixed appliances no more socially embarrassing than 
removable. 
Fleming, 
DiBiase, Sarri, 
Lee. 2009.41 
 N = 66 patients. 
 Aged 11-21 years. 
 Equally distributed 
amongst 
control/intervention 
groups. 
 Multi-centre randomised 
controlled trial. 
 Questionnaire with VAS at 4 
hours, 24 hours, 3 days and 1 
week after initial visit. 
 Randomised to either: 
- SmartClip self-ligating bracket 
system. 
- Conventional bracket system. 
 Pain experience during initial 
alignment. 
 Pain experience during 
insertion and removal of 
rectangular archwires. 
 Pain experience at 4 hours, 24 hours, 3 days, and 7 
days following appliance placement is independent of 
bracket type. 
 Insertion and removal of rectangular archwires may 
result in an enhanced pain experience with the 
SmartClip™ passive self-ligating appliance. 
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2.3: The impact of orthodontic pain for patients 
The literature suggests that up to 95% of orthodontic patients report pain at some 
stage during their treatment.38,41,42,43 However, the effect that this pain will have on a 
patient’s ongoing treatment varies between individuals. Pain during orthodontic 
treatment has been shown to be the most common reason for patients wanting to 
discontinue treatment and was ranked as the worst aspect of the treatment.44  
For patients who opt to continue with treatment, the true extent and impact of 
orthodontic pain can often differ from a patient’s own expectations. It has been 
shown that patients significantly under-estimate the changes they need to make in 
their diet, in response to pain, after archwire insertion. The influence of pain on diet 
was marked. In addition, it was found that patients who anticipated a greater effect of 
pain on their leisure activities, reported higher levels of pain and more disruption to 
their daily lives as a result.16 Therefore, it is important to ensure that patients are 
sufficiently informed of all aspects regarding the impact that orthodontic pain may 
have on their day-to-day lives. 
2.4: Pharmacological Interventions 
Pain relief in dentistry has been well studied in the literature but the management of 
pain associated with orthodontic treatment is less well known.45 As clinicians, we are 
often asked whether it will be necessary for patients to take pain killers during 
orthodontic treatment and if so, which is likely to be the most effective? Some 
studies have shown that pre-treatment doses of non-steroidal anti-inflammatory 
drugs (NSAIDs) may help to reduce the amount of pain experienced immediately 
after treatment.34 However, there is some uncertainty among orthodontists as to 
which painkillers are most suitable and whether pre-emptive analgesia is beneficial.  
2.4.1: Opioid 
Opioids, also referred to as narcotics, include codeine sulphate, tramadol and 
morphine sulphate. They may be classified as agonistic, agonist-antagonistic or 
partial agonist depending on their specific mode of action but they act on large A- δ 
fibres in the dorsal horn of the spinal cord. They bind to G-protein-coupled opiate 
receptors on inhibitory fibres, preventing stimulus of the gate, as earlier discussed, 
and therefore prevent transmission to the brain.46 However, the specific mechanism 
of action differs slightly when considering tramadol. In addition to the mechanism 
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described above, tramadol can act to inhibit the reuptake of monamines, causing an 
analgesic effect but limiting the osteoporotic changes seen with other opioids at a 
histological level.47 By acting in this non-opioid way it has been hypothesised that the 
effect on the rate of orthodontic tooth movement will be less with tramadol than 
experienced with other, traditional opioids; however, under experimental situations 
this has not been the case.47 
2.4.2: NSAIDs 
Non-steroidal anti-inflammatory drugs are the most popular method of pain control 
during orthodontic treatment.2,48 These include drugs like ibuprofen and aspirin. 
These drugs function by inhibition of the activity of the enzyme cyclooxygenase 
(COX), which modulates the transformation of prostaglandins from arachidonic acid 
in the cellular plasma membrane.49 As prostaglandins are responsible for pain; by 
inhibiting COX, prostaglandin production is suppressed and pain is therefore 
reduced. However, as has been discussed earlier, prostaglandins including PGE1 
and PGE2 are important mediators of bone resorption and suppression of their 
activity using NSAIDs has been suggested to affect the rate of orthodontic tooth 
movement.50 Kehoe et al.51 found a significant difference in the rate of tooth 
movement achieved with elastic separators in guinea pigs when comparing 
treatment with misoprostol or ibuprofen to a control group. However, the significance 
of this on a clinical level is negligible, with a 1mm average difference between 
intervention and control groups; and the doses used experimentally differ from those 
routinely used in practice. 
2.4.3: Paracetamol 
Paracetamol, known as Acetaminophen in the USA, has been available in the UK as 
an analgesic on prescription since 1956, and over-the-counter since 1963.52 The 
primary mechanism of action of paracetamol is similar to that of NSAIDs. It is 
believed to inhibit COX, with a predominant effect on COX-2, however; unlike 
NSAIDs; it is thought to act at a central nervous system level rather than acting over 
cell membranes.53 As a result, inhibition of prostaglandins is minimal and therefore it 
is thought that its use has no effect on the rate of tooth movement. However, 
although useful as an antipyretic and analgesic, it lacks an anti-inflammatory action 
and is therefore often used in combination with NSAIDs for management of pain. 
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2.4.4: Local Anaesthetic 
Local anaesthetic, in the form of a topical gels, have been suggested as safer 
alternatives to systemic analgesics as a method of pain management before or 
during orthodontic procedures.52 The mode of action of the gel is by localised 
delivery of the anaesthetic into the gingival crevice. Because of this, their use has 
been suggested during local orthodontic procedures such as band placement, 
archwire ligation or bracket removal.54 
2.4.5: Non-pharmacological Management 
In response to increasing concerns regarding the possible side effects related to 
regular use of analgesics and a rise in drug related allergies, alternative, non-
pharmacological management techniques have been developed.33 Interventions 
include the use of bite wafers and chewing gum,55 low level laser therapy to the 
periodontal tissues (LLLT), vibratory or transcutaneous electrical nerve stimulation 
(TENS),56,57 topical application of ice or cryotherapy, acupuncture or acupressure, 
and psychological intervention, for example, structured telephone call to the patients 
during treatment.33 
 
We will be investigating the relief of pain, using pharmacological interventions, 
arising during and after the placement of orthodontic appliances. This may include 
one or more of the following orthodontic interventions: separators, fixed braces, 
removable braces, headgear and during routine treatment to adjust appliances. We 
will not include pain relief using non-pharmacological interventions, as this is the 
topic of another Cochrane systematic review33 or following tooth extraction, 
placement of temporary anchorage devices (TADs) or surgical procedures 
associated with orthodontic treatment. 
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Chapter 3: Aims, Objectives and Null Hypothesis 
3.1: Aims 
The aims of this review were to determine: 
1. The effectiveness of pharmacological interventions for pain relief during 
orthodontic treatment;  
2. Whether there is a difference in the analgesic effect provided by different 
types, doses and timing of analgesia taken during orthodontic treatment. 
3.2: Objectives 
The objectives of this review were to search and analyse the literature systematically 
surrounding the effectiveness of drug interventions for orthodontic pain to establish 
the most effective drug regime for the prevention and/or management of pain during 
orthodontic treatment and to test the null hypothesis. 
3.3: Null hypothesis 
The null hypothesis of this review is that there is no difference in the analgesic effect 
provided by different types, forms and doses of pain management drugs taken 
during orthodontic treatment, which was tested against the alternate hypothesis of a 
difference. 
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Chapter 4: Methods 
4.1: Criteria for considering studies for this review 
4.1.1: Types of studies 
All randomised controlled clinical trials (RCTs) of orthodontic treatments where a 
pharmacological intervention for pain relief was compared concurrently to a placebo 
or no intervention or another pharmacological intervention. 
If a randomised controlled trial compared pharmacological and non-pharmacological 
interventions to a placebo or no intervention, the study was included but only the 
data for a pharmacological intervention were used. 
4.1.2: Types of participants 
4.1.2.1: Inclusion Criteria 
Trials were eligible for inclusion in the review if they recruited patients who had 
received pharmacological pain relief following any type of orthodontic treatment. 
All age groups were considered. 
4.1.2.2: Exclusion Criteria 
Trials were excluded from the review if they recruited patients who had received pain 
relief following surgical interventions, placement of temporary anchorage devices 
(TADs) and/or dental extractions in combination with orthodontic treatment. 
4.1.3: Types of interventions 
4.1.3.1: Active interventions 
The following active interventions to alleviate pain were assessed: 
 Opioid analgesics 
 Any NSAID 
 Paracetamol  
 Local anaesthetic 
Any intervention taken by any route, dose, form or combination, at any time during 
treatment was evaluated. 
Studies, in which the interventions were given at any time following treatment or up 
to 2 hours before treatment, were evaluated. 
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4.1.3.1: Controls 
Interventions were included if they were compared to each other, a placebo, or the 
same intervention but at a different dose, intensity or time interval. 
4.1.4: Types of outcome measures 
4.1.4.1: Primary Outcomes 
Patient reported pain intensity/pain relief measured on a visual analogue scale 
(VAS), numerical rating scale (NRS) or any categorical scale. 
4.1.4.2: Secondary Outcomes  
Harms were recorded and reported in descriptive terms. 
 Rescue analgesia (alternative pain relief taken/prescribed, including dose 
and time, following last treatment). 
 Adverse effects (harms) of pain treatment e.g. total gastro-intestinal side 
effects. 
 Quality of life and/or patient satisfaction. 
 Time off school/work. 
 Withdrawal from the study for any reason. 
 Failure to complete orthodontic treatment due to the pain experienced. 
 Response to treatment (defined as a reduction in pain by at least 50%). 
4.1.4.3: Comparisons 
1. Any analgesic, at any dose, taken at any time versus placebo at any dose taken 
at any time. If there was evidence of effectiveness, further analysis of the class 
and type of drug was undertaken. 
2. Opioid of any type, at any dose taken at any time versus placebo at any dose 
taken at any time. 
a. Subgroup analysis of type of opioid at any dose taken at any time versus 
placebo at any dose taken at any time. 
3. NSAID of any type, at any dose taken at any time versus placebo at any dose 
taken at any time. 
a. Subgroup analysis of type of NSAID at any dose taken at any time versus 
placebo at any dose taken at any time. 
4. Paracetamol at any dose taken at any time versus placebo at any dose taken at 
any time. 
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a. Subgroup analysis of type of paracetamol at any dose taken at any time 
versus placebo at any dose taken at any time. 
5. Local anaesthesia at any dose taken at any time versus placebo at any dose 
taken at any time. 
a. Subgroup analysis of type of local anaesthesia at any dose taken at any 
time versus placebo at any dose taken at any time. 
6. If there was effectiveness in any of the classes or subgroups, further analysis 
was undertaken to determine the effectiveness and harms at different doses of 
opioid/ NSAID/ paracetamol/ local anaesthetic versus placebo. 
7. Head to head comparisons of the best doses for each class and/or type of 
analgesic would have been undertaken if sufficient data had been available. 
8. Head to head comparisons of the best timing for each class and/or type of 
analgesic would have been undertaken if sufficient data had been available. 
9. Head to head comparisons of the best in each class and/or type of analgesic. 
4.2: Search methods for identification of studies 
4.2.1: Electronic searching 
For the identification of studies included or considered for this review, a detailed 
search strategy was developed for each database searched. These were based on 
the search strategy developed for MEDLINE but revised appropriately for each 
database. The search strategy used a combination of controlled vocabulary and free 
text terms based on the search strategy for MEDLINE (Appendix 3). For the 
MEDLINE search, the subject search was run with the Cochrane Highly Sensitive 
Search Strategy (CHSSS) for identifying randomised trials in MEDLINE: sensitivity-
maximizing version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in 
box 6.4.a. of the Cochrane Handbook for Systematic Reviews of Interventions 
version 5.1.0 (updated March 2011).57 
4.2.2: Databases searched 
The following databases were searched: 
 Cochrane Oral Health Group's Trials Register (to current date) 
 Cochrane Pain, Palliative and Supportive Care Group's Trials Register 
 Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane 
Library at current issue) 
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 MEDLINE (from 1966 to present) 
 EMBASE (from 1980 to present) 
 CINAHL (from 1982 to present). 
The date of the last search was 19th August 2016. 
4.2.3: Searching other resources 
A check was made to identify journals which had already been handsearched as part 
of the Cochrane Journal Handsearching Programme. The handsearching of the 
following journals would have then been updated to the most current issue if 
appropriate: 
 American Journal of Orthodontics and Dentofacial Orthopedics; 
 The Angle Orthodontist; 
 European Journal of Orthodontics; 
 Journal of Orthodontics; 
 Australian Orthodontic Journal; 
 Seminars in Orthodontics; 
 Orthodontics and Craniofacial Research; 
 Journal of Orofacial Orthopaedics. 
If it appeared, from searching the Cochrane Pain, Palliative and Supportive Care 
Group Trials Register, that relevant studies were being identified in non-orthodontic 
journals, these were also handsearched as necessary.  
The bibliographies of the clinical trials identified were checked for references to trials 
published outside the handsearched journals.  
Personal references were checked. 
Additionally, other resources such as The British Library EThOS service 
(http://ethos.bl.uk) were searched for relevant theses and ClinicalTrials.gov was 
searched for otherwise unpublished and ongoing studies. 
Conference proceeding of the European Orthodontic Congress, International 
Association of Dental Research, British Orthodontic Conference and American 
Association of Orthodontists were also searched to identify presented trials. 
4.2.4: Language 
Databases were searched to include papers and abstracts published in all languages 
and every effort was made to translate non-English papers. 
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4.2.5: Unpublished studies 
The first named authors of all trial reports were contacted in an attempt to identify 
unpublished studies and to obtain any further information about the trials. 
Trials databases were also searched to identify registered, ongoing trials. 
4.3: Data collection and analysis 
4.3.1: Management of records produced by the searches 
All references were downloaded into EndNote reference management software and 
merged to produce a single database to facilitate retrieval of relevant articles.  
Non-electronic references, that could not be downloaded, were entered into the 
database manually after which duplicates were removed. 
4.3.2: Selection of studies 
Two review authors (Aoife Monk (AM) and Jayne Harrison (JH) or Annabel Teague 
(AT)) assessed the titles and abstracts (when available) of all reports that were 
identified by the search strategy as being potentially relevant. This was carried out 
independently and in duplicate. 
For studies with insufficient information in the title and abstract to make a clear 
decision to exclude, or studies where there was disagreement between the review 
authors about eligibility, a full report was obtained. These full reports were then 
assessed independently and in duplicate by two review authors (AM and JH or AT) 
to establish whether or not the studies met the inclusion criteria. 
Disagreements were resolved by discussion between AM and JH. We consulted a 
third review author if we could not resolve disagreements. A record of all decisions 
made about the potentially eligible studies was kept. Full reports were also obtained 
for those studies that were ultimately included in this review. 
The review authors were not blinded to trial author(s), institution or site of 
publication. 
4.3.3: Data extraction and management 
Data extraction was carried out independently and in duplicate by two review authors 
(AM and JH or AT) using a pre-designed and piloted data collection form and saved 
electronically. We contacted study authors for clarification on missing data where 
necessary and feasible. We resolved any disagreements through discussion, 
consulting a third reviewer to achieve a consensus where necessary. We recorded 
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the following key data for each included study in the Characteristics of Included 
Studies table: 
 Trial design, source of participants, method of recruitment, recruitment period 
and study duration. 
 Inclusion/exclusion criteria, age and gender and ethnicity of participants, and 
number selected, excluded, randomised and analysed. 
 Detailed description of the invention and comparison including time, dose and 
route. Information relating to compliance was also noted where available.  
 Details of the outcomes reported, including method of assessment and time(s) 
assessed. 
 Details of sample size calculations, adverse effects, funding sources, 
declarations/conflicts of interest. 
The primary outcome was the relief of pain. Adverse events / harms (e.g. total 
gastro-intestinal side effects) were recorded and the results reported in descriptive 
terms. 
All outcome data were extracted. They were then grouped into the timepoints which 
we felt were the most clinically relevant: 2 hours, 6 hours and 24 hours following the 
orthodontic procedure (placement or adjustment of appliance). If outcome data were 
reported at other time points, then consideration was given to examining those as 
well. 
4.3.4: Assessment of risk of bias in included studies 
The Cochrane risk of bias tool was used to assess the methodological quality of the 
studies. This was undertaken independently and in duplicate by the two review 
authors (AM and JH) as a part of the data extraction process. This was carried out 
using the Cochrane domain-based, two-part tool as described in Chapter 8 of the 
Cochrane Handbook for Systematic Reviews of Inteventions.58 Seven specific 
domains were investigated: random sequence generation; allocation concealment; 
blinding of participants and personnel, blinding of outcome assessment; incomplete 
outcome data; selective outcome reporting and ‘other sources of bias’. These are 
discussed in more detail below. 
Each domain was assigned a judgement of high, low or unclear as an indication of 
its risk of bias according to the following criteria: 
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 Low risk of bias (plausible bias unlikely to seriously alter the results) if all 
domains were at low risk of bias; 
 High risk of bias (plausible bias that seriously weakens confidence in the 
results) if one or more domains were at high risk of bias; or 
 Unclear risk of bias (plausible bias that raises some doubt about the results) if 
one or more domains were at unclear risk of bias. 
Sequence generation, allocation concealment and selective outcome reporting were 
assessed for the study as a whole. Blinding and incomplete outcome data were 
assessed on the level of the study and for each outcome as appropriate. 
4.3.4.1: Method of sequence generation 
Adequate sequence generation 
 Referring to the use of a random component including random number table; 
using a computer random number generator, repeated coin tossing, dealing 
previously shuffled cards or envelopes, throwing dice, drawing of lots or 
minimization*.  
 Restricted or stratified randomisation can also be included. 
*Minimization may be implemented without a random element as a means of making 
small groups closely similar with respect to several characteristics. This is 
considered to be equivalent to being random.  
Inadequate sequence generation 
 Quasi-randomisation, where the sequence has been generated by odd or 
even date of birth, some rule based on date (or day) of admission, hospital or 
clinic record number, or allocation based on judgement of the clinician. 
4.3.4.2: Method of allocation concealment 
Adequate concealment schemes 
 Central allocation (including telephone, web-based and pharmacy-controlled 
randomization). 
 Sequentially numbered drug containers of identical appearance or opaque, 
sealed envelopes.  
Inadequate concealment schemes 
 Using an open random allocation schedule (e.g. a list of random numbers). 
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 Assignment envelopes were used without appropriate safeguards (e.g. if 
envelopes were unsealed or non-opaque or not sequentially numbered), 
alternation or rotation, date of birth, case record number and any other 
explicitly unconcealed procedure.  
Unclear concealment schemes 
 Insufficient information to permit judgement of ‘Yes’ or ‘No’.  
 This is usually the case if the method of concealment is not described or not 
described in sufficient detail to allow a definite judgement – for example, if the 
use of assignment envelopes is described, but it remains unclear whether 
envelopes were sequentially numbered, opaque and sealed.  
4.3.4.3: Blinding of participants, personnel and outcome assessors 
Adequate blinding 
 No blinding, but the review authors judge that the outcome and the outcome 
measurement are not likely to be influenced by lack of blinding;  
 Blinding of participants and key study personnel ensured, and unlikely that the 
blinding could have been broken;  
 Either participants or some key study personnel were not blinded, but 
outcome assessment was blinded and the non-blinding of others unlikely to 
introduce bias.  
Inadequate blinding 
 No blinding or incomplete blinding, and the outcome or outcome 
measurement is likely to be influenced by lack of blinding;  
 Blinding of key study participants and personnel attempted, but likely that the 
blinding could have been broken;  
 Either participants or some key study personnel were not blinded, and the 
non-blinding of others likely to introduce bias.  
Unclear 
 Insufficient information to permit judgement of ‘Yes’ or ‘No’; or the study did 
not address this outcome.  
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4.3.4.4: Incomplete outcome data  
Adequately addressed 
 No missing outcome data;  
 Reasons for missing outcome data unlikely to be related to true outcome (for 
survival data, censoring unlikely to be introducing bias);  
 Missing outcome data balanced in numbers across intervention groups, with 
similar reasons for missing data across groups;  
 For dichotomous outcome data, the proportion of missing outcomes 
compared with observed event risk not enough to have a clinically relevant 
impact on the intervention effect estimate;  
 For continuous outcome data, plausible effect size (difference in means or 
standardized difference in means) among missing outcomes not enough to 
have a clinically relevant impact on observed effect size;  
 Missing data have been imputed using appropriate methods.  
Inadequately addressed 
 Reason for missing outcome data likely to be related to true outcome, with 
either imbalance in numbers or reasons for missing data across intervention 
groups;  
 For dichotomous outcome data, the proportion of missing outcomes 
compared with observed event risk enough to induce clinically relevant bias in 
intervention effect estimate;  
 For continuous outcome data, plausible effect size (difference in means or 
standardized difference in means) among missing outcomes enough to 
induce clinically relevant bias in observed effect size;  
 ‘As-treated’ analysis done with substantial departure of the intervention 
received from that assigned at randomization;  
 Potentially inappropriate application of simple imputation.  
Unclear 
 Insufficient reporting of attrition/exclusions to permit judgement of ‘Yes’ or ‘No’ 
(e.g. number randomized not stated, no reasons for missing data provided);  
 The study did not address this outcome.  
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4.3.4.5: Selective outcome reporting  
Adequate outcome reporting 
 The study protocol is available and all of the study’s pre-specified (primary 
and secondary) outcomes that are of interest in the review have been 
reported in the pre-specified way;  
 The study protocol is not available but it is clear that the published reports 
include all expected outcomes, including those that were pre-specified 
(convincing text of this nature may be uncommon).  
Inadequate outcome reporting 
 Not all of the study’s pre-specified primary outcomes have been reported;  
 One or more primary outcomes is reported using measurements, analysis 
methods or subsets of the data (e.g. subscales) that were not pre-specified;  
 One or more reported primary outcomes were not pre-specified (unless clear 
justification for their reporting is provided, such as an unexpected adverse 
effect);  
 One or more outcomes of interest in the review are reported incompletely so 
that they cannot be entered in a meta-analysis;  
 The study report fails to include results for a key outcome that would be 
expected to have been reported for such a study.  
Unclear 
 Insufficient information to permit judgement of ‘Yes’ or ‘No’. It is likely that the 
majority of studies will fall into this category.  
4.3.4.6: Other potential threats to validity  
Adequate  
 The study appears to be free of other sources of bias.  
Inadequate 
The study: 
 Had a potential source of bias related to the specific study design used; or  
 Stopped early due to some data-dependent process (including a formal-
stopping rule); or  
 Had extreme baseline imbalance; or  
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 Has been claimed to have been fraudulent; or  
 Had some other problem.  
Unclear 
 Insufficient information to assess whether an important risk of bias exists; or  
 Insufficient rationale or evidence that an identified problem will introduce bias.  
4.3.5: Measure of treatment effect 
For continuous outcomes (e.g. pain measured on a visual analogue scale) where 
studies used the same scale, we used the mean values and standard deviations 
(SDs) reported in the studies in order to express the estimate of effect as mean 
difference (MD) with 95% confidence interval (CI). Where different scales were used 
we would have considered expressing the treatment effect as standardised mean 
difference (SMD) with 95% CI. 
4.3.6: Unit of analysis issues 
The participant was the unit of analysis. 
4.3.7: Dealing with missing data 
We attempted to contact the author(s) of all included studies, where feasible, for 
clarification, missing data, and details of any outcomes that may have been 
measured but not reported. We were unable to use the methods described in 
Section 7.7.3 of the Cochrane Handbook for Systematic Reviews of Interventions to 
estimate missing SDs due to unclear or unavailable data.58 We did not use any other 
statistical methods or perform any further imputation to account for missing data. 
4.3.8: Assessment of heterogeneity 
When a sufficient number of studies were included in any meta-analyses, we 
assessed clinical heterogeneity by examining the characteristics of the studies, the 
similarity between the types of participants, the interventions, and the outcomes. We 
also assessed heterogeneity statistically using a chi-square (chi2) test, where a P 
value < 0.1 indicated statistically significant heterogeneity. We quantified 
heterogeneity using the I2 statistic. A guide to interpretation of the I2 statistic given in 
Section 9.5.2 of the Cochrane Handbook for Systematic Reviews of Interventions is 
as follows58: 
 0% to 40%: might not be important; 
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 30% to 60%: may represent moderate heterogeneity; 
 50% to 90%: may represent substantial heterogeneity; 
 75% to 100%: considerable heterogeneity. 
4.3.9: Assessment of reporting bias 
If at least 10 studies were included in a meta-analysis, we planned to assess 
publication bias according to the recommendations on testing for funnel plot 
asymmetry, as described in Section 10.4 of the Cochrane Handbook for Systematic 
Reviews of Interventions.58 If asymmetry was identified, we would examine possible 
causes. It was not possible to assess publication bias in this way because, although 
we had a sufficient number of studies in our meta-analyses for the primary outcome, 
they were split into subgroups containing less than 10 studies. 
4.3.10: Data synthesis 
We only carried out meta-analyses where there were studies of similar comparisons 
reporting the same outcomes. We combined MDs for continuous data, and would 
have combined RRs for dichotomous data had any been reported. Our general 
approach was to use a random-effects model. With this approach, the CIs for the 
average intervention effect were wider than those that would have been obtained 
using a fixed-effect approach, leading to a more conservative interpretation. We 
used an additional table to report the results from studies not suitable for inclusion in 
a meta-analysis, including data analysed by treatment intervention. 
4.3.11: Subgroup analysis and investigation of heterogeneity 
We carried out subgroup analyses according to type of pharmacological intervention 
given and different interventions. We stated in the protocol that we would also use 
dose, timing and class as categories for subgroup analyses. However, these 
categories were very closely related, and there were insufficient numbers of studies 
with these differing populations and so it did not make sense to do so. 
4.3.12: Sensitivity analysis 
As all studies except one were at high risk of both performance and detection bias, it 
was not possible to test the robustness of our results by performing sensitivity 
analyses based on excluding the studies at unclear or high risk of bias from the 
analyses. If any meta-analyses had included several small studies and a single very 
large study, we would have undertaken a sensitivity analysis comparing the effect 
P a g e  | 32 
 
 
estimates from both random-effects and fixed-effect models. If these were different 
we would have reported on both analyses as part of the results section, and we 
would have considered possible interpretation.  
4.3.13: Cross-over trials 
The treatment effects from crossover trials were combined with those from parallel 
group trials where appropriate. Data from only the first round of the trial were used 
and treated as a parallel trial.  
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Chapter 5: Results 
5.1: Description of studies 
5.1.1: Results of the search 
The electronic database search identified 588 references to studies and 4 additional 
articles were identified from additional sources (authors of this review). 290 of the 
studies were duplicates, leaving 302 studies. 262 were discarded by screening the 
titles and abstracts. Of the remaining 40 articles, we obtained full-text articles where 
possible, and excluded 5 of the studies at this stage. The remaining 35 studies 
appeared to meet our inclusion criteria and we were finally able to include 22 of the 
studies. Of the remaining 13 studies, 6 are awaiting assessment due to insufficient 
information in the abstract or trial registry record, to allow inclusion in the review and 
7 presented insufficient data for inclusion in the analyses, having made attempts to 
contact authors to obtain the data. This process is presented as a flow chart in 
Figure 2. 
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Figure 2. Study flow diagram. 
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5.1.2: Included studies 
Twenty-two studies, involving a total of 2,110 participants (n =1,800) were included 
in this review. 
5.1.3: Characteristics of the trial designs and settings 
Design 
Twenty-one studies were of parallel design, with the remaining one study using a 
cross-over design (Eslamian 201459). Five studies had two arms (Bradley 200760; 
Kluemper 200261; Lauritano 200062; Ousehal 200963; Yassaei 201264); fifteen studies 
had three arms however, four of these studies had one arm excluded from this 
review because it involved data relating to non-pharmacological interventions (Wang 
201265) or non-comparable data (Bernhardt 200166; Minor 200967; Steen-Law 
200034). One study had five arms, with three of those arms being excluded from this 
review because they involved data relating to non-pharmacological interventions 
(Farzanegan 201268). One study had 6 arms (Polat March 200548).  
Setting 
Six studies were conducted in the USA (Bernhardt 200166; Kawamoto 201069; 
Kluemper 200261; Minor 200968; Salmassian 200970; Steen Law 200034), five in Iran 
(Eslamian 201459; Farzanegan 201268; Najafi 201571; Nik 201672; Yassaei 201264), 
three in Turkey (Polat March 200548; Polat September 200573; Tunçer 201474), two in 
India (Gupta 201475; Kohli 201176) and one in each of Brazil (Bradley 200760), China 
(Wang 201265), Italy (Paganelli 199378), Morocco (Ousehal 200963), Spain (Lauritano 
200062) and the UK (Bradley 200760). 
There were fifteen single centre studies, two with two centres (Eslamian 201459; 
Kawamoto 201069), one with three centres (Bradley 200760) and four studies in which 
it was unclear as to how many centres were involved (Kluemper 200261; Polat March 
200548; Polat September 200573; Tunçer 201474).  
Funding 
Three studies reported their funding source (Bradley 200760; Najafi 201571; Wang 
201265), all of which were in the form of independent funding from government, 
charities or universities. The remaining nineteen studies did not report any funding 
source.  
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Conflict of interest 
Five studies declared that there were no conflicts of interest (Bruno 201177; Gupta 
201475; Najafi 201571; Salmassian 200970; Wang 201265), whilst the other seventeen 
did not mention conflicts of interest. 
5.1.4: Characteristics of the participants 
There were 2,110 participants randomized to interventions (including only the 
intervention groups relevant to this review), of which 1,800 were included in the 
studies’ analyses. Ages ranged from 9 to 34 years. In general, there were 
comparable numbers of males and females in the studies however, two studies 
recruited only female participants (Farzanegan 201268; Yassaei 201264) and two 
studies reported large gender variations between groups at baseline (Najafi 201571; 
Tunçer 201474). 
5.1.5: Orthodontic interventions 
In ten studies, participants had placement of an initial aligning archwire (Farzanegan 
201268; Gupta 201475; Lauritano 200062; Najafi 201571; Ousehal 200963; Polat March 
200548; Polat September 200573; Salmassian 200970; Tunçer 201474; Wang 201265). 
In nine of the studies, participants had separators placed (Bernhardt 200166; Bradley 
200760; Bruno 201177; Kawamoto 201069; Kohli 201176; Minor 200967; Nik 201672; 
Steen Law 200034). Two studies included participants who were in the middle of 
treatment (Eslamian 201459; Paganelli 199378) and one study included patients who 
had brackets placed only, without placement of an archwire (Kluemper 200261). 
5.1.6: Characteristics of the interventions and comparisons 
Paracetamol 
Six studies compared paracetamol with a control group (Gupta 201475; Kawamoto 
201069; Nik 201672; Polat March 200548; Salmassian 200970); all of which had a 
control group who received a placebo intervention. One study compared 
paracetamol with calcium (Yassaei 201264). 
NSAIDs 
Fourteen studies compared NSAIDs with a control group (Bruno 201177; Eslamian 
201459; Farzanegan 201268; Gupta 201475; Kawamoto 201069; Kohli 201176; Minor 
200967; Nik 201672; Paganelli 199378; Polat March 200548; Polat September 200573; 
Salmassian 200970; Tunçer 201474; Wang 201265). Two of these studies compared 
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NSAIDs with both a placebo group and a group with no intervention (Bruno 201177; 
Paganelli 199378). Nine studies compared NSAIDs with paracetamol (Bradley 
200760; Gupta 201475; Kawamoto 201069; Najafi 201571; Nik 201672; Polat March 
200548; Polat September 200573; Salmassian 200970; Tunçer 201474). Five studies 
compared the different classes of NSAIDs with one another (Kohli 201176; Lauritano 
200062; Najafi 201571; Polat March 200548; Polat September 200573). Two studies 
compared ibuprofen taken pre-emptively with ibuprofen taken post-operatively 
(Bernhardt 200166; Steen Law 200034).  
Local anaesthetic 
Two studies compared benzocaine local anaesthetic with a control. One of these 
studies had the benzocaine intervention in chewing gum form (Eslamian 201459) and 
one had the benzocaine intervention in wax form for the management of orthodontic 
related ulceration (Kluemper 200261). One group compared NSAIDs with local 
anesthetic (Eslamian 201459).  
Duration 
The duration of treatment varied between studies, from one dose one hour before 
treatment to seven days of treatment. However, one study had a duration of 
treatment lasting 30 days (Yassaei 201264). 
5.1.7: Characteristics of the outcomes 
5.1.7.1: Primary outcome 
For the primary outcome of pain, we were interested in either the pain relief or pain 
intensity, and also different levels of severity. All included studies measured pain 
intensity using a 10cm visual analogue scale (VAS), reported in either centimetres or 
millimetres. For the purposes of this review, VAS data, in relation to the primary 
outcome, were analysed in millimetres. Therefore, in studies that recorded results in 
centrimetres, the data were converted into millimetres. Most studies recorded this 
value based on an overall summary of the participant’s pain experience however, 
some studies reported pain intensity for additional specified activities.  
Seven studies recorded pain intensity during chewing, biting, fitting front teeth 
together and fitting posterior teeth together (Bernhardt 200166; Farzanegan 201268; 
Kohli 201176; Minor 200967; Polat March 200548; Polat September 200573; Steen-Law 
200034). One study recorded pain intensity during chewing, biting and teeth not 
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touching (Kawamoto 201069); one study recorded pain intensity during chewing, rest 
and fitting posterior teeth together (Najafi 201571) and one study recorded pain 
intensity during chewing, fitting front teeth together and fitting back teeth together 
(Tunçer 201474). For the purposes of this review, data for chewing only were 
included in the analysis for these studies. 
A total of twenty-three time points were recorded across all twenty-two included 
studies. These ranged from one hour pre-treatment to 30 days post-treatment. We 
decided to include data from 2 hours, 6 hours and 24 hours for our analysis as we 
thought these were the most important time points from a clinical perspective, in 
addition to being some of the most commonly reported time points across all studies. 
It was also evident from the data that the peak in pain intensity occurred at 24 hours, 
after which it rapidly reduced regardless of intervention and therefore we thought that 
analysing data beyond this point would provide little valuable information. As a result, 
data from Kluemper 200261; Paganelli 199378 and Yassaei 201264 did not contribute 
to the overall analyses due to variations in time points used to measure their primary 
outcome. 
Although all studies reported mean VAS measurements for pain intensity in addition 
to standard deviation, a number of studies had to be excluded following attempts to 
contact the authors because data relating to the primary outcome were presented 
unclearly, without standard deviations or in median and interquartile format (Abtahi 
200679; Arantes 200980; Bird 200781; Ngan 199482; Patel 201083; Sudhakar 201484; 
Young 200585). Data presented in standard error format were converted 
appropriately to present standard deviation. 
5.1.7.2: Secondary outcomes 
Rescue analgesia 
Use of rescue analgesia was reported in six studies (Bernhardt 200166; Bradley 
200760; Bruno 201177; Najafi 201571; Steen-Law 200034; Tunçer 201474). However, 
data relating to class and dose were not reported in any study, and timing was 
reported in only one study (Bradley 200760), despite all studies stating that patients 
were asked to record this information on the VAS questionnaires.  
Adverse events 
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Adverse events were only reported by Bradley 200760. All other studies did not 
mention adverse events. We therefore decided to report this outcome in narrative 
form.  
Quality of life and/or patient satisfaction 
Patient satisfaction was not reported for any study. The authors of one study 
reported quality of life assessed by the Short Form-36 Health Survey (SF-36) at 
baseline and 30 days and Self-Rating Anxiety Scale (SAS) at baseline and at 30 
days (Wang 201265). One study reported anxiety and depression status measured 
using the Hospital Anxiety and Depression Scale (HADS) (Yassaei 201264). One 
study reported affective states assessed with the State and Trait Anxiety Inventory 
(STAI) and the Positive Affect Negative Affect Schedule (PANAS) (Minor 200967). 
Time off school/work 
No studies reported this outcome. 
 
Withdrawal from the study 
Twelve studies reported withdrawal of participants for a variety of reasons. In some 
studies, is it was unclear if this withdrawal was a decision taken by the participant or 
the researchers. For the purposes of this review, in these cases all participants have 
been considered as withdrawal from the study. 
 
Failure to complete orthodontic treatment due to the pain experienced 
No studies reported this outcome. 
 
Response to treatment  
Response to treatment was defined as a reduction in pain by at least 50%. This was 
not reported in any study. 
5.1.8: Excluded Studies 
We excluded eighteen studies (See Appendix 2: Characteristics of excluded studies) 
from this review for the following reasons: 
 Confounding due to co-interventions and therefore not possible to attribute 
effect to specific analgesic (Ireland 201686; Murdock 201087). 
 Not a randomized controlled trial (RCT): systematic reviews (Angelopoulou 
201288; Ashley 201689;  Xiaoting 201090). 
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 Inadequate data presented to allow inclusion in analyses (Abtahi 200679; 
Arantes 200980; Bird 200781; Ngan 199482; Patel 201083; Sudhakar 201484; 
Young 200685). 
 Insufficient information in the abstract or trial registration record to allow 
inclusion (Cherubini 200391; Eslamian 201692; Moradinejad 201493; Ogata 
199994; Parks 200195; Rooke 201296). 
5.2: Risk of bias in included studies 
5.2.1: Allocation 
5.2.1.1: Random sequence generation 
Ten studies described an adequate method of random sequence generation 
(Bernhardt 200166; Bradley 200760; Bruno 201177; Farzanegan 201268; Gupta 201475; 
Kawamoto 201069; Najafi 201571; Oueshal 200963; Paganelli 199378; Wang 201265), 
including both information published in the papers and further information received 
via correspondence with the authors. These ten papers were therefore assessed as 
being at low risk of bias for this domain. The remaining twelve studies simply stated 
that participants were randomized, however either did not describe their methods, or 
the method remained unclear, so they were assessed as being at unclear risk of bias 
for this domain. 
5.2.1.2: Allocation concealment 
Eleven studies described an adequate method of allocation concealment (Bernhardt 
200166; Bradley 200760; Eslamian 201459; Gupta 201475; Kawamoto 201069; 
Kluemper 200261; Najafi 201571; Nik 201672; Oueshal 200963; Paganelli 199378; 
Wang 201265), including both information published in the papers and further 
information received via correspondence with the authors. These eleven papers 
were therefore assessed as being at low risk of bias for this domain. Ten of the 
remaining studies did not mention any methods used to conceal the random 
sequence, and we assessed them as being at unclear risk of bias. One study, 
through correspondence of the author, stated that the allocation was not concealed 
as so was assessed as being a high risk of bias for this domain (Bruno 201177). 
Overall, eight studies were at low risk of selection bias, meaning that we assessed 
both of the above domains as being at low risk of bias (Bernhardt 200166; Bradley 
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200760; Gupta 201475; Kawamoto 201069; Najafi 201571; Ousehal 200963; Paganelli 
199378; Wang 201265). 
5.2.2: Blinding 
5.2.2.1: Blinding of participants and personnel (performance bias) 
Fourteen studies described adequate methods of blinding of participants and 
personnel and were therefore assessed as being a low risk of bias for this domain 
(Bernhardt 200166; Bradley 200760; Eslamian 201459; Farzanegan 201268; Kawamoto 
201069; Kluemper 200261; Kohli 201176; Najafi 201571; Nik 201672; Polat March 
200548; Polat September 200573; Salmassian 200970; Steen-Law 200034; Tunçer 
201474). It was not possible to blind participants to the type of intervention allocated 
in four studies (Bruno 201177; Oueshal 200963; Paganelli 199378; Wang 201265). 
These four papers were therefore assessed as being at high risk of bias for this 
domain. The remaining four studies only stated that blinding was achieved however, 
they did not describe their methods and so they were assessed as being at an 
unclear risk of bias for this domain (Gupta 201475; Lauritano 200062; Minor 200967; 
Yassaei 201264). 
5.2.2.2: Blinding of outcome assessment (detection bias) 
Fourteen studies described an adequate method of blinding of outcome assessment 
(Bernhardt 200166; Bradley 200760; Bruno 201177; Eslamian 201459; Kawamoto 
201069; Kohli 201176; Najafi 201571; Nik 201672; Oueshal 200963; Paganelli 199378; 
Salmassian 200970; Steen-Law 200034; Wang 201265; Yassaei 201264). These 
fourteen papers were therefore assessed at being at low risk of bias for this domain. 
Eight studies only stated that blinding was achieved however, they did not describe 
their methods and so there were assessed as being at unclear risk of bias for this 
domain (Farzanegan 201268; Gupta 201475; Kluemper 200261; Lauritano 200062; 
Minor 200967; Polat March 200548; Polat September 200573; Tunçer 201474). 
5.2.3: Incomplete outcome data 
Five studies were at high risk of attrition bias (Bernhardt 200166; Bruno 201177; 
Kawamoto 201069; Najafi 201571; Steen-Law 200034) due to high numbers of attrition 
across the studies. The remaining seventeen studies had negligible or no attrition 
and were therefore assessed as being at low risk of attrition bias. 
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5.2.4: Selective reporting 
Two studies were at high risk of selective reporting bias. One of these studies did not 
report outcomes for all time points investigated (Lauritano 200062). The other did not 
report on the outcome of bite efficiency as measured with a modified mastication 
performance index (Minor 200967). One study was unclear about the time points at 
which outcomes were measured and therefore was assessed as unknown risk for 
selective reporting (Yassaei 201264). The remaining nineteen studies appropriately 
reported on all outcomes and were therefore assessed as being at low risk for this 
domain.  
5.2.5: Other potential sources of bias 
Six studies were assessed as high risk of other sources of bias a result of gender 
bias in sampling. Two of these papers recruited only female participants 
(Farzanegan 201268; Yassaei 201264); whilst the other four had large variations in 
the groups at baseline (Najafi 201571; Ousehal 200963; Tunçer 201474; Wang 
201265). The remaining sixteen studies were not considered to have any other 
potential sources of bias and were therefore assessed as being at low risk of bias for 
this domain.   
5.2.6: Overall risk of bias 
Only one study was assessed as being at low overall risk of bias (Bradley 200760). 
Eight studies were assessed as being at unknown overall risk of bias (Eslamian 
201459; Gupta 201475; Kluemper 200261; Kohli 201176; Nik 201672; Polat March 
200548; Polat September 200573; Salmassian 200970; Steen-Law 200034). The 
remaining thirteen studies were assessed as being at high overall risk of bias (Figure 
3 and Figure 4).
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Figure 3: Risk of bias summary: Review authors' judgements about each risk of bias item for each included study. 
 
 
 
 
 
 
 
 
 
P a g e  | 44 
 
 
 
 
Figure 4: Risk of bias graph: Review authors' judgements about each risk of bias item presented as percentages across all included 
studies. 
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5.3: Effects of interventions 
5.3.1: Comparison 1: Analgesic versus control (placebo or no treatment) 
Pain 
At 2 hours and 6 hours, ten studies were combined in a meta-analysis. Four of these 
studies (Bruno 201177; Farzanegan 201268; Kawamoto 201069; Minor 200967), were 
all at high risk of bias; whilst the remaining six studies (Eslamian 201459; Gupta 
201475; Kohli 201176; Nik 201672; Polat March 200548; Polat September 200573), 
were at an unknown risk of bias. In total, 607 participants were analysed, at 2 hours 
and 6 hours.  
At 24 hours, two additional studies (Tunçer 201474; Wang 201265), both at high risk 
of bias, resulted in a total of twelve studies being combined in a meta-analysis. In 
total, 964 participants were analysed for 24 hours. 
The meta-analysis showed that analgesics reduced mean pain intensity during 
orthodontic treatment at:  
 2 hours (Mean Difference (MD) -15.71, 95% confidence interval (CI) -20.75 to 
-10.68, P < 0.00001) (Figure 5);  
 6 hours (MD -24.33, 95% CI -30.71 to -17.95, P =< 0.00001) (Figure 6); and  
 24 hours (MD -24.33, 95% CI -30.71 to -17.95, P < 0.00001) (Figure 7) when 
compared to a control.  
However, there was moderate heterogeneity (I2 = 55%) at 2 hours and substantial (I2 
= 70%) heterogeneity at 6 and 24 hours. It was thought that this may be related in 
part to the methods relating to the orthodontic intervention carried out; which are 
explored in more detail in further analyses. 
Rescue analgesia 
Two studies in this subgroup (Bruno 201177; Tunçer 201474) reported that 
participants required rescue medication during the study. Tunçer 201474 reported 
that 2 participants required rescue medication; whilst Bruno 201177 reported 6 
participants required the use of analgesic medication during the study. No further 
information was available relating to class, dose or timing. 
Adverse events 
No studies in this subgroup reported any adverse events. 
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Quality of life and/or patient satisfaction 
One study (Wang 201265) reported quality of life assessed using SF-36 and found 
that, at 30 days, using the there was a significant alleviation in the scale of bodily 
pain, however there were no significant differences in other variables of the SF-36 
results among the three groups. The study also recorded SAS and found that the 
scores were not significantly different among the groups. 
One study (Minor 200967) reported quality of life assessed using STAI and PANAS 
and found that there were no significant differences between the treatment groups. 
Time off school/work 
No studies in this subgroup reported this outcome. 
Withdrawal from the study 
Eight studies in this subgroup experienced withdrawal from the study:  
 Polat March 200548 reported withdrawal of 22 participants who did not return 
questionnaires and 8 participants who were too old (>30 years old); n = 
30/150, 20%. 
 Salmassian 200970 reported withdrawal of 4 participants who did not return in 
a timely manner and 2 participants who withdrew consent after archwire 
placement; n = 6/66, 9.1%. 
 Tunçer 201474 reported withdrawal of 3 participants who did not return 
questionnaires; n = 3/46, 6%. 
 Bruno 201177 reported withdrawal of 18 participants who had missing or 
incomplete information, 2 participants who lost their diaries and were unwilling 
to continue, 6 participants who used analgesic medication during the study, 
and 10 participants who had discomfort due to elastics and sought treatment 
elsewhere; n = 36/87, 41.4%. 
 Eslamian 201459 reported withdrawal of 4 participants; however, the reason is 
only stated as ‘loss to follow-up’; n = 4/30, 13.3%. 
 Kawamoto 201069 reported withdrawal of 9 participants who failed to return 
questionnaires; n = 9/35, 25.7%. 
 Nik 201672 reported withdrawal of 8 participants who did not take the drug, 3 
participants who did not complete the questionnaires and 1 for reasons not 
discussed in the paper; n = 12/101, 12%. 
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 Wang 201265 reported withdrawal of 7 participants who did not wish to 
complete the follow-up questionnaire; 7 participants withdrew due to 
discomfort of orthodontic treatment; 4 who lost the questionnaires, 2 were 
withdrawn because thought they had not received treatment and 1 was 
withdrawn for an unknown reason; n = 21/450, 4.7%. 
All other studies included in this analysis experienced no withdrawal of participants. 
This amounted to a total withdrawal of 121 participants from a total of 964 
participants in this subgroup. 
Failure to complete orthodontic treatment due to the pain experienced 
No studies in this subgroup reported this outcome. 
Response to treatment 
No studies in this subgroup presented data in a way which facilitated assessment of 
this outcome. 
5.3.1.1: Paracetamol versus control 
At 2 hours and 6 hours, four studies were combined in a meta-analysis. Three of 
these studies (Gupta 201475; Nik 201672; Polat March 200548), were at an unknown 
risk of bias; whilst the remaining study (Kawamoto 201069) was at high risk of bias. In 
total, 107 participants were included in the meta-analysis, for 2 hours and 4 hours. 
At 24 hours, two additional studies were included in the meta-analysis. One of these 
studies (Tunçer 201474) was at high risk of bias; whilst the other study (Salmassian 
200970), was at an unknown risk of bias. In total, 161 participants were included in 
the meta-analysis for 24 hours.  
The meta-analysis showed that paracetamol reduced mean pain intensity during 
orthodontic treatment at:  
 2 hours (MD -11.90, 95% CI -18.36 to -5.44, P < 0.00001) (Figure 5);  
 6 hours (MD -19.34, 95% CI -24.80 to -13.88, P < 0.00001) (Figure 6); and  
 24 hours (MD -22.09, 95% CI -35.99 to -8.18, P < 0.00001) (Figure 7) when 
compared to a placebo.  
However, although there was no heterogeneity at 2 or 6 hours (I2 = 0%), at 24 hours 
there was substantial heterogeneity (I2 = 65%). It was thought that this may have 
been due in part to the methods relating to the orthodontic intervention; which have 
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been broken down further and explored in relation to the effect of the intervention on 
pain following separator placement and pain following placement of an initial 
archwire.  
In relation to separator placement, paracetamol was shown to be effective at 
reducing pain at 2 and 6 hours, however there was no difference in comparison with 
a control at 24 hours. Additionally, there was no heterogeneity at 2 or 6 hours (I2 = 
0%), however, the heterogeneity increased to considerable heterogeneity at 24 
hours (I2 = 76%) (Table 3).  
For archwire placement, paracetamol was shown to be effective at reducing pain at 
2, 6 and 24 hours. There was no heterogeneity at 2 hours (I2 = 0%), low 
heterogeneity, which may not be important, at 6 hours (I2 = 6%), but again, there was 
an increase to considerable heterogeneity at 24 hours (I2 = 85%) (Table 4). 
5.3.1.2: Local anaesthetic versus control 
One study (Kluemper 200261), at an unknown risk of bias, compared topical 
benzocaine wax with a placebo wax at initial archwire placement, analysing data 
from 70 patients. However, the data were recorded at time points not in keeping with 
those of interest in this review and therefore did not contribute to our analysis. 
One study (Eslamian 201459), at an unknown risk of bias, compared topical 
benzocaine chewing gum with a placebo chewing gum mid-treatment, analysing data 
from 36 participants. This showed that topical benzocaine chewing gum reduced 
mean pain intensity following tying-in of an archwire at:  
 2 hours (MD -35.00, 95% CI -49.4 to -20.54, P < 0.00001) (Figure 5);  
 6 hours (MD -24.33, 95% CI -30.71to -17.95, P < 0.00001) (Figure 6); and  
 24 hours (MD -24.33, 95% CI -30.71 to -17.95, P < 0.00001) (Figure 7), when 
compared to a placebo. 
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Figure 5: Forest plot of comparison 1: Analgesic versus control, outcome: 1.1 2 hours [Pain(VAS)]. 
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Figure 6: Forest plot of comparison 1: Analgesic versus control, outcome: 1.2 6 hours [Pain(VAS)].
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Figure 7: Forest plot of comparison 1: Analgesic versus control, outcome: 1.3 24 hours [Pain(VAS)]. 
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Table 3: Paracetamol versus control – separator placement [Pain(VAS)] 
Experimental Intervention Outcome 
No. of studies 
(no. of participants) 
Effect Measure MD  
(95% CI) 
P-value for effect P-value heterogeneity I2 (%) 
2 hours 
Paracetamol Pain VAS 2 (79) -11.51 (-19.15, -3.86) 0.003 0.77 0% 
6 hours 
Paracetamol Pain VAS 2 (79) -16.00 (-24.65, -7.34) 0.0003 0.38 0% 
24 hours 
Paracetamol Pain VAS 2 (79) -21.51 (-54.10, 11.09) 0.2 0.04 76% 
 
 
Table 4: Paracetamol versus control – initial archwire placement [Pain(VAS)] 
Experimental Intervention Outcome 
No. of studies 
(no. of participants) 
Effect Measure MD 
(95% CI) 
P-value for effect P-value heterogeneity I2 (%) 
2 hours 
Paracetamol Pain VAS 2 (70) -14.04 (-21.51, -6.58) 0.0002 0.88 0% 
6 hours 
Paracetamol Pain VAS 2 (70) -21.03 (-27.19, -14.87) < 0.00001 0.30 6% 
24 hours 
Paracetamol Pain VAS 4 (141) -21.55 (-40.42, -2.68) 0.03 0.0001 85% 
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5.3.1:3: Comparison 2: NSAID versus control 
At 2 hours and 6 hours, ten studies were combined in a meta-analysis. Four of these 
studies (Bruno 201177; Farzanegan 201268; Kawamoto 201069; Minor 200967), were 
all at high risk of bias; whilst the remaining six studies (Eslamian 201459; Gupta 
201475; Kohli 201176; Nik 201672; Polat March 200548; Polat September 200573), 
were at an unknown risk of bias. In total, 506 participants were analysed, for 2 hours 
and 6 hours.  
Eight different classes of NSAID’s were investigated across the twelve studies. 
Seven studies investigated ibuprofen (Farzanegan 201268; Kawamoto 201069; Kohli 
201176; Minor 200967; Nik 201672; Polat March 200548; Polat September 200573); two 
investigated naproxen sodium (Polat March 200548; Polat September 200573); one 
study investigated aspirin (Polat March 200548); one study investigated etoricoxib 
(Gupta 201475); one study investigated flurbiprofen (Polat March 200548); one study 
investigated lumiracoxib (Bruno 201177); one study investigated piroxicam (Kohli 
201176), and one investigated Ketoprofen in chewing gum form (Eslamian 201459). 
For the purposes of this review these have been analysed by subgroup by class and 
then combined to give an overall meta-analysis for the comparison. 
At 24 hours, twelve studies were combined in a meta-analysis. Five of these studies 
(Bruno 201177; Kawamoto 201069; Farzanegan 201268; Tunçer 201474, Wang 
201265), were all at high risk of bias; whilst the remaining seven studies (Eslamian 
201459; Gupta 201475; Kohli 201176; Nik 201672; Polat March 200548; Polat 
September 200573; Salmassian 200970), were at an unknown risk of bias. In total, 
817 participants were analysed for 24 hours. 
Again; eight different classes of NSAID’s were investigated across the twelve 
studies. Nine studies investigated ibuprofen (Kohli 201176; Kawamoto 201069; 
Farzanegan 201268; Polat March 200548; Polat September 200573; Nik 201672; 
Salmassian 200970; Tunçer 201474, Wang 201265); two investigated naproxen 
sodium (Polat March 200548; Polat September 200573); one study investigated 
aspirin (Polat March 200548); one study investigated etoricoxib (Gupta 201475); one 
study investigated flurbiprofen (Polat March 200548); one study investigated 
lumiracoxib (Bruno 201177); one study investigated piroxicam (Kohli 201176), and one 
investigated Ketoprofen in chewing gum form (Eslamian 201459).  
P a g e  | 54 
 
 
The meta-analysis showed that analgesics reduced mean pain intensity during 
orthodontic treatment at 2 hours (MD -15.22, 95% CI -21.49 to -8.96], P < 0.00001) 
(Figure 8); 6 hours (MD -15.22, 95% CI -21.49 to -8.96, P =< 0.00001) (Figure 9); 
and 24 hours (MD -24.33, 95% CI -30.71 to -17.95, P < 0.00001) (Figure 10) when 
compared to a control. However there was substantial heterogeneity (I2 = 67%) at 2 
hours, and considerable heterogeneity at 6 hours (I2 = 77%) and at 24 hours (I2 = 
82%). It was again thought that this may have been due in part to the methods 
relating to orthodontic intervention; which have been broken down further and 
explored in relation to the effect of the intervention on pain following separator 
placement, placement of an initial archwire or the effect on pain mid-treatment. In 
relation to separator placement, NSAIDs were shown to be effective at reducing pain 
at 2, 6 and 24 hours, in comparison with a control. The results for heterogeneity 
improved, with low heterogeneity which may not be important at 2 hours (I2 = 23%), 
no heterogeneity at 6 hours (I2 = 0%), and moderate heterogeneity at 24 hours (I2 = 
42%) (Table 5). For archwire placement, NSAIDs were shown to be effective at 
reducing pain at 2, 6 and 24 hours, in comparison with a control. However 
heterogeneity remained with moderate heterogeneity at 2 hours (I2 = 47%), low 
heterogeneity (I2 = 10%), and considerable heterogeneity at 24 hours (I2 = 85%) 
(Table 6).  In relation to mid-treatment patients, NSAIDs, in the form of ketoprofen 
chewing gum, were shown to be effective at reducing pain at 2, 6 and 24 hours, in 
comparison with a control (Table 7).
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Figure 8: Forest plot of comparison 2: NSAID versus control, outcome: 2.1 2 hours [Pain(VAS)]. 
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Figure 9: Forest plot of comparison 2: NSAID versus control, outcome: 2.2 6 hours [Pain(VAS)]. 
 
P a g e  | 57 
 
 
Figure 10: Forest plot of comparison 2: NSAID versus control, outcome: 2.3 24 hours [Pain(VAS)]. 
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Table 5: Ibuprofen versus control – separator placement [Pain(VAS)] 
 
Experimental Intervention Outcome 
No. of studies  
(no. of participants) 
Effect Measure MD  
(95% CI) 
P-value for effect P-value heterogeneity I2 (%) 
2 hours 
Ibuprofen 
Pain VAS 
4 (152) -12.80 (-17.59 to -8.01) <0.00001 0.91 0% 
Lumiracoxib 1 (51) -5.32 (-112.20 to 1.56) 0.13 0.73 0% 
Piroxicam 1 (45) -29.70 (-48.01, -11.39) 0.001 N/A N/A 
Subtotal 5 (248) -11.10 (-15.78, -6.42) <0.00001 0.25 23% 
6 hours 
Ibuprofen 
Pain VAS 
4 (150) -23.41 (-41.43, -5.39) 0.01 0.0001 86% 
Lumiracoxib 1 (51) -7.06 (-16.55, 2.43) 0.14 0.67 0% 
Piroxicam 1 (45) -40.50 (-57.37, -23.63) <0.00001 N/A N/A 
Subtotal 5 (248) -8.80 (-13.47 to -4.12) 0.0002 0.97 0% 
24 hours 
Ibuprofen  3 (118) -21.85 (-37.33, -6.37) 0.006 0.07 62% 
Lumiracoxib  1 (51) -17.58 (-31.62, -3.54) 0.01 0.57 0% 
Piroxicam  1 (45) -36.10 (-51.33, -20.87) <0.00001 N/A N/A 
Subtotal  4 (214) -23.66 (-32.81, -14.51) <0.00001 0.12 42% 
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Table 6: Ibuprofen versus control – initial archwire placement [Pain(VAS)] 
Experimental Intervention Outcome 
No. of studies  
(no. of patients) 
Effect Measure MD  
(95% CI) 
P-value for effect P-value heterogeneity I2 (%) 
2 hours 
Aspirin 
Pain VAS 
1 (25) -26.20 (-56.37, 3.97) 0.09 N/A N/A 
Etoricoxib 1 (30) -32.00 (-38.09 to -25.91) <0.00001 N/A N/A 
Flurbiprofen 1 (25) -21.00 (-51.34, 9.34) 0.17 N/A N/A 
Ibuprofen 3 (75) -6.02 (-20.52, 8.47) 0.42 0.45 0% 
Naproxen Sodium 2 (55) -20.80 (-39.42, -2.18) 0.03 0.55 0% 
Subtotal 4 (210) -19.23 (-29.90, -8.56) 0.0004 0.07 47% 
6 hours 
Aspirin 
Pain VAS 
1 (25) -39.30 (-69.71, -8.89) 0.01 N/A N/A 
Etoricoxib 1 (30) -41.00 (-46.77 to -35.23) < 0.00001 N/A N/A 
Flurbiprofen 1 (25) -22.00 (-52.86, 8.86) 0.16 N/A N/A 
Ibuprofen 3 (75) -20.87 (-35.21, -6.52) 0.004 0.91 0% 
Naproxen Sodium 2 (55) -36.87 (-54.82, -18.92) < 0.0001 0.84 0% 
Subtotal 4 (210) -35.42 (-42.15, -28.68) < 0.00001 0.35 10% 
24 hours 
Aspirin 
Pain VAS 
1 (25) -41.20 (-71.99, -10.41) 0.09 N/A N/A 
Etoricoxib 1 (30) -54.00 (-60.34 to -47.66) <0.00001 N/A N/A 
Flurbiprofen 1 (25) -10.40 (-41.69, 20.89) 0.51 N/A N/A 
Ibuprofen 6 (420) -19.71 (-33.60, -5.82) 0.005 0.004 71% 
Naproxen Sodium 2 (55) -28.61 (-66.08, 8.86) 0.13 0.05 75% 
Subtotal 7 (555) -26.26 (-37.81, -14.71) < 0.0001 < 0.00001 85% 
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Table 7: NSAID versus control – mid-treatment [Pain (VAS)] 
Experimental Intervention Outcome 
No. of studies 
(no. of patients) 
Effect Measure MD 
(95% CI) 
P-value for effect P-value heterogeneity I2 (%) 
2 hours 
Ketoprofen (chewing gum) Pain VAS 1 (48) MD -22.00 (-36.14, -7.86) 0.002 N/A N/A 
6 hours 
Ketoprofen (chewing gum) Pain VAS 1 (48) MD -40.50 (-57.37, -23.63) <0.00001 N/A N/A 
24 hours 
Ketoprofen (chewing gum) Pain VAS 1 (48) MD -40.50 (-57.37, -23.63) <0.00001 N/A N/A 
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5.3.2: Comparison 3: NSAID versus paracetamol 
Pain 
At 2 hours and 6 hours, seven studies were combined in a meta-analysis. Three of 
these studies (Kawamoto 201069; Najafi 201571; Ousehal 200963), were at high risk 
of bias; three studies (Gupta 201475; Nik 201672; Polat March 200548), were at an 
unknown risk of bias; and one study was assessed as low risk of bias (Bradley 
200760). In total, 664 participants were analysed, for 2 hours and 6 hours.  
At 24 hours, nine studies were combined in a meta-analysis. Four of these studies 
(Kawamoto 201069; Najafi 201571; Tunçer 201474; Ousehal 200963), were all at high 
risk of bias; four studies (Gupta 201475; Nik 201672; Polat March 200548; Salmassian 
200970), were at an unknown risk of bias; and one study was assessed as low risk of 
bias (Bradley 200760).  In total, 734 participants were analysed for 24 hours. 
Six different classes of NSAIDs were investigated across the nine studies. Eight 
studies investigated ibuprofen (Bradley 200760; Kawamoto 201069; Najafi 201571; Nik 
201672; Ousehal 200963; Polat March 200548; Salmassian 200970; Tunçer 201474). 
One study investigated each of the following: aspirin (Polat March 200548), Etorixocib 
(Gupta 201475), Flurbiprofen (Polat March 200548), meloxicam (Najafi 201571), and 
naproxen sodium (Polat March 200548).  For the purposes of this review these have 
been analysed by subgroup, by class and then combined to give an overall meta-
analysis for the comparison. 
The meta-analysis showed that, although the results favoured NSAIDs slightly for the 
reduction of mean pain intensity during orthodontic treatment at 2 hours and 6 hours, 
there was no significant difference at:  
 2 hours (MD -2.92, 95% CI -8.48 to 2.65, P 0.30) (Figure 11);  
 6 hours (MD -5.17, 95% CI -11.71 to 1.37, P =< 0.12) (Figure 12); and  
 24 hours (MD -0.51, 95% CI -8.93 to 7.92, P < 0.91) (Figure 13) when 
compared to paracetamol.  
However, there was substantial heterogeneity (I2 = 63%) at 2 hours, and 
considerable heterogeneity at 6 hours (I2 = 72%) and at 24 hours (I2 = 82%). It was, 
again, thought that this may have been due in part to the methods relating to 
orthodontic intervention; which have been broken down further and explored in 
relation to the effect of the intervention on pain following separator placement and 
placement of an initial archwire.  
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In relation to separator placement, NSAIDs were shown to be no more effective at 
reducing pain at 2, 6 and 24 hours, in comparison with paracetamol. The results for 
heterogeneity improved, with low heterogeneity, which may not be important at 2 
hours (I2 = 6%), moderate heterogeneity at 6 hours (I2 = 40%), and no heterogeneity 
at 24 hours (I2 = 0%) (Table 8).  
For archwire placement, NSAIDs were also shown to be no more effective at 
reducing pain at 2, 6 and 24 hours, in comparison with paracetamol. Heterogeneity 
in these results remained, with substantial heterogeneity at 2 hours (I2 = 73%) and 6 
hours (I2 = 63%), and considerable heterogeneity at 24 hours (I2 = 82%) (Table 9).   
Rescue analgesia 
Two studies in this subgroup (Bradley 200760; Najafi 201571) reported that 
participants required rescue medication during the study. Bradley 200760 reported 
that 18 participants required rescue medication. The percentages of subjects who 
took additional analgesia were 9% (7 patients) in the paracetamol group and 14% 
(11 patients) in the ibuprofen group (P = 0 37 with the chi-square test for 
association). The study states that ‘the additional analgesics were most often taken 
at bedtime or on day one after separator placement’ however, no additional 
information was available regarding class, dose or specific timing. Najafi 201571 
reported 18 patients used other analgesics during the time. No further information 
was available relating to class, dose or timing. 
Adverse events 
One study (Bradley 200760) reported one participant (<1%) experienced a suspected 
adverse reaction. Further information was provided in an additional paper97 detailing 
an incident involving a 12-year-old male with no relevant medical history and no 
history of drug allergy. “Following 2 doses of the intervention analgesia, the patient 
was still experiencing discomfort and self-medicated with 1000 mg of paracetamol. 
Several hours later he suddenly developed a rash on all parts of his body described 
as ‘red, blotchy and itchy’. There were no other symptoms. The patient attended his 
GMP the following day and was prescribed a course of anti-histamines. He did not 
report the adverse reaction to the trial coordinators until 1 week after the trial drugs 
were given, at which time the rash had completely resolved and the patient was 
symptom-free. A provisional diagnosis of drug hypersensitivity to either the trial drug 
or to the paracetamol was made. Since one of the trial drugs was also paracetamol 
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we decided to break the randomization code for this patient to determine which drug 
the patient had received. The trial drug given was found to be paracetamol, 
suggesting a drug hypersensitivity reaction to paracetamol. Before a controlled Drug 
Provocation Test (DPT) could be organized, the patient took another dose of 
paracetamol on the advice of his GMP. On this occasion there was no reaction to the 
drug, suggesting a previous false positive result. Since the patient had already taken 
paracetamol without event, the DPT was deemed unnecessary.98” 
Quality of life and/or patient satisfaction 
No studies in this subgroup reported this outcome. 
Time off school/work 
No studies in this subgroup reported this outcome. 
Withdrawal from the study 
Seven studies in this subgroup experienced withdrawal of participants from the 
study: 
 Polat March 200548 reported withdrawal of 22 participants who did not return 
questionnaires and 8 participants who were too old (>30 years old); n = 
30/150, 20%. 
 Salmassian 200970 reported withdrawal of 4 participants who did not return in 
a timely manner and 2 participants who withdrew consent after archwire 
placement; n = 6/66, 9.1%. 
 Tunçer 201474 reported withdrawal of 3 participants who did not return 
questionnaires; n = 3/46, 6%. 
 Bradley 200760 reported withdrawal of 9 participants who did not return 
questionnaires, and 19 participants who did not fulfil inclusion criteria; n = 
28/187, 15%. 
 Najafi 201571 reported withdrawal of 46 participants who did not complete the 
questionnaire correctly, 16 who did not return questionnaires and 18 
participants who took additional analgesics; n = 80/321, 25%. 
 Kawamoto 201069 reported withdrawal of 9 participants who failed to return 
questionnaires; n = 9/35, 25.7%. 
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 Nik 201672 reported withdrawal of 8 participants who did not take the drug, 3 
participants who did not complete the questionnaires and 1 for reasons not 
discussed in the paper; n = 12/101, 12%. 
All other studies included in this analysis experienced no withdrawal of participants. 
This amounted to a total withdrawal of 168 participants from a total of 734 
participants in this subgroup. 
Failure to complete orthodontic treatment due to the pain experienced 
No studies in this subgroup reported this outcome. 
Response to treatment 
No studies in this subgroup presented data in a way which facilitated assessment of 
this outcome. 
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Figure 11: Forest plot of comparison 3: NSAID versus paracetamol, outcome: 3.1 2 hours [Pain(VAS)]. 
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Figure 12: Forest plot of comparison 3: NSAID versus paracetamol, outcome: 3.2 6 hours [Pain(VAS)]. 
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Figure 13: Forest plot of comparison 3: NSAID versus paracetamol, outcome: 3.3 24 hours [Pain(VAS)]. 
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Table 8: NSAID versus paracetamol – separator placement [Pain (VAS)] 
Experimental Intervention Outcome 
No. of studies  
(no. of patients) 
Effect Measure MD (95% CI) P-value for effect P-value heterogeneity I2 (%) 
2 hours 
Ibuprofen 
Pain VAS 
4 (351) -3.36 (-7.00, 0.28) 0.07 0.46 0% 
Meloxicam 1 (127) 1.40 (-4.89, 7.69) 0.66 N/A N/A 
Subtotal 4 (478) -2.16 (-5.44, 1.12) 0.20 0.37 6% 
6 hours 
Ibuprofen 
Pain VAS 
4 (351) -4.53 (-10.23, 1.18) 0.12 0.14 44% 
Meloxicam 1 (127) 0.50 (-6.85, 7.85) 0.89 N/A N/A 
Subtotal 4 (478) -3.35 (-8.05, 1.35) 0.16 0.15 40% 
24 hours 
Ibuprofen 
Pain VAS 
4 (351) 1.38 (-3.22, 5.98) 0.56 0.71 0% 
Meloxicam 1 (127) -0.30 (-11.40, 10.80) 0.96 N/A N/A 
Subtotal 4 (478) 1.14 (-3.11, 5.39) 0.60 0.83 0% 
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Table 9: NSAID versus paracetamol – initial archwire placement [Pain (VAS)] 
Experimental 
Intervention 
Outcome 
Number of studies (number of 
patients) 
Effect Measure MD 
(95% CI) 
P-value for 
effect 
P-value 
heterogeneity 
I2 
(%) 
2 hours 
Aspirin 
Pain VAS 
1 (25) -10.90 (-35.87, 14.07) 0.39 N/A N/A 
Etoricoxib 1 (30) -20.00 (-28.42, -11.58) < 0.00001 N/A N/A 
Flurbiprofen 1 (40) -5.70 (-20.82, 9.42) 0.46 N/A N/A 
Ibuprofen 2 (81) 14.63 (0.77, 28.50) 0.04 0.97 0% 
Naproxen Sodium 1 (25) 2.50 (-24.63, 29.63) 0.86 N/A N/A 
Subtotal 3 (201) -2.230 (-16.06, 11.61) 0.75 0.002 73% 
6 hours 
Aspirin 
Pain VAS 
1 (25) -8.70 (-36.03, 18.63) 0.53 N/A N/A 
Etoricoxib 1 (30) -21.00 (-27.09, -14.91) < 0.00001 N/A N/A 
Flurbiprofen 1 (40) 8.60 (-19.23, 36.43) 0.54 N/A N/A 
Ibuprofen 2 (81) 4.10 (-10.28, 18.48) 0.58 0.88 0% 
Naproxen Sodium 1 (25) -9.00 (-37.89, 19.89) 0.54 N/A N/A 
Subtotal 3 (201) -5.66 (-18.97, 7.64) 0.40 0.02 63% 
24 hours 
Aspirin 
Pain VAS 
1 (25) 5.10 (-20.77, 30.97) 0.70 N/A N/A 
Etoricoxib 1 (30) -22.00 (-27.06, -16.94) < 0.00001 N/A N/A 
Flurbiprofen 1 (25) 35.90 (9.44, 62.36) 0.008 N/A N/A 
Ibuprofen 4 (151) -1.36 (-13.04, 10.33) 0.82 0.21 33% 
Naproxen Sodium 1 (25) -2.60 (-27.11, 21.91) 0.84 N/A N/A 
Subtotal 5 (256) -0.37 (-14.41, 13.67) 0.96 < 0.00001 82% 
P a g e  | 70 
 
 
5.3.3: Comparison 4: NSAID pre-emptive versus NSAID post-treatment 
Pain 
Two studies (Bernhardt 200166; Steen-Law 200034), at high risk of bias, compared 
ibuprofen taken pre-emptively with ibuprofen taken post-treatment for the placement 
of separators, analysing 69 participants. This showed that pre-emptive ibuprofen 
reduced mean pain intensity following separator placement at 2 hours (MD -11.33, 
95% CI -16.09 to -6.58, P < 0.00001) (Figure 14) when compared with ibuprofen 
taken post-treatment. However there was no difference at 6 hours (MD -8.43, MD -
30.37 to 13.50, P < 0.45) (Figure 15); or 24 hours (MD -9.74, 85% CI -47.88 to 
28.40, P < 0.62) (Figure 16), when compared to ibuprofen taken post-treatment. 
Additionally, although there was no heterogeneity at 2 hours (I2 = 0%), there was 
substantial heterogeneity at 6 hours (I2 = 72%), and considerable heterogeneity at 24 
hours (I2 = 87%).  
Rescue analgesia 
Both studies in this subgroup reported that participants required rescue medication 
during the study. One study (Bernhardt 200166) reported 22 participants required 
additional analgesics during the study. Although the study stated that these 22 
patients were evenly distributed among the 3 groups in the study, no further 
information was available relating to class, dose or timing and participants from 
group A did not contribute to the analysis in this review. 
One study (Steen-Law 200034) reported 17 participants required additional 
analgesics during the study, 4 in the pre-emptive ibuprofen group; 6 in the post-
treatment ibuprofen group and 7 in the control group, who did not contribute to the 
analysis in this review. No further information was available relating to class, dose or 
timing. 
Adverse events 
No studies in this subgroup reported any adverse events. 
Quality of life and/or patient satisfaction 
No studies in this subgroup reported this outcome. 
Time off school/work 
No studies in this subgroup reported this outcome. 
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Withdrawal from the study 
One study in this subgroup experienced withdrawal of 3 participants who did not 
return questionnaires (Steen-Law 200034). 
The other study included in this analysis experience no withdrawal of participants. 
Failure to complete orthodontic treatment due to the pain experienced 
No studies in this subgroup reported this outcome. 
Response to treatment 
No studies in this subgroup presented data in a way that facilitated assessment of 
this outcome. 
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Figure 14: Forest plot of comparison 4: NSAID pre-emptive versus post-treatment, outcome: 4.1 2hrs[Pain (VAS)]. 
 
 
Figure 15: Forest plot of comparison 4: NSAID pre-emptive versus post-treatment, outcome: 4.2 6hrs[Pain (VAS)]. 
 
 
Figure 16: Forest plot of comparison 4: NSAID pre-emptive versus post-treatment, outcome: 4.3 24hrs[Pain (VAS)]. 
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5.3.5: Comparison 5: NSAID versus local anaesthetic 
Pain 
One study (Eslamian 201459) at unknown risk of bias, compared ketoprofen chewing 
gum with benzocaine chewing gum, for the relief of pain mid-treatment, analysing 48 
participants. This showed that ketoprofen (NSAID) chewing gum did not reduce 
mean pain intensity mid-treatment at: 
 2 hours (MD -11.33, 95% CI -16.09 to -6.58, P 0.12) (Figure 17);  
 6 hours (MD -8.43,95% CI -30.37 to 13.50, P 0.33) (Figure 18); or  
 24 hours (MD -9.74, 95% CI -47.88 to 28.40, P 0.26) (Figure 19) when 
compared to benzocaine (local anaesthetic) chewing gum. 
Adverse events 
No studies in this subgroup reported any adverse events. 
Quality of life and/or patient satisfaction 
No studies in this subgroup reported this outcome. 
Time off school/work 
No studies in this subgroup reported this outcome. 
Withdrawal from the study 
The study included in this subgroup reported withdrawal of 4 participants, however 
the reason was only stated as lost to follow-up. 
Failure to complete orthodontic treatment due to the pain experienced 
No studies in this subgroup reported this outcome. 
Response to treatment 
No studies in this subgroup presented data in a way that facilitated assessment of 
this outcome. 
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Figure 17: Forest plot of comparison 5: NSAID versus local anaesthetic, outcome: 5.1 2hrs[Pain (VAS)]. 
 
 
Figure 18: Forest plot of comparison 5: NSAID versus local anaesthetic, outcome: 5.2 6hrs[Pain (VAS)]. 
 
 
Figure 19: Forest plot of comparison 5: NSAID versus local anaesthetic, outcome: 5.3 24hrs[Pain (VAS)]. 
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5.3.6: Comparison 6: Paracetamol versus calcium 
Pain 
One study (Yassaei 201264), at high risk of bias, compared paracetamol and calcium 
for the relief of pain mid-treatment, analysing 40 participants. However data were 
recorded at baseline and 4 days after treatment and therefore did not contribute to 
our analysis. 
Adverse events 
No studies in this subgroup reported any adverse events. 
Quality of life and/or patient satisfaction 
This study reported psychotic status as measured using the HADS. The reported 
mean and maximum HADS was 11.28 and 19 in the calcium group. The mean and 
maximum HADS was 10.52 and 20 in the acetaminophen group. The minimum 
HADS in both groups was 2. There was no significant difference between the mean 
HAD scale of the two groups before or after intervention. 
Time off school/work 
No studies in this subgroup reported this outcome. 
Withdrawal from the study 
There was no withdrawal from the study included in this analysis. 
Failure to complete orthodontic treatment due to the pain experienced 
No studies in this subgroup reported this outcome. 
Response to treatment 
No studies in this subgroup presented data in a way that facilitated assessment of 
this outcome. 
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Chapter 6: Discussion 
6.1: Summary of main results 
Twenty-two randomised controlled trials (RCTs) met our eligibility criteria and were 
included in this review. We assessed the body of evidence for each comparison and 
outcome and performed a meta-analysis where appropriate for the main outcome of 
pain intensity at 2 hours, 6 hours and 24 hours after orthodontic treatment. All data 
were measured using a Visual Analogue Scale (VAS) with most studies comparing 
the effectiveness of drug interventions following either placement of separators or 
placement of an initial aligning archwire. 
 
Analgesic versus control 
We found evidence that analgesics were effective at reducing pain intensity at 2 
hours, 6 hours and 24 hours following orthodontic treatment.  
Subgroup analysis by drug type found that paracetamol, NSAIDs and local 
anaesthetic were all effective at reducing pain intensity at 2 hours, 6 hours and 24 
hours when compared with either a placebo or control group.  
When further subgroup analyses were performed, grouping the data by orthodontic 
intervention carried out: 
 NSAIDs were found to be significantly more effective at reducing pain 
intensity when compared with a control group at all time points, regardless of 
the orthodontic intervention.  
 Paracetamol was found to be significantly more effective at reducing pain 
intensity when compared with a control group at all time points when an initial 
archwire was placed; however, was effective only at 2 hours and 6 hours 
following placement of separators. By 24 hours, there was no significant 
difference between the effectiveness of paracetamol or a control group on 
pain intensity following the placement of separators. 
 
NSAID versus paracetamol 
We found no statistically significant difference between the effective of NSAIDs and 
paracetamol at reducing pain intensity at 2 hours, 6 hours or 24 hours following 
either the placement of separators or placement of an initial aligning archwire. 
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Subgroup analysis by class of NSAID found weak evidence based on one study 
(Gupta 201475) that etoricoxib was significantly better than paracetamol at reducing 
pain at 2 hours, 6 hours and 24 hours following placement of an initial archwire. 
However, due to the size of the study and its risk of bias, no recommendation can be 
made to support one drug over the other. 
Similarly, we found weak evidence based on one study (Polat March 200548) that 
flurbiprofen was significantly better than paracetamol at reducing pain at 2 hours, 6 
hours and 24 hours following placement of an initial archwire. However, due to the 
size of the study and its risk of bias, no recommendation can be made to support 
one drug intervention over the other. 
 
Pre-emptive NSAID versus post-treatment NSAID 
We found some evidence that ibuprofen taken 1 hour prior to separator placement 
significantly reduces pain intensity at 2 hours when compared to ibuprofen taken 
post-treatment. Worth noting is that this effect at 2 hours was seen, even when 
ibuprofen was taken immediately after treatment. However, at 6 hours and 24 hours, 
there was no significant difference detected.  
 
NSAID versus local anaesthetic 
One study (Eslamian 201459) compared the use of topical ketoprofen chewing gum 
(NSAID) with benzocaine chewing gum (local anaesthetic). This small study showed 
no significant difference between the pain intensity following treatment when either 
ketoprofen or benzocaine are taken and therefore no recommendation can 
be made to support one intervention over the other. 
 
Paracetamol versus calcium 
There was insufficient evidence to determine whether there was a difference 
between the outcomes reported in a comparison between paracetamol and calcium  
from the single small study which evaluated this comparison.  
6.2: Potential biases and limitations of the studies 
Bias has been reduced in this systematic review by using a broad, sensitive search 
of multiple databases with no restrictions on language. We have also searched for 
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unpublished studies and data, and have included studies reported in all languages. 
However numerous potential biases have been detected, both within and between, 
individual studies included in this review.  
Seven studies had to be excluded from the analysis (Arantes 200980; Ngan 199482; 
Abtahi 200679; Bird 200781; Patel 201083; Sudhakar 201484; Young 200685) due to 
inconsistencies or inappropriately presented data which would have otherwise led to 
inclusion in the meta-analysis of the comparisons relating to analgesics versus 
control and NSAID versus paracetamol.  
Data were not presented in any study to allow for analysis of the secondary outcome 
of response to treatment. Additionally, data were not presented in any study relating 
to the class, dose or specific timing of rescue analgesia taken, despite being 
recorded in six studies. This presents a potential bias and limitation as it may be that 
one intervention required more additional analgesics than another, ultimately 
influencing their pain intensity that has otherwise been attributed to the trial 
intervention. 
A number of included studies had small sample sizes, which in some cases did not 
reach the number required to detect a difference based on the sample size 
calculations. Additionally, multiple studies with three or more arms required the 
sample sizes to be split for purposed of comparison. The control arm sample size 
was split for the comparison of analgesics versus control in ten studies (Bruno 
201177; Eslamian 201459; Gupta 201475; Kawamoto 201069; Kohli 201176; Nik 201672; 
Polat March 200548; Polat September 200573; Salmassian 200970; Tunçer 201474). 
The paracetamol arm sample size was split for the head-to-head comparison of 
NSAIDs versus paracetamol in two studies (Najafi 201571; Polat March 200548). This 
resulted in small numbers of participants and wide confidence intervals in the final 
analysis which may have impacted on the overall outcome.  
Another limitation of the studies was heterogeneity, which was identified in varying 
degrees across all comparisons. Of note are the: 
 Moderate heterogeneity for analgesics versus control at 2 hours;  
 Substantial heterogeneity for:  
o analgesics versus control at 6 hours and 24 hours;  
o NSAIDs versus control at 2 hours;  
o NSAID versus paracetamol at 2 hours and  
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o pre-emptive versus post-treatment NSAIDs at 6 hours; and 
 Considerable heterogeneity for:  
o paracetamol versus control at 24 hours;  
o NSAIDs versus control at 6 hours and 24 hours;  
o NSAID versus paracetamol at 6 hours and 24 hours and  
o pre-emptive versus post-treatment NSAIDs at 24 hours.  
The cause of this was thought to be both clinical heterogeneity, relating to individual 
variations in participant responses to pain, particularly in those studies which 
recruited only female participants; differences in methodology relating to class and 
timing of interventions and small sample sizes; and statistical heterogeneity, due to 
the overall pooling of data and the large number of studies included in the meta-
analyses. Further sub-group analyses, by orthodontic intervention, were carried out 
to determine if this was the cause for the heterogeneity and, although it did account 
for some heterogeneity, by reducing the I2 in most cases by some extent, 
heterogeneity still remained. It was felt that further subgroup analysis to try and 
account for heterogeneity, for example by timing of intervention, was not appropriate 
due to the small number of studies. We therefore allowed for the heterogeneity by 
using a random effects model. 
 
6.3: Agreements and disagreements with other studies or reviews 
Three other reviews were found that reported on similar comparisons and outcomes 
to this review (Angelopoulou 201288; Ashley 201689; Xiaoting 201090). Angelopoulou 
201288 and Xiaoting 201090 report the efficacy of ibuprofen with lower confidence 
than we have reported. Although each of these reviews found a significant difference 
between ibuprofen when compared with a control, Angelopoulou 201288 found it was 
only significant at 2 hours and 6 hours following placement of separators or an initial 
aligning archwire, whilst Xiaoting 201090 reported the difference as significant only at 
6 hours and 24 hours following placement an initial aligning archwire. The difference 
in confidence is due to the greater number of studies that we have included in our 
systematic review when compared to the previous reviews. This is most likely due to 
the publication of several studies within the last few years since the other reviews 
were published. 
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Additionally, Xiaoting 201090 reports that there was no difference in pain control 
between ibuprofen and paracetamol, supporting the findings of this review. 
The Cochrane review by Ashley 201689 reports the efficacy of pre-emptive ibuprofen 
at 2 hours, which supports our conclusion that pre-emptive ibuprofen is effective at 
reducing pain following treatment. However, unlike this review, they did not 
investigate the effectiveness at any additional time points beyond 2 hours.  
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Chapter 7: Authors Conclusions 
7.1: Implications for practice 
There is moderate to low quality evidence that the use of analgesics reduces the 
pain associated with orthodontic treatment.  
Due to the lack of evidence we remain uncertain as to whether the use of systemic 
NSAIDs or paracetamol is more effective, or whether the use of topical NSAIDs or 
local anaesthetic is more effective at reducing pain associated with orthodontic 
treatment.   
There is low quality evidence that the use of pre-emptive ibuprofen, taken 1 hour 
before orthodontic treatment, significantly reduces pain up to 2 hours after treatment, 
however the effect appears to reduce over time and is no longer significant at 6 
hours and beyond. 
7.2: Implications for research 
In view of the quality of the studies identified in this systematic review, it has been 
difficult to draw definitive conclusions as to the best drug to recommend to patients 
and whether taking an analgesic before treatment is effective.  
The results of this review imply that there is a need for more long-term, well 
designed and reported randomised controlled clinical studies to assess the efficacy 
of drug interventions with relation to NSAIs and paracetamol. 
When designing future studies, the following need to be considered: 
 Clear inclusion and exclusion criteria should be set, taking into consideration 
factors which can effect patient’s perception of pain, particularly gender. 
 An a priori sample size calculation should be carried out. 
 Adequate reporting of rescue analgesics taken by participants in each arm of 
the trial. We recommend the following: 
o Type of drug taken; 
o Dose of drug taken; 
o Time at which drug was taken. 
 Adverse effects should be reported; and if none were encountered, this 
should be recorded. 
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 Reports of clinical trials would be improved by following the guidelines 
produced by the CONSORT group to ensure that all relevant information is 
provided. 
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Appendix 1: Characteristic of Studies (ordered by ID) 
 
Bernhardt 2001 
Methods Setting: University of Iowa, College of Dentistry, Department of 
Orthodontics. 
Design: Parallel RCT (3 arms). 
Number of centres: 1. 
Study duration: Not reported. 
 
Participants Inclusion criteria: (1) Scheduled to begin comprehensive orthodontic 
treatment,;(2) No prophylactic 
antibiotic coverage required; (3) No debilitating systemic diseases; (4) 
Currently not using antibiotics or 
analgesics; (5) No contraindication to the use of ibuprofen; and (6) A 
maximum age of 16 years and a minimum weight requirement of 88 
pounds (the weight requirement was based on Food and Drug 
Administration–approved over-the-counter pediatric dosage labelling 
guidelines). 
Exclusion criteria: None outlined in the methods however later 
excluded participants who did not agree to participate, did not return 
completed questionnaire or those who took additional "rescue" 
medication. 
Orthodontic intervention: Separator placement. 
Patient Sampling: 
n=114 recruited and randomised; 
n=63 returned their completed questionnaire; 
n=22 excluded from analysis for taking additional medication (evenly 
distributed between the 3 groups); 
n=41 data analysed for (aged 9 yrs 3 months - 16 yrs 11 months); 
Gp 1 (n=13) 10 male:3 female, mean age 12.1 + 1.6; 
Gp 2 (n=14) 4 male:10 female, mean age 13.5 + 1.9; 
Gp 3 (n=14) 6 male:8 female, mean age12.8 + 1.5. 
 
Interventions NSAID versus placebo/pre-emptive versus post-emptive 
Ibuprofen (400mg) vs. control (lactose placebo); 
Gp 1: Ibuprofen 1hr before placement, followed by ibuprofen 6hrs after 
initial dose. 
Gp 2: Ibuprofen 1hr before placement, followed by placebo 6hrs after 
initial dose. 
Gp 3: Placebo 1hr before placement, followed by ibuprofen 6hrs after 
initial dose. 
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded at 2, 6, 
10/bedtime (Primary outcome), 17/awakening, 24 hours and 2, 3 and 7 
days (secondary outcome) after separator placement. 
Pain was recorded during the following activities: 
 Chewing. 
 Biting [Not an outcome of this review]. 
 Fitting back teeth together [Not an outcome of this review]. 
 Fitting front teeth together [Not an outcome of this review]. 
 
Notes Conflict of interests/funding: No source of funding reported. 
Adverse events/Harm: 22 participants excluded from analysis for 
taking additional medication. No harms reported. 
 
 
94 
Data handling by review authors: The data presented for the 
analysis is based on Figure 1 showing mean pain scores (mean + 
SEM) for chewing. The SEM was used to calculate SD. Data from Gp 1 
did not contribute to the analyses, Gp 2 and 3 data were used for the 
comparison of pre-emptive versus post-emptive analgesia. 
Other information of note: Wide variation in gender at baseline for Gp 
1: "a wide range of individual variation was noted in the pain levels 
reported, which resulted in large standard deviations. Another possible 
explanation is the uneven distribution of male and female patients 
among the groups".  
Only pain during chewing data is reflected in this systematic review. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Quote: "Patients were randomly assigned to 1 
of 3 experimental groups"; "The randomization 
of which of the three experimental conditions 
the patients were assigned to was computer 
generated". 
Comment: Appears to be adequate 
randomisation. 
 
Allocation concealment 
(selection bias) 
Low risk Quote: "Patients were randomly assigned to 1 
of 3 experimental groups"; "The randomization 
of which of the three experimental conditions 
the patients were assigned to was computer 
generated". 
Comment: Appears to be adequate allocation 
concealment. 
 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Quote: "The ibuprofen and placebo capsules 
were identical in appearance. The patient, 
research assistant, and investigator were 
blinded to each subject’s experimental group." 
Comment: Adequate method of blinding. 
 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Quote: "The ibuprofen and placebo capsules 
were identical in appearance. The patient, 
research assistant, and investigator were 
blinded to each subject’s experimental group." 
Comment: Adequate method of blinding. 
 
Incomplete outcome data 
(attrition bias) 
 
High risk 73/114 drop-outs = 64% attrition (36% 
completion). High number of drop-outs, but 
equally distributed across the groups. 
 
Selective reporting 
(reporting bias) 
Low risk Data for outcomes of this review were 
reported appropriately. 
 
Other bias Low risk No other sources of bias detected. 
 
 
Bradley 2007 
Methods Setting: Dorset County Hospital Dorchester; Royal United 
Hospitals, Bath; and, Southmead Hospital, Bristol. 
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Design: Parallel (2 arms). 
Number of centres: 3. 
Study duration: February 2004-December 2005 (23 months). 
 
Participants Inclusion criteria: (1) Age between 12 and 16 years; (2) No 
history of peptic ulceration, or renal, hepatic, or cardiac 
impairment; (3) No history of asthma requiring steroid inhalers or 
unstable asthma in the last year; (4) No history of adverse 
reactions to ibuprofen or paracetamol; and (5) Currently not using 
analgesics or antibiotics. 
Exclusion criteria: Not specified. 
Orthodontic intervention: Separator placement. 
Patient Sampling: 
n=208 selected; 
n=21 excluded; 
n=21 refused to participate; 
n=187 randomised (Gp 1 n=92; Gp 2 n=95); 
n=28 drop-outs/excluded from analysis (Lost to follow-up [not 
returning questionnaire]: Gp 1 n=6, Gp 2 n=3; Did not fulfil 
inclusion criteria Group 1 n=9, Gp 2 n=10); 
n=159 data analysed for; 
Gp 1 (n=77) male n=28: female n=49, mean age 13.7 + 1.0; 
Gp 2 (n=82) male n=29: female n=53, mean age 13.8 + 1.2. 
Age p=0.38 (independent-samples t test) 
Sex: p=1.00 (chi-square test for association) male 35.8%: female 
64.2%. 
 
Interventions NSAID versus paracetamol 
Ibuprofen (400mg; 2x200mg caplet) vs. paracetamol (1g; 
2x500mg caplet); provided pre-emptively to separator placement, 
and again post-treatment. 
Gp 1: Ibuprofen 1hr before placement, followed by ibuprofen 6hrs 
after initial dose. 
Gp 2: Paracetamol 1hr before placement, followed by paracetamol 
6hrs after initial dose.  
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded at 2, 6, 
10/bedtime (primary outcome), 24 hours and 2, 3 and 7 days 
(secondary outcome) after separator placement. 
 
Notes Conflict of interests/funding: "We thank the Clinical Trials team 
in the Pharmacy Production Unit at the Royal Hallamshire Hospital, 
Sheffield, for supplying the drugs and performing the 
randomization, and the patients who participated in this trial." Both 
ibuprofen and paracetamol supplies were cited as being produced 
by Boots Company, Nottingham, United Kingdom. 
Adverse events/Harm: 18 participants required additional 
medication. 
Quote: "During this trial 1 patient experienced a suspected adverse 
reaction to paracetamol. This was reported in more detail in the 
reference paper by McAlinden et al, "since one of the trial drugs 
was also paracetamol we decided to break the randomization code 
for this patient to determine which drug the patient had received. 
The trial drug given was found to be paracetamol, suggesting a 
drug hypersensitivity reaction to paracetamol". 
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Data handling by review authors: Study reports Group 1 as 
paracetamol arm of trial, and Group 2 as ibuprofen arm. 
In order to align with this systematic review's own protocol, the 
figures for Groups 1 and 2 have been inverted to reflect ibuprofen 
as an intervention and paracetamol as its control. 
Other information of note: Intention to treat analysis noted in 
methods, but only completing patients were analysed. 
An intention-to-treat analysis was carried out on the 18 patients 
who required additional analgesia. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Quote: "The drugs were supplied 
according to a restricted randomization 
method in blocks of 8 to ensure that equal 
numbers of patients were allocated to 
each group." 
Comment: Block randomisation carried 
out therefore it can be assumed that this 
was adequate. 
 
Allocation concealment 
(selection bias) 
Low risk Quote: "The analgesics were in the form 
of identical capsules and were stored in 
sealed, numbered containers. The random 
allocation sequence was concealed in an 
envelope and held centrally." 
Comment: Adequate method of allocation 
concealment. 
 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Quote: "The investigator, the clinicians, 
the subjects, and the statistician were all 
blinded to each subject’s treatment group." 
Comment: Adequate method of blinding. 
 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Quote: "The investigator, the clinicians, 
the subjects, and the statistician were all 
blinded to each subject’s treatment group." 
Comment: Adequate method of blinding. 
 
Incomplete outcome 
data (attrition bias) 
 
Low risk 28/187 drop outs = 15% attrition (85% 
completion). 
 
Selective reporting 
(reporting bias) 
Low risk Data for outcomes of this review were 
reported appropriately. 
Other bias Low risk No other sources of bias detected. 
 
Bruno 2011 
Methods Setting: Dentistry School of Universidade Federal Fluminense, 
(Niterói, RJ, Brazil). 
Design: Parallel (3 arms). 
Number of centres: 1. 
Study duration: Not reported. 
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Participants Inclusion criteria: 1) At least 18 years of age; 2) Presence of 
second molars and second bicuspids, since separating elastics 
had to be fixed on the first molars; 3) No clinical signs of gingival 
inflammation. 
Exclusion criteria: 1)Use of any medication that could interfere 
with results >2 weeks before the procedure; 2) Any of the following 
conditions, screened through a questionnaire: cardiopathies, 
nephropathies, hepatopathies and/or gastrointestinal disorders, 
diabetes, high cholesterol, blood vessel obstructions, allergy to 
anti-inflammatory drugs, intolerance to lactose, pregnancy. 
Orthodontic intervention: Separator placement. 
Patient Sampling: 
n=87 recruited and randomised; 
n=38 drop-out/excluded from analysis (n=18 missing or incomplete 
information; n=10 discomfort due to elastic sought treatment 
elsewhere; n=6 used analgesic medication during the study; n=2 
lost their diaries and were unwilling to be resubmitted to the 
intervention; 
n=51 data analysed; 
Gp A (n=17) 4 male:13 female, mean age 24.64; 
Gp B (n=17) 4 male:13 female, mean age 22.64; 
Gp C (n=17) 5 male:12 female, mean age 22.47. 
 
Interventions NSAID versus placebo 
Lumiracoxib (400mg) vs. placebo vs no treatment; provided 
pre-emptively to separator placement. 
Gp A: Lumiracoxib 1hr before separator placement. 
Gp B: Placebo 1hr before separator placement.  
Gp C: No intervention. 
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded at 2, 6, 24 
hours and 2 and 4 days after separator placement. 
 
Notes Conflict of interests/funding: Quote: "The authors have reported 
no conflicts of interest." 
Adverse events/Harm: Not reported. 
Data handling by review authors: Study reports Group A as 
placebo arm, group B as Lumiracoxib arm and group C as control 
arm. 
For the purposes of aligning with this systematic review's own 
protocol, the figures for Groups A and B have been inverted to 
reflect ibuprofen as an intervention and placebo and no treatment 
as its controls. 
Other information of note: Data for means and standard 
deviations were received via correspondence with the author. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Quote: "Patients were randomly assigned 
into one of three groups by drawing lots. 
To ensure similarity in size of the groups, 
randomisation was stratified in blocks of 
ten (permuted-block randomisation)." 
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Comment: Block randomisation carried 
out therefore it can be assumed that this 
was adequate. 
 
Allocation concealment 
(selection bias) 
High risk Quote: "Patients were randomly assigned 
into one of three groups by drawing lots"; 
"As each volunteer attended the 
Department of Orthodontics, in 
Universidade Federal Fluminense (the 
University), he was allocated to the group 
following the last participant had entered. 
The search was not started with the 
sample enclosed." 
Comment: Allocation concealment was 
not achieved. 
 
Blinding of participants 
and personnel 
(performance bias) 
High risk Quote: "The placebo and lumiracoxib 
capsules were perfectly identical and 
neither the researchers nor the subjects 
knew the group of each subject. Patients 
of the non-medication group knew about 
the use of capsules by the other two 
groups." 
Comment: Adequate method of blinding 
where appropriate. Not possible to blind 
participants and personnel to allocated 
control group. 
 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Quote: "The VAS was given to a 
statistician blinded to the study group." 
Comment: Adequate method of blinding. 
 
Incomplete outcome 
data (attrition bias) 
 
High risk 36/87 drop-out = 41.4% attrition (58.6% 
completion). 
 
Selective reporting 
(reporting bias) 
Low risk Raw data not presented in paper, only 
statistical analysis and significance. 
Further information regarding data was 
received via correspondence with the 
author. 
 
Other bias Low risk No other source of bias detected. 
 
Eslamian 2014 
Methods Setting: Orthodontics Department of Shahid Beheshti University, 
School of Dentistry and a private clinic in Tehran. 
Design: Cross-over (3 arms). 
Number of centres: 2. 
Study duration: Not reported. 
 
Participants Inclusion criteria: No pain at the onset of study, complaint of pain 
over 50 based on the VAS in previous sessions, 6-8mm crowding, 
no use of analgesics during the study period, no history of 
renal or river disease or any other contraindication for the use of 
understudy medications. Comment: "river disease" spelling error 
present in paper. 
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Exclusion criteria: Those not signing the consent form, used 
analgesics and anti-inflammatory drugs during the study, did not 
complete the questionnaire, did not use or improperly used 
benzocaine or ketoprofen chewing gums. 
Orthodontic intervention: Mid-treatment adjustments. 
Patient Sampling: 
n=30 recruited and randomised; 
n=4 drop-out/excluded from analysis; 
n=26 data analysed; 
Gp A (n=26) 12 male:14 female, mean age 18.07 + 3.19; 
Gp B (n=26) 12 male:14 female, mean age 18.07 + 3.19; 
Gp C (n=26) 12 male:14 female, mean age 18.07 + 3.19. 
 
Interventions NSAID versus placebo/local anaesthetic versus 
placebo/NSAID versus local anaesthetic Ketoprofen chewing 
gum vs. benzocaine chewing gum vs. placebo chewing gum; 
provided post-operatively following appliance adjustments. 
Gp A: Ketoprofen chewing gum every 8 hours for 3 days after 
treatment. 
Gp B: Benzocaine chewing gum every 8 hours for 3 days after 
treatment.  
Gp C: Placebo chewing gum every 8 hours for 3 days after 
treatment. 
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded at 2, 6, 24 
hours and day 2 10am and 6pm, day 3 10am and 6pm and 7 days 
after appliance adjustment. 
 
Notes Conflict of interests/funding: Not reported. 
Adverse events/Harm: Not reported. 
Data handling by review authors: Study does not allocate 
intervention to specific group labels. For the purposes of this 
systematic review, Group A has been allocated as the ketoprofen 
arm, group B as the benzocaine arm and group C as control arm. 
Other information of note: Data for means and standard 
deviations were received via correspondence with the author. 
Orthodontic intervention involved in the study was described as 
"fixed orthodontic treatment". This was clarified as involving retie of 
an 0.016" or 0.018" Nickel Titanium archwire through 
correspondence with the author. 
4-week washout period allowed between interventions. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Quote: "Thirty patients were randomly 
divided into three groups of 10"; "In the 
first session patients 1-10 receive 
ketoprofen, 11-20 receive benzocaine, 21-
30 receive placebo gums. In the next visit 
1-10 benzocaine, 11-20 placebo, 21-30 
ketoprofen; and in the last visit 1-10 
placebo, 11-20 ketoprofen, 21-30 
benzocaine". 
Comment: Inadequate information 
regarding how method of randomisation 
 
 
100 
was carried out therefore unable to make 
a judgement on appropriateness. 
 
Allocation concealment 
(selection bias) 
Low risk Quote: "Thirty patients were randomly 
divided into three groups of 10"; "random 
allocation by a third person who was 
responsible for explaining to the patients". 
Comment: Appears to be adequate 
allocation concealment. 
 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Quote: "The placebo chewing gum was 
manufactured with the same shape and 
packaging as the experimental gums. 
Patients and those administering the gums 
among patients were blinded to the type of 
chewing gums". 
Comment: Adequate method of blinding. 
 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Quote: "Questionnaires were analysed by 
a statistician blinded to the group 
allocation of patients". 
Comment: Adequate method of blinding. 
 
Incomplete outcome 
data (attrition bias) 
 
Low risk 4/30 drop-outs = 13.3% attrition (86.7% 
completion). However, the reason for 
drop-out is unclear. 
 
Selective reporting 
(reporting bias) 
Low risk Unclear data presented in paper however 
clarification received from correspondence 
with the author. 
 
Other bias Low risk Unclear reporting throughout paper 
however verified by correspondence with 
the author. 
 
 
Farzanegan 2012 
Methods Setting: Orthodontic clinic of Mashhad University of Medical 
Sciences in Iran. 
Design: Parallel (5 arms). 
Number of centres: 1. 
Study duration: Not reported. 
 
Participants Inclusion criteria: Female orthodontic patients between 13 and 
18 years of age, scheduled for fixed orthodontic treatment, the 
patients had no systemic diseases and were not receiving 
analgesic therapy. They had moderate crowding (4-8 mm) 
according to Little’s irregularity index. 
All patients needed extraction of the 4 first premolars for 
orthodontic reasons, and the extractions were scheduled to be 
finished at least 2 weeks before the placement of the orthodontic 
appliances. 
Exclusion criteria: None specified. 
Orthodontic intervention: Initial archwire placement. 
Patient Sampling: 
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n=50 recruited and randomised and analysed: 
Gp 1 (n=10) female only, age data not reported; 
Gp 2 (n=10) female only, age data not reported; 
Gp 3 (n=10) female only, age data not reported; 
Gp 4 (n=10) female only, age data not reported; 
Gp 5 (n=10) female only, age data not reported. 
 
Interventions NSAID versus placebo 
Ibuprofen (400mg) vs. placebo vs chewing gum vs. soft 
viscoelastic bite wafer vs. hard viscoelastic bite wafer; 
provided after initial archwire placement. 
Gp 1: Ibuprofen immediately after archwire placement and at 8-
hour intervals for a week if pain persisted. 
Gp 2: Placebo immediately after archwire placement and at 8-hour 
intervals for a week if pain persisted. 
Gp 3: Gum chewed for 5mins immediately after archwire 
placement and at 8 hour intervals for a week if pain persisted. 
Gp 4: Soft bite wafer chewed or bit down on for 5minutes at 8-hour 
intervals for a week if pain persisted. 
Gp 5: Hard bite wafer chewed or bit down on for 5minutes at 8-
hour intervals for a week if pain persisted. 
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded at 2, 6, 
bedtime, 24 hours and 2, 3 and 7 days after placement of 
initial archwires. 
Pain was recorded during the following activities: 
 Chewing. 
 Biting [Not an outcome of this review]. 
 Fitting front teeth together [Not an outcome of this 
review]. 
 Fitting posterior teeth together [Not an outcome of this 
review]. 
 
Notes Conflict of interests/funding: Not reported. 
Adverse events/Harm: Not reported. “None had used any 
analgesics”. 
Data handling by review authors: Study reports Group 1 as 
placebo arm and Group 2 as ibuprofen arm. 
For the purposes of aligning with this systematic review's own 
protocol, the figures for Groups 1 and 2 have been inverted to 
reflect ibuprofen as an intervention and placebo as its control. 
Data for Group 3, 4 and 5 have not been included for the purposes 
of this review. 
Other information of note: Only pain during chewing data were 
reflected in this systematic review. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Quote: "The subjects were randomly 
assigned to 1 of 5 parallel groups in a 
1:1:1:1:1 ratio according to their clinical 
entrance number and a random number 
table." 
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Comment: Block randomisation carried 
out therefore it can be assumed that this 
was adequate. 
 
Allocation concealment 
(selection bias) 
Unclear risk Quote: "The subjects were randomly 
assigned to 1 of 5 parallel groups". 
Comment: Inadequate information 
regarding how method of allocation 
concealment was carried out therefore 
unable to make a judgement on 
appropriateness. 
 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Quote: "The subjects in these 2 groups 
(ibuprofen & placebo) were blinded about 
the drug that they took." 
Comment: Adequate method of blinding 
was carried out where appropriate for Gp 
1 and Gp 2. Not possible to blind 
participants and personnel regarding 
allocation to Gp 3, 4 or 5. 
 
Blinding of outcome 
assessment (detection 
bias) 
Unknown risk Inadequate information regarding method 
of blinding of outcome assessment. 
 
Incomplete outcome 
data (attrition bias) 
 
Low risk 0/50 drop-outs = 0% attrition (100% 
completion). 
 
Selective reporting 
(reporting bias) 
Low risk Data for outcomes of this review were 
reported appropriately. 
 
Other bias High risk Study carried out on female patients only, 
therefore subject to sampling bias and not 
necessarily generalisable to the 
population. 
 
 
Gupta 2014 
Methods Setting: Department of Orthodontics, AECS Maaruti College of 
Dental Sciences and Research Centre, Bangalore, India. 
Design: Parallel (3 arms). 
Number of centres: 1. 
Study duration: Not reported. 
 
Participants Inclusion criteria: Patients undergoing bonding and initial 
archwire placement using a 0.014/0.016 inch NiTi wire in at least in 
one arch. 
Exclusion criteria: Patients were not allowed to be currently 
taking any antibiotics or analgesics, they could have no allergy to 
NSAIDs and no oral pathology nor could they have had a tooth 
extracted at least 2 weeks before bonding. 
Orthodontic intervention: Initial archwire placement. 
Patient Sampling: 
n=45 recruited and randomised (23 F: 22 M; aged 15-22); 
n=0 loss to follow-up; 
n=45 data analysed; 
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Group 1 (n=15) 8 male:7 female, age data not reported; 
Group 2 (n=15) 7 male:8 female, age data not reported. 
Group 3 (n=15) 7 male:8 female, age data not reported. 
 
Interventions NSAID versus paracetamol, NSAID versus Etoricoxib, NSAID 
versus placebo 
Paracetamol (500mg) vs. etoricoxib (60mg) vs. placebo; 
provided 1 hour before initial archwire placement and post-
operatively. 
Gp 1: Paracetamol 1 hour before and thrice daily for 3 days after 
archwire placement. 
Gp 2: Etoricoxib 1 hour before and once daily for 3 days after 
archwire placement. 
Gp 3: Placebo 1 hour before and thrice daily for 3 days after 
archwire placement. 
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded at 2, 6, 
bedtime, 24 hours and 2nd day at night-time, 48 hours after initial 
archwire placement and 3rd day at night-time. 
 
Notes Conflict of interests/funding: "M. Gupta, S. Kandula, S.M. 
Laxmikant, S.S. Vyavahare, B.H.R. Satheesha, and C.S. 
Ramachandra state that there are no conflicts of interest. All 
studies on humans described in the present manuscript were 
carried out with the approval of the responsible ethics committee 
and in accordance with national law and the Helsinki Declaration of 
1975 (in its current, revised form). Informed consent was obtained 
from all patients included in studies." 
Adverse events/Harm: Not reported. “None of them had resorted 
to using any kind of additional medication”> 
Data handling by review authors: Study reports Group 2 as 
placebo arm and Group 3 as etoricoxib arm. 
For the purposes of aligning with this systematic review's own 
protocol, the figures for Groups 2 and 3 have been inverted to 
reflect etoricoxib as an intervention and placebo as its control. 
Other information of note: Time points for 1st day bedtime, 2nd 
and 3rd day night-time’s are not specified. 1st day bedtime has 
been assumed to be approximately 10hours, 2nd day night-time 
has been assumed to be approximately 31hrs and 3rd day night-
time as approximately 53hrs. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Quote: "Patients were randomly assigned 
to three different groups and blinding was 
done using the SNOSE technique 
(sequentially numbered opaque sealed 
envelopes)" 
Comment: Appears to be adequate 
randomisation. 
 
Allocation concealment 
(selection bias) 
Low risk Quote: "Patients were randomly assigned 
to three different groups and blinding was 
done using the SNOSE technique 
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(sequentially numbered opaque sealed 
envelopes)." 
Comment: Appears to be adequate 
allocation concealment. 
 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk Quote: "Patients were enrolled in this 
double-blind, prospective study". 
Comment: Described as double-blind but 
inadequate information regarding how 
blinding was carried out therefore unable 
to make a judgement on appropriateness. 
 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk Quote: "Patients were enrolled in this 
double-blind, prospective study". 
Comment: Described as double-blind but 
inadequate information regarding how 
blinding was carried out therefore unable 
to make a judgement on appropriateness. 
 
Incomplete outcome 
data (attrition bias) 
 
Low risk 0/45 drop-out = 0% (100% completion). 
 
Selective reporting 
(reporting bias) 
Low risk Data for outcomes of this review were 
reported appropriately. 
 
Other bias Low risk No other source of bias detected. 
 
 
Kawamoto 2010 
Methods Setting: 2 private practices in Lee’s Summit, Missouri. 
Design: Parallel (3 arms). 
Number of centres: 2. 
Study duration: Not reported. 
 
Participants Inclusion criteria: (1) Started orthodontic treatment that required 
banding of posterior teeth and placement of two or more 
separators; (2) Able to swallow analgesic pills; (3) English 
speaking; (4) 9 to 17 years of age; (5) Minimum weight 
requirement of 88 pounds based on mg/kg paediatric dosage 
recommendations. 
Exclusion criteria: Current orthodontic or space maintenance 
appliances, if there was a contraindication to the use of 
acetaminophen or ibuprofen, if they were currently taking 
antibiotics or analgesics, had cognitive impairment, or any 
systemic disease that in the assessment of the investigator might 
impact pain perception. 
Orthodontic intervention: Separator placement. 
Patient Sampling: 
n=35 enrolled; 
n=9 drop-outs/excluded from analysis (Gp 1=4, Gp 2=2, Gp 3=3 all 
failed to return questionnaires); 
n=26 data analysed for: 
Gp 1 (n=7) male n=1: female n=6, mean age 12.7 + 1.3; 
Gp 2 (n=10) male n=3: female n=7, mean age 13.0 + 1.6; 
Gp 3 (n=9) male n=5: female n=4, mean age 12.6 + 1.8. 
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Interventions NSAID versus placebo; NSAID versus Paracetamol; 
Paracetamol versus placebo. 
Ibuprofen (400mg) vs. paracetamol (650mg) vs. placebo 
(640mg Avicel); provided pre-emptively and post-treatment to 
separator placement. 
Gp 1: Ibuprofen 1hr before placement and 6hrs after initial dose. 
Gp 2: Paracetamol 1hr before placement and 6hrs after initial 
dose. 
Gp 3: Placebo 1hr before placement and 6hrs after initial dose. 
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded immediately 
before and after, 2, 6, bedtime, 24 hours after separator 
placement. 
Pain was recorded during the following activities: 
 Chewing. 
 Teeth not touching [Not an outcome of this review]. 
 Biting [Not an outcome of this review]. 
 
Notes Conflict of interests/funding: Not reported. 
Adverse events/Harm: Not reported. 
Data handling by review authors: Study reports Gp 1 as placebo 
arm and Gp 3 as ibuprofen arm. 
For the purposes of aligning with this systematic review's own 
protocol, the figures for Gps 1 and 3 have been inverted to reflect 
ibuprofen as an intervention and placebo as its control. 
Other information of note: Only pain during chewing data were 
reflected in this systematic review. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Quote: "Computer generated random 
patient coding and group allocation was 
utilized". 
Comment: Appears to be adequate 
randomisation. 
 
Allocation concealment 
(selection bias) 
Low risk Quote: "The random allocation 
assignments were concealed and 
inaccessible to the investigator." 
Comment: Appears to be adequate 
allocation concealment. 
 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Quote: "The ibuprofen, acetaminophen, 
and placebo tablets were compounded by 
a licensed pharmacist (O’Brien Pharmacy, 
Kansas City, MO) according to 
specifications and were all provided in 
identical white opaque capsules. 
Medications and placebo tablets were 
packed and distributed in sealed, coded 
envelopes"; "Subjects, patients and 
investigator would be blinded to group 
allocation". 
Comment: Adequate method of blinding. 
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Blinding of outcome 
assessment (detection 
bias) 
Low risk Quote: "The random allocation 
assignments were concealed and 
inaccessible to the investigator"; 
"Subjects, patients and investigator would 
be blinded to group allocation". 
Comment: Adequate method of blinding. 
 
Incomplete outcome 
data (attrition bias) 
 
High risk 9/35 drop-out = 25.7% attrition (74.3% 
completion). 
 
Selective reporting 
(reporting bias) 
Low risk Data for outcomes of this review were 
reported appropriately. 
 
Other bias Low risk No other source of bias detected. 
 
 
Kluemper 2002 
Methods Setting: Graduate Orthodontic Clinic at the University of Kentucky 
College of Dentistry and the full-time and part-time faculty 
practices. 
Design: Parallel (2 arms). 
Number of centres: Unclear. 
Study duration: Not reported. 
 
Participants Inclusion criteria: Orthodontic treatment included full, fixed 
orthodontic appliances (braces). Males and females were included. 
Periodontal tissues were in good health. No systemic disease that 
would compromise normal healing (e.g., diabetes) was present. No 
medications were taken at the time of the study. 
Exclusion criteria: None specified. 
Orthodontic intervention: Separator placement. 
Patient Sampling: 
n=80 randomised (Group 1 n=40; Group 2 n=40); 
n=10 drop-outs/excluded from analysis 
(Lost to follow-up: not returning questionnaire=7; did not require 
pain relief=3); 
n=70 data analysed for: 
Group 1 (n=35) male n=18: female n=17, mean age 23.8 +10.3; 
Group 2 (n=35) male n=16: female n=19, mean age 25.2 + 8.6. 
Age p=0.5. 
Sex: p=0.6. 
 
Interventions Local anaesthetic wax versus placebo 
Benzocaine wax vs. placebo; provided post-treatment for topical 
use, not applied until 24hours after visit. 
Gp 1: Orthodontic menthol wax, medicated with 20% benzocaine. 
Gp 2: Unmedicated orthodontic wax (without menthol). 
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded at baseline, 
1, 17, 29, 41, 53 hours after baseline. 
 
Notes Conflict of interests/funding: Not reported. The benzocaine wax 
product received a patent by the United States Patent and 
Trademark Office (Patent No.6,074,674) 
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Adverse events/Harm: Not reported. 
Data handling by review authors: Only intervention study data 
included in this review. Study does not allocate intervention to 
specific group labels. For the purposes of this systematic review, 
Group 1 has been allocated as the benzocaine arm and group 2 as 
the control arm. 
Although multiple time points measured, intervention not taken 
until 24 hours after visit, therefore data from this study has not 
contributed to analyses in this systematic review. 
Other information of note: Much of the details in the paper relate 
to the pilot (e.g. the inclusion criteria) prior to the RCT. Both are 
presented collectively in the paper. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Quote: "The medicated and unmedicated 
waxes were randomized and were 
contained in numerically coded cases." 
Comment: Inadequate information 
regarding how method of randomisation 
was carried out therefore unable to make 
a judgement on appropriateness. 
 
Allocation concealment 
(selection bias) 
Low risk Quote: "The medicated and unmedicated 
waxes were randomized and were 
contained in numerically coded cases." 
Comment: Appears to be adequate 
allocation concealment. 
 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Quote: "The patients received dental wax 
without knowing whether the anaesthetic 
was incorporated into the wax". 
Comment: Described as double-blind, 
both identically prepared however "neither 
the benzocaine nor the menthol" was 
included in the placebo. Intervention and 
control possess different tastes, but 
patients unlikely to recognise if active drug 
or not, or to discuss with other 
participants. 
 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk Quote: "Randomised double-blind 
prospective RCT". 
Comment: Described as double-blind but 
inadequate information regarding how 
blinding was carried out therefore unable 
to make a judgement on appropriateness. 
 
Incomplete outcome 
data (attrition bias) 
 
Low risk 10/80 drop-out = 12.5% attrition (87.5% 
completion). 
 
Selective reporting 
(reporting bias) 
Low risk Data for outcomes of this review were 
reported appropriately. 
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Other bias Low risk No other source of bias detected. 
 
 
Kohli 2011 
Methods Setting: Department of Orthodontics & Dentofacial Orthopedics, 
Hitkarini Dental College & Hospital, Jabalpur, India. 
Design: Parallel (3 arms). 
Number of centres: 1. 
Study duration: Not reported. 
 
Participants Inclusion criteria: (1) At least 13 years of age and not older than 
20 years of age; (2) Beginning orthodontic treatment for the first 
time; (3) Reporting no contraindications or adverse reactions 
related to ibuprofen and piroxicam; (4) Currently not using any 
antibiotics; and (5) Meeting a minimum weight requirement of 88 
pounds, as per Food and Drug Administration–approved-over-the-
counter paediatric dosage labelling guidelines. In addition, patients 
were required to provide written informed consent for participation 
in the study. 
Exclusion criteria: None specified. 
Orthodontic intervention: Separator placement. 
Patient Sampling: 
n=90 randomised (Group 1 n=30; Group 2 n=30; Group 3 n=30); 
n=0 drop-out/excluded from analysis; 
n=90 analysed (45 males and 45 females); 
Group 1 (n= 30) male n=15: female n=15, mean age 14.7 + 3.4; 
Group 2 (n=30) male n=15: female n=15, mean age 14.2 + 2.8; 
Group 3 (n=30) male n=15: female n=15, mean age 15.1 + 3.6. 
 
Interventions NSAID versus placebo versus NSAID 
Ibuprofen (400mg) vs. piroxicam (20mg) vs. placebo; provided 
1 hour pre-emptively. 
Gp 1: Ibuprofen 1 hour before separator placement. 
Gp 2: Placebo 1 hour before separator placement. 
Gp 3: Piroxicam 1 hour before separator placement. 
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded at 2, 6, 
bedtime, 24 hours and 2, 3 and 7 days after separator placement. 
Pain was recorded during the following activities: 
 Chewing. 
 Biting [Not an outcome of this review]. 
 Fitting front teeth together [Not an outcome of this review]. 
 Fitting posterior teeth together [Not an outcome of this 
review]. 
 
Notes Conflict of interests/funding: Not reported. 
Adverse events/Harm: Not reported. “None of them had resorted 
to the usage of any kind of ‘rescue medication.’” 
Data handling by review authors: Study reports Group 1 as 
placebo arm of trial, Group 2 as ibuprofen arm and Group 3 as 
piroxicam arm. 
For the purposes of aligning with this systematic review's own 
protocol, the figures for Groups 1 and 2 have been inverted to 
reflect ibuprofen as an intervention and piroxicam and placebo as 
its controls. 
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Other information of note: Only pain during chewing data were 
reflected in this systematic review. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Quote: "30 patients were randomly 
assigned to the three experimental 
groups". 
Comment: Inadequate information 
regarding how method of randomisation 
was carried out therefore unable to make 
a judgement on appropriateness. 
 
Allocation concealment 
(selection bias) 
Unclear risk Quote: "30 patients were randomly 
assigned to the three experimental 
groups". 
Comment: Inadequate information 
regarding how method of allocation 
concealment was carried out therefore 
unable to make a judgement on 
appropriateness. 
 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Quote: "The investigational drug 
pharmacy at the institute dispensed the 
drugs so that the investigator would be 
blinded to the experimental group." 
Comment: Described as double-blind but 
inadequate information regarding how 
blinding of participants was carried out 
therefore unable to make a judgement on 
appropriateness. 
 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Quote: "The investigational drug 
pharmacy at the institute dispensed the 
drugs so that the investigator would be 
blinded to the experimental group." 
Comment: Adequate method of blinding. 
 
Incomplete outcome 
data (attrition bias) 
 
Low risk 0/90 drop-outs =0% attrition (100% 
completion). 
 
Selective reporting 
(reporting bias) 
Low risk Data for outcomes of this review were 
reported appropriately. 
 
Other bias Low risk No other source of bias detected. 
 
 
Lauritano 2000 
Methods Setting: San Raffaele Hospital, Madrid. 
Design: Parallel (2 arms). 
Number of centres: 1. 
Study duration: Not reported. 
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Participants Inclusion criteria: 1) Mobile patients, male and female aged 
between 18-40 were fitted with a brace; 2) Moderate or severe 
pain in the mouth region was measured using the 'visual analogue 
scale' as per the protocol; 3) At least 1 of the two signs of 
inflammation (oedema or hyperaemia) of a moderate intensity, or 
severe on a point scale from 0 to 3; 4) Written consent was 
obtained from the patient. 
Exclusion criteria: None specified. 
Orthodontic intervention: Initial archwire placement. 
Patient Sampling: 
n=120 patients selected and randomised; 
n=0 drop-outs/excluded from analysis 
n=120 data analysed for: 
Group 1 (n=60) gender and age data not reported; 
Group 2 (n=60) gender and age data not reported. 
 
Interventions NSAID versus NSAID 
Ketoprofen (160mg) vs. benzidamine chloride (22.5mg); 
mouthwash provided post-operatively. 
Gp 1: Ketoprofen 10ml in 100ml of water twice a day (after 
breakfast and the evening meal) for up to 7 days. 
Gp 2: Benzidamine chloride 15ml 1twice a day (after breakfast and 
the evening meal) for up to 7 days. 
 
Outcomes Primary outcome: Pain score (Visual Analogue Scale (VAS)) - 
Recorded at baseline, day 1, 2, 3, 4, 5, 6, and 7 1 hour after 
breakfast and 1 hour after the evening meal. 
Secondary outcome: The seriousness of the following signs – 
oedea and hyperaemia were measured on a graduated scale of 0-
3 (3 being intense pain). The pain was measured by the person 
conducting the experiment, on examination of the oral cavity when 
the brace was initially fitted, on the second visit and on the third 
and final visit. 
The resolution of any signs of inflammation was deducted from the 
data produced regarding seriousness, flowing the same marking 
procedure (complete remission of inflammation, a good 
improvement, slight improvement, no effect) 0=a complete 
remission. 
 
Notes Conflict of interests/funding: Not reported. 
Adverse events/Harm: Not discussed. 
Data handling by review authors: Although multiple time points 
measured, data has only been presented at 4 days. Therefore, 
data from this study has not been used for this systematic review. 
No information is provided relating to drop-outs, it has been 
assumed that all participants returned questionnaires and 
contributed to the final analysis. 
Other information of note: This paper has been translated from 
Italian with additional correspondence from the author. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Quote: "Randomised study in the single 
caesium for parallel groups". 
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Comment: Inadequate information 
regarding how method of randomisation 
was carried out therefore unable to make 
a judgement on appropriateness. 
 
Allocation concealment 
(selection bias) 
Unclear risk Quote: "Randomised study in the single 
caesium for parallel groups". 
Comment: Inadequate information 
regarding how method of allocation 
concealment was carried out therefore 
unable to make a judgement on 
appropriateness. 
 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk Quote: "The study was carried out in 120 
patients submitted to orthodontic therapy 
by oral route, under single blind 
conditions." 
Comment: Described as single-blind but 
inadequate information regarding how 
blinding was carried out therefore unable 
to make a judgement on appropriateness. 
 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk Quote: "The study was carried out in 120 
patients submitted to orthodontic therapy 
by oral route, under single blind 
conditions." 
Comment: Described as single-blind but 
inadequate information regarding how 
blinding was carried out therefore unable 
to make a judgement on appropriateness. 
 
Incomplete outcome 
data (attrition bias) 
 
Low risk 0/120 drop-outs =0% attrition (100% 
completion). 
 
Selective reporting 
(reporting bias) 
High risk Data for outcomes at all time points 
recorded were not reported, only data for 4 
days was available. 
 
Other bias Low risk No other sources of bias detected. 
 
 
Minor 2009 
Methods Setting: University of Florida orthodontic clinic. 
Design: Parallel (3 arms). 
Number of centres: 1. 
Study duration: 37 months. 
 
Participants Inclusion criteria: (1) At least 13 and not older than 30 years of 
age; (2) Not pregnant; (3) Beginning orthodontic treatment for the 
first time; (4) Orthodontic treatment required the placement of at 
least 1 separator in each of the 4 quadrants; (5) No 
contraindications or adverse reactions to ibuprofen or almonds; 
and (6) written informed consent to participate. 
Exclusion criteria: None specified. 
Orthodontic intervention: Separator placement. 
Patient Sampling: 
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n=51 enrolled; 
n=0 drop-outs/excluded from analysis; 
n=51 data analysed for: 
Gp A (n=16) male n=6: female n=10, mean age 17.6 +/-5.0; 
Gp B (n=17) male n=10: female n=7, mean age 14.9 +/-2.7; 
Gp C (n=18) male n=5: female n=13, mean age 16.4 +/-3.6. 
 
Interventions NSAID versus placebo 
Ibuprofen (400mg) vs. placebo; provided pre- and post-treatment 
to separator placement, or post-treatment, or both. 
Gp A: Ibuprofen 1hr before placement, 3hrs after and 7hrs after 
placement. 
Gp B: Placebo 1hr before placement, ibuprofen 3hrs and 7hrs 
after placement. 
Gp C: Placebo 1hr before placement, placebo 3hrs and 7hrs after 
placement. 
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded at pre-
treatment expectation of pain, 2, 6, 10/bedtime, 17/awakening, 24 
hours and 2, 3 and 7 days after separator placement. 
Pain was recorded during the following activities: 
 Chewing. 
 Biting [Not an outcome of this review]. 
 Fitting front teeth together [Not an outcome of this review]. 
 Fitting posterior teeth together [Not an outcome of this 
review]. 
Masticatory efficiency test (masticatory performance index [Not an 
outcome of this review]. 
Expectation of pain (Visual Analogue Scale (VAS)) [Not an 
outcome of this review]. 
Affective states (State and Trait Anxiety Inventory (STAI)) [Not an 
outcome of this review]. 
 
Notes Conflict of interests/funding: None reported. 
Adverse events/Harm: Not discussed. 
Data handling by review authors: Only pain during chewing data 
required for this systematic review however it was unclear from the 
published data what the VAS measurements are presented - Table 
III labelled as chewing but the discussion states that the data for 
chewing was not included. Mean VAS data for 24 hours shows 
values of over 10cm, despite a 10cm VAS being used. Therefore, 
data for 24 hours has been excluded for the purposes of this 
review. 
For the purposes of this review, data from Gp B has not been 
used, data from Gp A and C have been used for the comparison of 
NSAID versus placebo. 
Other information of note: Pain during chewing data as 
presented in Table III is reflected in this systematic review. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Quote: "They were randomly assigned to 
1 of 3 groups stratified by sex." 
Comment: Inadequate information 
regarding how method of randomisation 
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was carried out therefore unable to make 
a judgement on appropriateness. 
 
Allocation concealment 
(selection bias) 
Unclear risk Quote: "They were randomly assigned to 
1 of 3 groups stratified by sex." 
Comment: Inadequate information 
regarding how method of allocation was 
carried out therefore unable to make a 
judgement on appropriateness. 
 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk Quote: "Placebo-controlled, double-blind, 
parallel arm, prospective study". 
Comment: Described as double-blind but 
inadequate information regarding how 
blinding of participants and personnel was 
carried out therefore unable to make a 
judgement on appropriateness. 
 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk Quote: "Placebo-controlled, double-blind, 
parallel arm, prospective study". 
Comment: Described as double-blind but 
inadequate information regarding how 
blinding of outcome assessment was 
carried out therefore unable to make a 
judgement on appropriateness. 
 
Incomplete outcome 
data (attrition bias) 
 
Low risk 0/51 drop-outs=0% attrition (100% 
completion). 
 
Selective reporting 
(reporting bias) 
High risk Study protocol not available. Individual 
VAS scores for biting, chewing, fitting front 
teeth, and fitting back teeth not recorded. 
10cm VAS used but measurements show 
values of >10cm at 24 hours for all 3 
groups. 
 
Other bias Low risk No other sources of bias detected. 
 
 
Najafi 2015 
Methods Setting: Orthodontic Clinic of Dental School at Shiraz University of 
Medical Sciences, Iran. 
Design: Parallel (3 arms). 
Number of centres: 1. 
Study duration: Not reported. 
 
Participants Patient Sampling: 
Inclusion criteria: 1. Need separator placement to begin 
orthodontic treatment in the maxillary arch; 2. Aged 15 years or 
older; 3. Were informed and signed the written informed consent, 
4. Not currently using antibiotics, analgesics, anti-inflammatory, 
anti-coagulative, diuretics, oral anti diabetics, lithium, cyclosporine, 
and methotrexate; 5. No need for antibiotic prophylaxis; 6. No 
chronic systemic disease or clotting disorders; 7. Not reporting 
contraindication for NSAIDs; 8. Not pregnant or nursing. 
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Exclusion criteria: None specified but excluded participants who 
took additional analgesics. 
Orthodontic intervention: Separator placement. 
Patient Sampling: 
n=349 assessed for eligibility (Group 1=107, Group 2=107, Group 
3=107); 
n=28 excluded (12 did not meet inclusion criteria, 16 decided not to 
participate); 
n=321 enrolled and randomised; 
n=16 drop-outs (Group 1=5, Group 2=7, Group 3=4 lost to follow-
up); 
n=64 excluded from analysis (Group 1=26, Group 2=24, Group 
3=14 did not complete questionnaire correctly (n=46) /took 
additional analgesics (n=18)); 
n=241 data analysed for: 
Gp 1 (n=76) male n=21: female n=55, mean age 22.1 + 3.2; 
Gp 2 (n=76) male n=19: female n=57, mean age 21.7 + 3.5; 
Gp 3 (n=89) male n=21: female n=68, mean age 21.2 + 3.8. 
 
Interventions NSAID versus NSAID; NSAID versus paracetamol 
Ibuprofen (400mg) vs. paracetamol (650mg) vs. meloxicam 
(7.5mg); provided pre-emptively to separator placement. 
Gp 1: Ibuprofen 1hr before separator placement. 
Gp 2: Paracetamol 1hr before separator placement. 
Gp 3: Meloxicam 1hr before separator placement. 
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded at 
immediately, 2, 6, 24 and 48 hours after separator placement. 
Pain was recorded during the following activities: 
 Chewing. 
 Rest [Not an outcome of this review]. 
 Fitting posterior teeth together [Not an outcome of this 
review]. 
 
Notes Conflict of interests/funding: This work was supported by the 
Vice-Chancellery of Shiraz University of Medical Science (2168). 
The authors declare that they have no competing interests. 
Adverse events/Harm: Not reported. 
Data handling by review authors: Study does not allocate 
intervention to specific group labels. For the purposes of this 
systematic review, Group 1 has been allocated as the Ibuprofen 
arm, Group 2 as the paracetamol arm and group 3 as the 
meloxicam arm. 
Although referred to as acetaminophen, this group has been 
referred to as paracetamol for the purposes of this review. 
Other information of note: Only pain during chewing data were 
reflected in this systematic review. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Quote: "The block randomization method 
was used with block length 9, and number 
of repetition for each group n = 3, to 
allocate subjects in each group. This 
method was used separately for each sex 
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group to provide groups with equal 
numbers of male and female." 
Comment: Appears to be adequate 
randomisation. 
 
Allocation concealment 
(selection bias) 
Low risk Quote: "The block randomization method 
was used with block length 9, and number 
of repetition for each group n = 3, to 
allocate subjects in each group. This 
method was used separately for each sex 
group to provide groups with equal 
numbers of male and female." 
Comment: Inadequate information 
regarding how method of allocation was 
carried out therefore unable to make a 
judgement on appropriateness. 
 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Quote: "In each group, all tablets were 
covered by identical gelatin cover, so the 
investigators, the patients, and the 
statistician were all blind to the treatment 
groups." 
Comment: Appears to be adequate 
blinding. 
 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Quote: "In each group, all tablets were 
covered by identical gelatin cover, so the 
investigators, the patients, and the 
statistician were all blind to the treatment 
groups." 
Comment: Appears to be adequate 
blinding. 
 
Incomplete outcome 
data (attrition bias) 
 
High risk 80/321=25% drop-out (75% completion). 
 
Selective reporting 
(reporting bias) 
Low risk Data for outcomes of this review were 
reported appropriately. 
 
Other bias High risk Large gender variation at baseline, more 
females in all groups indicating sampling 
bias. 
 
 
Nik 2016 
Methods Setting: Dental faculty of Tehran University of Medical Sciences. 
Design: Parallel (3 arms). 
Number of centres: 1. 
Study duration: Not reported. 
 
Participants Inclusion criteria: All patients started orthodontic treatment that 
required separators, had no systemic or gastrointestinal diseases, 
had not taken analgesics or any other drugs currently, had no 
contraindication to the use of either acetaminophen or liquefied 
ibuprofen, their weight was above 40 kg, and their first molar were 
without decay or filling or periodontal problem. The last criterion 
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was checked through clinical observation, probing, and panoramic 
radiographs. 
Exclusion criteria: None specified, however later stated they 
would exclude patients who had taken additional analgesics. 
Orthodontic intervention: Separator placement. 
Patient Sampling: 
n=101 randomised; 
n=12 drop-outs/excluded from analysis (Did not take drugs 
correctly=8; did not complete questionnaire=3); 
n=89 data analysed for: 
Gp 1 (n=29) male n=13: female n=16, mean age 15.6 +/- 4.17; 
Gp 2 (n=32) male n=14: female n=18, mean age 15.8 +/- 3.49; 
Gp 3 (n=28) male n=12: female n=16, mean age 15.3 +/-3.15. 
 
Interventions NSAID versus placebo; paracetamol versus placebo; NSAID 
versus paracetamol 
Ibuprofen (400mg) vs. paracetamol (650mg) vs. placebo; 
provided pre-emptively to separator placement. 
Gp 1: Ibuprofen 1hr before separator placement and every 6 hours 
until 24 hours (5 doses). 
Gp 2: Paracetamol 1hr before separator placement and every 6 
hours until 24 hours (5 doses). 
Gp 3: Placebo 1hr before separator placement and every 6 hours 
until 24 hours (5 doses). 
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded at 
immediately, 2, 6, bedtime and 24 hours after separator 
placement. 
 
Notes Conflict of interests/funding: Not reported. 
Adverse events/Harm: Not reported. 
Data handling by review authors: Study does not allocate 
intervention to specific group labels. For the purposes of this 
systematic review, Group 1 has been allocated as the ibuprofen 
arm, Group 2 as the paracetamol arm and group 3 as the placebo 
arm. 
Although referred to as acetaminophen, this group has been 
referred to as paracetamol for the purposes of this review. 
Gender data presented as a percentage, calculated as values for 
the purposes of this review. 
Other information of note: No baseline information provided 
about groups before drop-out. Mean age for Gp 2 differs 
throughout study. For the purposes of the review, the data from 
Table 1 has been used. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Quote: "To divide the patients into three 
groups, block randomization method was 
used. Each block contained three coded 
pockets (acetaminophen, liquefied 
ibuprofen, and placebo) and consisted of 
one sex (male or female)." 
Comment: Inadequate information 
regarding how randomisation was carried 
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out therefore unable to make a judgement 
on appropriateness. 
 
Allocation concealment 
(selection bias) 
Low risk Quote: "The random allocation and coding 
of drugs was performed by an operator 
outside the study and was concealed in an 
envelope." 
Comment: Appears to be adequate 
allocation concealment. 
 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Quote: "To ensure that the patients were 
blind to the experimental group, the 
analgesics and placebo were placed in 
identical capsules"; "In each group, the 
male to female ratio was equal, and the 
patient and the operator were blind of the 
kind of drug." 
Comment: Appears to be adequate 
blinding. 
 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Quote: "The patients were asked to put 
each questionnaire in a pocket and seal it 
after marking the scale"; "randomized 
triple blinded clinical trial". 
Comment: Appears to be adequate 
blinding. 
 
Incomplete outcome 
data (attrition bias) 
 
Low risk 12/101=12% drop-out (88% completion). 
 
Selective reporting 
(reporting bias) 
Low risk Data for outcomes of this review were 
reported appropriately. 
 
Other bias Low risk No other sources of bias detected. 
 
 
Ousehal 2009 
Methods Setting: Orthodontic consultation and dental treatment unit, Ibn 
Rochd Hospital Center, Casablanca, Morocco. 
Design: Parallel (2 arms). 
Number of centres: 1. 
Study duration: Not reported. 
 
Participants Inclusion criteria: No drug treatment during the study; good oral 
hygiene; good general health; adults stratified by age group with 
presenting malocclusion requiring orthodontic treatment; consent 
provided. 
Exclusion criteria: Contra-indication to the use of paracetamol or 
ibuprofen; taking medication including short-term anti-inflammatory 
analgesics or long-term corticosteroids; drop-outs; patient non-
compliance. 
Orthodontic intervention: Initial archwire placement. 
Patient Sampling: 
n=56 randomised and analysed: 
Gp A (n=27); 
Gp B (n=29). 
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Overall: female n=39 (69.9%): male n=17 (30.4%); age 
<15=21.4%: aged >15=78.6%. 
 
Interventions NSAID versus paracetamol 
Ibuprofen (600mg; 2x300mg p/day for 5 days) vs. paracetamol 
(2g; 4x500mg p/day for 7 days) 
Gp A: Ibuprofen provided immediately post-treatment, daily oral 
dose thereafter. 
Gp B: Paracetamol provided immediately post-treatment, daily oral 
dose thereafter. 
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded at 2, 6, 24 
hours and 2, 3 and 7 days after placement of initial archwire. 
 
Notes Conflict of interests/funding: Not reported. 
Adverse events/Harm: Not reported. 
Data handling by review authors: Additional information received 
through correspondence with the author. 
Other information of note: Original paper translated from French 
to English. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Quote: "The randomisation was carried 
out by a computer algorithm; random 
block was performed by the software". 
Comment: Computer generated block 
randomisation carried out therefore 
appears to be adequate. 
 
Allocation concealment 
(selection bias) 
Low risk Quote: "The distribution of study subjects 
was determined by a biostatistician who 
gave us the list of participants to the 
study". 
Comment: Appears to be adequate 
allocation concealment. 
 
Blinding of participants 
and personnel 
(performance bias) 
High risk Quote: "Double-blind was impossible 
because the patient could read the tablet 
trade name". 
Comment: Blinding of the drugs was not 
carried out therefore it was assumed that 
the researcher supplying the intervention 
and the participants were not blinded. 
 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Quote: "Drug distribution was done with a 
single-blind method; single investigators 
were unaware of the drug". 
Comment: Appears to be adequate 
blinding. 
 
Incomplete outcome 
data (attrition bias) 
 
Low risk 0/56=0% drop-out (100% completion). 
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Selective reporting 
(reporting bias) 
Low risk Data for outcomes of this review were 
reported appropriately. 
 
Other bias High risk Large gender and age variation at 
baseline, more females in all groups and 
majority of participants aged >15 years 
indicating sampling bias. 
 
 
Paganelli 1993 
Methods Setting: Orthodontic Clinic, Dental School, University of Brescia, 
Italy. 
Design: Parallel (3 arms). 
Number of centres: 1. 
Study duration: Not reported. 
 
Participants Inclusion criteria: Healthy; 12 to 16 years; oral membrane lesions 
from 2-6mm caused by wearing a fixed brace; available to 
participate in the study. 
Exclusion criteria: Already treated for orthodontic or systemic 
pain during the last month; syndromes or mental retardation; 
unavailable to participate to the study; not suffering from anxiety 
according to parents’ rating; no history of dental treatment refusal. 
Orthodontic intervention: Within 1 month of fixed or removable 
appliance fit. 
Patient Sampling: 
n=60 selected, randomised and analysed: 
(<14 years n=30; >14 years n=30; male n=30; female n=30) 
Gp 1 (n=20) male n=10: female n=101, mean age 14 + 2; 
Gp 2 (n=20) male n=10: female n=10, mean age 14 + 2. 
Gp 3 (n=20) male=10: female=10, mean age 14 + 2. 
 
Interventions NSAID versus placebo 
Flurbiprofen (10ml 0.25% mouthwash; 3 times daily for 7 days) 
vs. placebo (10ml mouthwash; 2 minute rinse duration; 3 
times daily for 7 days) vs. control; 
Gp 1: Flurbiprofen; provided post-operatively to separator 
placement. 
Gp 2: Placebo; provided post-operatively to separator placement. 
Gp 3: Control, no treatment. 
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded at baseline, 
3 and 7 days after separator placement. 
 
Notes Conflict of interests/funding: Not reported. 
Adverse events/Harm: "2 cases of reduced taste sensation with 
Flurbiprofen which did not cause discontinuation"; "No local or 
systemic ADRs were reported". 
Data handling by review authors: Additional information received 
through correspondence with the author. Although multiple time 
points measured, due to variations in the time points of interest to 
this review, data from this study has not been used for this 
systematic review. 
Other information of note: Original paper translated from Italian 
to English. All patients had pre-existing ulceration and had started 
orthodontic treatment within the last month. 
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Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Quote: "Separated randomization lists 
furnished by the statistical department of 
our university, conceived with a variable 
block size of 3, 6 and 9, and stratified for 
lesion type (vestibular ulcers, lower labial 
fraenum lesions, keratinized mucosa 
lesions, aphthous ulcers, decubitus 
ulcers), age (more than 14 and less than 
14 years) and gender (5x2x2=20 strata), in 
order to obtain homogeneous and 
comparable group." 
Comment: Appears to be adequate 
randomisation. 
 
Allocation concealment 
(selection bias) 
Low risk Quote: "Allocation concealment was 
obtained identifying patients with a 
progressive numeration from 1 to 60, after 
a casual names draw, and groups with a 
letter from A to C, assigned by lot." 
Comment: Appears to be adequate 
allocation concealment. 
 
Blinding of participants 
and personnel 
(performance bias) 
High risk Quote: "Single blinding: patients were not 
aware of the treatment received". 
Comment: Adequate blinding of 
participants however no randomisation of 
personnel.  
 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Quote: "The statistician who analyzed 
outcome data were not blind regarding 
study aims but he was blind regarding 
treatment assigned to every single 
patient." 
Comment: Appears to be adequate 
blinding. 
 
Incomplete outcome 
data (attrition bias) 
 
Low risk 0/50 drop-outs = 0% attrition (100% 
completion). 
 
Selective reporting 
(reporting bias) 
Low risk Data for outcomes of this review were 
reported appropriately. 
 
Other bias Low risk No other sources of bias detected. 
 
Polat March 2005 
Methods Setting: Unspecified location, Turkey. 
Design: Parallel (6 arms). 
Number of centres: Not reported. 
Study duration: Not reported. 
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Participants Inclusion criteria: No prophylactic antibiotic cover required; no 
systemic diseases; no current use of antibiotics or analgesics; no 
contraindication to the use of NSAID; minimum weight requirement 
based on Food and drug administration-approved over the counter 
pediatric dosage labeling guidelines; no teeth extraction at least 2 
weeks before bonding. 
Exclusion criteria: Patients with minor or extreme crowding and 
patients with open bite. 
Orthodontic intervention: Initial archwire placement. 
Patient Sampling: 
n=150 randomised; 
n=30 drop-outs/excluded from analysis (n=22 did not return 
questionnaires; n=8 over 30 years of age); 
n=120 data analysed for: 
Gp 1 (n=20) male n=10: female n=10, mean age 15.0 + 3.7; 
Gp 2 (n=20) male n=15: female n=5, mean age 15.0 + 2.8; 
Gp 3 (n=20) male n=13: female n=7, mean age 15.0 + 4.5; 
Gp 4 (n=20) male n=15: female n=5, mean age 16.0 + 4.6; 
Gp 5 (n=20) male n=13: female n=7, mean age 15.0 + 2.9; 
Gp 6 (n=20) male n=10: female n=10, mean age 16.0 + 6.1. 
 
Interventions NSAID versus placebo; NSAID versus NSAID; NSAID versus 
paracetamol; NSAID versus aspirin; NSAID versus placebo 
Aspirin (300mg) vs. ibuprofen (600mg) vs. flurbiprofen 
(100mg) vs. paracetamol (500mg) vs. naproxen sodium 
(550mg) vs. placebo (lactose); pre-emptively and post-treatment 
following archwire placement. 
Gp 1: Aspirin 1 hr before, and 6 hrs after bonding appointment. 
Gp 2: Ibuprofen 1 hr before, and 6 hrs after bonding appointment. 
Gp 3: Flurbiprofen 1 hr before, and 6 hrs after bonding 
appointment. 
Gp 4: Paracetamol 1 hr before, and 6 hrs after bonding 
appointment 
Gp 5: Naproxen sodium; provided 1 hr pre-operatively. 
Gp 6: Placebo; provided 1 hr pre-operatively. 
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded at 2, 6, 
bedtime, 24 hours and 2, 3 and 7 days after initial archwire 
placement. 
Pain was recorded during the following activities: 
 Chewing. 
 Biting [Not an outcome of this review]. 
 Fitting front teeth together [Not an outcome of this review]. 
 Fitting posterior teeth together [Not an outcome of this 
review]. 
 
Notes Conflict of interests/funding: Not reported. 
Adverse events/Harm: Not reported. “None had taken additional 
medication”. 
Data handling by review authors: Study reports Group 1 as 
placebo arm of trial and Group 6 as aspirin arm. 
For the purposes of aligning with this systematic review's own 
protocol, the figures for Groups 1 and 3 have been inverted to 
reflect aspirin as an intervention and placebo as a control. 
Although referred to as acetaminophen, this group has been 
referred to as paracetamol for the purposes of this review. 
 
 
122 
Other information of note: Only pain during chewing data were 
reflected in this systematic review. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Quote: "Patients were randomly assigned 
to one of six experimental groups." 
Comment: Inadequate information 
regarding how randomisation was carried 
out therefore unable to make a judgement 
on appropriateness. 
 
Allocation concealment 
(selection bias) 
Unclear risk Quote: "Patients were randomly assigned 
to one of six experimental groups." 
Comment: Inadequate information 
regarding how allocation was carried out 
therefore unable to make a judgement on 
appropriateness. 
 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Quote: "All tablets were identical in color, 
and the patient and research assistant 
were both blind". 
Comment: Appears to be adequate 
blinding. 
 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk Quote: "All tablets were identical in color, 
and the patient and research assistant 
were both blind". 
Comment: Inadequate information 
regarding assessment, unclear if assessor 
is blinded to the intervention. 
 
Incomplete outcome 
data (attrition bias) 
 
Low risk 22/150 drop-outs = 15% attrition (85% 
completion) 
 
Selective reporting 
(reporting bias) 
Low risk Data for outcomes of this review were 
reported appropriately. 
 
Other bias Low risk No other sources of bias detected. 
 
 
Polat September 2005 
Methods Setting: Unspecified location, Turkey. 
Design: Parallel (3 arms). 
Number of centres: Not reported. 
Study duration: Not reported. 
 
Participants Inclusion criteria: No prophylactic antibiotic cover required; no 
systemic diseases; no current use of antibiotics or analgesics; no 
contraindication to the use of NSAID; minimum weight requirement 
based on Food and drug administration-approved over the counter 
pediatric dosage labeling guidelines; no teeth extraction at least 2 
weeks before bonding. 
Exclusion criteria: No patient with a history of systemic disease. 
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Orthodontic intervention: Initial archwire placement. 
Patient Sampling: 
n=60 randomised; 
n=0 drop-outs/excluded from analysis; 
n=60 data analysed for: 
Gp 1 (n=20) male n=14: female n=6, mean age 15.0 +/- 2.2; 
Gp 2 (n=20) male n=13: female n=7, mean age 17.0 +/- 7.0; 
Gp 3 (n=20) male n=10: female n=10, mean age 16.0 +/-6.1. 
 
Interventions NSAID versus placebo; NSAID versus NSAID 
Naproxen sodium (550mg; 1 dose) vs. ibuprofen (400mg; 1 
dose) vs. placebo (lactose; 1 dose); pre-emptively before 
archwire placement. 
Gp 1: Naproxen sodium; provided 1 hr pre-operatively. 
Gp 2: Ibuprofen; provided 1 hr pre-operatively. 
Gp 3: Placebo; provided 1 hr pre-operatively. 
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded at 2, 6, 
bedtime, 24 hours and 2, 3 and 7 days initial archwire placement. 
Pain was recorded during the following activities: 
 Chewing. 
 Biting [Not an outcome of this review]. 
 Fitting front teeth together [Not an outcome of this review]. 
 Fitting posterior teeth together [Not an outcome of this 
review]. 
 
Notes Conflict of interests/funding: Not reported. 
Adverse events/Harm: Not reported. “None of them had taken 
additional medication”. 
Data handling by review authors: Study reports Group 1 as 
placebo arm of trial, Group 2 as ibuprofen arm and Group 3 as 
naproxen sodium arm. 
For the purposes of aligning with this systematic review's own 
protocol, the figures for Groups 1 and 3 have been inverted to 
reflect naproxen sodium as an intervention and placebo as its 
control. 
Although referred to as acetaminophen, this group has been 
referred to as paracetamol for the purposes of this review. 
Other information of note: Only pain during chewing data is 
reflected in this systematic review. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Quote: "Twenty patients were randomly 
assigned to each of the three experimental 
groups." 
Comment: Inadequate information 
regarding how randomisation was carried 
out therefore unable to make a judgement 
on appropriateness. 
 
Allocation concealment 
(selection bias) 
Unclear risk Quote: "Twenty patients were randomly 
assigned to each of the three experimental 
groups." 
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Comment: Inadequate information 
regarding how allocation was carried out 
therefore unable to make a judgement on 
appropriateness. 
 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Quote: "The patient and research 
assistant were blinded to each subject’s 
experimental group". 
Comment: Appears to be adequate 
blinding. 
 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk Quote: "The patient and research 
assistant were blinded to each subject’s 
experimental group". 
Comment: Inadequate information 
regarding assessment, unclear if assessor 
is blinded to the intervention. 
 
Incomplete outcome 
data (attrition bias) 
 
Low risk 0/60 drop-outs = 0% attrition (100% 
completion) 
 
Selective reporting 
(reporting bias) 
Low risk Data for outcomes of this review were 
reported appropriately. 
 
Other bias Low risk No other sources of bias detected. 
 
 
Salmassian 2009 
Methods Setting: Orthodontic Graduate Clinic, University of Colorado 
School of Dentistry. 
Design: Parallel (3 arms). 
Number of centres: 1. 
Study duration: Not reported. 
 
Participants Inclusion criteria: (1) Scheduled to begin comprehensive 
orthodontic treatment (banding/bonding of at least 10 teeth in 1 
arch and archwire placement in at least 1 arch); (2) Extractions, if 
required, performed at least 2 weeks before appliance and 
archwire placement; (3) Healthy with no significant medical 
findings; (4) No prophylactic antibiotic coverage required; (5) 
Currently not taking antibiotics or analgesics; (6) No 
contraindications to the use of acetaminophen or ibuprofen; (7) No 
lactose intolerance; (8) Minimum age of 12 years and minimum 
weight of 88 lbs (as required by the FDA for the use of over-the-
counter pediatric dosage label guidelines); 
and (9) Maximum age of 18 years to exclude adults. 
Exclusion criteria: None specified. 
Orthodontic intervention: Initial archwire placement. 
Patient Sampling: 
n=66 enrolled; 
n=6 excluded from analysis (Did not return in timely manner for 
follow up appointments (n=4), consent withdrawn after archwire 
placement (n=2)); 
n=60 data analysed for: 
Group 1 (n=21) male n=9: female n=12, age data not reported; 
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Group 2 (n=19) male n=12: female n=7, age data not reported; 
Group 3 (n=20) male n=10: female n=10, age data not reported. 
 
Interventions NSAID versus placebo; NSAID versus paracetamol; 
Paracetamol versus placebo 
Paracetamol (600mg) vs. ibuprofen (400mg) vs. placebo (2 
tablets); 
Gp 1: Paracetamol; immediately after each VAS time point, 
starting 3hrs pre-operatively. 
Gp 2: Ibuprofen; immediately after each VAS time point, starting 
3hrs pre-operatively. 
Gp 3: Placebo; immediately after each VAS time point, starting 
3hrs pre-operatively. 
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded at 3, 7, 19, 
24, 31 and 48 hours and 3, 4 and 7 days after initial archwire 
placement. 
 
Notes Conflict of interests/funding: "The authors report no commercial, 
proprietary, or financial interest in the products or companies 
described in this article." 
Adverse events/Harm: Not reported. “No patients took additional 
analgesics during the study period”. 
Data handling by review authors: Although referred to as 
acetaminophen, this group has been referred to as paracetamol for 
the purposes of this review. 
Other information of note: No discrimination was made between 
various activities (eating, chewing, or biting) when VAS was 
recorded. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Quote: "Random group allocation and 
coding of patients were made by a 
coinvestigator (W.C.S)". 
Comment: Inadequate information 
regarding how randomisation was carried 
out therefore unable to make a judgement 
on appropriateness. 
 
Allocation concealment 
(selection bias) 
Unclear risk Quote: "Random group allocation and 
coding of patients were made by a 
coinvestigator (W.C.S)". 
Comment: Inadequate information 
regarding how allocation was carried out 
therefore unable to make a judgement on 
appropriateness. 
 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Quote: "The subjects and the main 
investigator (R.S) were blinded to the 
group allocation"; "The ibuprofen, 
acetaminophen, and placebo tablets[….] 
were all identical in shape and colour". 
Comment: Appears to be adequate 
blinding. 
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Blinding of outcome 
assessment (detection 
bias) 
Low risk Quote: "The subjects and the main 
investigator (R.S) were blinded to the 
group allocation"; "The ibuprofen, 
acetaminophen, and placebo tablets [....] 
were all identical in shape and colour". 
Comment: Appears to be adequate 
blinding. 
 
Incomplete outcome 
data (attrition bias) 
 
Low risk 6/66 drop-out = 9.1% attrition (90.9% 
competition). 
 
Selective reporting 
(reporting bias) 
Low risk Data for outcomes of this review were 
reported appropriately. 
 
Other bias Low risk No other sources of bias detected. 
 
 
Steen-Law 2000 
Methods Setting: University of Iowa College of Dentistry's Department of 
Orthodontics. 
Design: Parallel (3 arms). 
Number of centres: 1. 
Study duration: Not reported. 
 
Participants Inclusion criteria: (1) Was scheduled to begin comprehensive 
orthodontic treatment, (2) Required no prophylactic antibiotic 
coverage, (3) Had no debilitating systemic diseases, (4) 
was not currently using antibiotics or analgesics, (5) Had no 
contraindication to the use of ibuprofen, and (6) Had a maximum 
age of 16 years and a minimum weight of 88 pounds. This weight 
requirement was based on FDA-approved over-the-counter 
pediatric dosage labeling guidelines. 
Exclusion criteria: None specified. 
Orthodontic intervention: Separator placement. 
Patient Sampling: 
n=115 selected; 
n=4 refused to participate; 
n=111 randomised; 
n=52 drop-out/lost to follow-up (did not receive separators at their 
next appointment=28, did not take medications and return 
questionnaires=3); 
n=63 data analysed (male=15: female=38); 
Gp A (n=22) male n=10: female n=12, mean age 13.4 + 1.7; 
Gp B (n=19) male n=6: female n=13, mean age 13.3 + 1.4; 
Gp C (n=22) male n=9: female n=13, mean age 13.1 + 1.8. 
 
Interventions Ibuprofen (400mg) pre-emptive vs. ibuprofen (400mg) post-
treatment vs. placebo (lactose); provided pre-emptively to 
separator placement, or post-treatment. 
Gp A: Ibuprofen 1 hour before separator placement, placebo 
immediately after appointment. 
Gp B: Placebo 1 hour before separator placement, ibuprofen 
immediately after appointment. 
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Gp C: Placebo 1 hour before separator placement, placebo 
immediately after appointment. 
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded at 2, 6, 24 
hours and 2, 3 and 7 days after separator placement. 
Pain was recorded during the following activities: 
 Chewing. 
 Biting [Not an outcome of this review]. 
 Fitting front teeth together [Not an outcome of this review]. 
 Fitting posterior teeth together [Not an outcome of this 
review]. 
 
Notes Conflict of interests/funding: Not reported. 
Adverse events/Harm: Not reported. Rescue analgesia requires 
in 10 patients – n=4/18% Gp A, n=6/32% Gp B. 
Data handling by review authors: The data presented for the 
analysis is based on Figure 1 showing mean pain scores (mean + 
SEM) for chewing. The SEM was used to calculate SD. 
Data from Gp C did not contribute to the analyses, Gp A and B 
data were used for the comparison of pre-emptive versus post-
emptive analgesia. 
Other information of note: Only pain during chewing data is 
reflected in this systematic review. No baseline information has 
been provided regarding the initial groups at randomisation before 
loss to follow-up. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Quote: "Subjects were randomly 
assigned to 1 of 3 experimental 
conditions". 
Comment: Inadequate information 
regarding how randomisation was 
carried out therefore unable to make a 
judgement on appropriateness. 
 
Allocation concealment 
(selection bias) 
Unclear risk Quote: "Subjects were randomly 
assigned to 1 of 3 experimental 
conditions". 
Comment: Inadequate information 
regarding how allocation was carried 
out therefore unable to make a 
judgement on appropriateness. 
 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Quote: "The ibuprofen and placebo 
tablets were alike in appearance. The 
placebo tablets were hardpressed and 
not readily dissolved, thus preventing a 
detectable difference in taste. The 
investigator, clinician, and patient were 
blinded to each subject’s experimental 
group." 
 
 
128 
Comment: Appears to be adequate 
blinding. 
 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Quote: "The ibuprofen and placebo 
tablets were alike in appearance. The 
placebo tablets were hardpressed and 
not readily dissolved, thus preventing a 
detectable difference in taste. The 
investigator, clinician, and patient were 
blinded to each subject’s experimental 
group." 
Comment: Appears to be adequate 
blinding. 
 
Incomplete outcome 
data (attrition bias) 
 
High risk 52/111 drop-outs = 46.8% attrition 
(53.2% completion). 
 
Selective reporting 
(reporting bias) 
Low risk Data for outcomes of this review were 
reported appropriately. 
 
Other bias Low risk No other sources of bias detected. 
 
 
Tuncer 2014 
Methods Setting: Unspecified location, Turkey. 
Design: Parallel (3 arms). 
Number of centres: Not reported. 
Study duration: Not reported. 
 
Participants Inclusion criteria: 1. No prophylactic antibiotic coverage required, 
2. No history of systemic diseases or allergies, 3. No current use of 
antibiotics or analgesics, 4. No contraindication to the use of 
NSAID, 5. No teeth extraction at least 4 weeks before bonding, 6. 
No history of orthodontic treatment, 7. Not being in the menstrual 
period for female patients and 8. Minimal crowding of maximum 7 
mm that can be treated without extractions. 
Exclusion criteria: Patients with open bites; also have excluded 
participants who had additional doses of analgesic although not 
stated in the exclusion criteria. 
Orthodontic intervention: Initial archwire placement. 
Patient Sampling: 
n=60 selected; 
n=12 excluded/refused to participate (reasons not reported); 
n=48 randomised; 
n=3 drop-out/lost to follow-up (Group 1=2 additional dose 
consumption, Group 2=0, Group 3=1 lost to follow-up). 
n=45 data analysed (male=14: female=31); 
Group 1 (n=15) male n=17: female n=8, mean age 114.66 +/-2.06; 
Group 2 (n=15) male n=4: female n=11, mean age 14.36 +/-1.91; 
Group 3 (n=15) male n=3: female n=12, mean age 14.5 +/-2.0. 
 
Interventions NSAID versus placebo; NSAID versus Paracetamol; 
Paracetamol versus placebo 
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Ibuprofen (400mg) vs. paracetamol (500mg) vs. placebo 
(lactose); provided pre-emptively and post-treatment following 
archwire placement. 
Gp 1: Ibuprofen 1 hour before archwire placement, and 6 hours 
after. 
Gp 2: Paracetamol 1 hour before archwire placement, and 6 hours 
after. 
Gp 3: Placebo 1 hour before archwire placement, and 6 hours 
after. 
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded at: pre-
treatment, post-treatment and 1, 2, 3, 7 days after initial archwire 
placement. 
Pain was recorded during the following activities: 
 Chewing. 
 Fitting front teeth together [Not an outcome of this review]. 
 Fitting back teeth together [Not an outcome of this review]. 
Prostaglandin E2 (PGE2) levels in the gingival crevicular fluid 
(GCF) at the time points specified [Not an outcome of this review]. 
 
Notes Conflict of interests/funding: Not reported. 
Adverse events/Harm: Not reported. 
Data handling by review authors: Median and IQR data 
presented in the paper - author contacted to obtain mean and 
standard deviation data. 
Other information of note: Only pain during chewing data is 
reflected in this systematic review. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Quote: "Forty-six patients were randomly 
allocated to one of three study groups in 
order". 
Comment: Inadequate information 
regarding how randomisation was carried 
out therefore unable to make a judgement 
on appropriateness. 
 
Allocation concealment 
(selection bias) 
Unclear risk Quote: "Forty-six patients were randomly 
allocated to one of three study groups in 
order". 
Comment: Inadequate information 
regarding how allocation was carried out 
therefore unable to make a judgement on 
appropriateness. 
 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Quote: "The groups were named as A, B, 
and C and both the patient and the 
investigator (ZT), who was responsible 
from the clinical part of the study, did not 
have any knowledge about the type of 
analgesic that were given to each group. 
The tablets were identical in shape and 
colour and did not have any markings or 
labels that represented brand name. The 
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tablets were put in small pill boxes with a 
sticker containing the name of the group. 
The pills were put in the boxes by the 
second investigator, and the first 
investigator who coordinated the clinical 
part of the study did not have any 
knowledge about the grouping.” 
Comment: Appears to be adequate 
blinding. 
 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk Quote: "Prospective, randomized, double-
blind, placebo-controlled study". 
Comment: Inadequate information 
regarding blinding to make a judgement on 
appropriateness. 
 
Incomplete outcome 
data (attrition bias) 
 
Low risk 3/46 drop-out = 6% attrition (94% 
completion). 
 
Selective reporting 
(reporting bias) 
Low risk Data for outcomes of this review were 
reported appropriately. 
 
Other bias Low risk Large gender variation at baseline, more 
males in Gp A, more females in Gp B and 
C indicating sampling bias. 
 
 
Wang 2012 
Methods Setting: West China Stomatology Hospital of Sichuan University. 
Design: Parallel (3 arms). 
Number of centres: 1. 
Study duration: 12 months. 
 
Participants Inclusion criteria: (1) patients aged over 10 yrs; (2) patients who 
were able to comprehend and complete the study; (3) patients who 
consented to the research procedures and signed an informed 
consent; and (4) minors with permission from a parent or legal 
guardian. 
Exclusion criteria: (1) they had undergone previous orthodontic 
treatment; (2) they had recently experienced a toothache; (3) they 
were diagnosed concurrently as having infectious diseases and/or 
systemic diseases; (4) they had used analgesics within 3 days 
prior to orthodontic treatment or exhibited a contraindication to 
NSAIDs; (5) they displayed excessive anxiety as confirmed by the 
Trait-Anxiety Inventory (T-AI) score (males, ≥ 56; females, ≥ 57) 
and State- Anxiety Inventory (S-AI) score (males, ≥ 53; females, ≥ 
55) (Shek, 1993); (6) their pain threshold was less than 3 sec or 
greater than 60 sec; or (7) their endurance time was greater than 5 
min according to the cold pressor test (CPT; Johnson and Petrie, 
1997). 
Orthodontic intervention: Initial archwire placement. 
Patient Sampling: 
n=502 assessed for eligibility; 
n=52 excluded (14 did not meet criteria, 33 declined to participate, 
5 other reasons); 
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n=450 randomised: 
n=21 drop-out/lost to follow-up (7 did not wish to complete follow-
up questionnaire (Gp 1=3, Gp 2=1, Gp 3=3); 7 withdrew due to 
discomfort of orthodontic treatment (Gp 1=2, Gp 2=2, Gp 3=3); 4 
lost questionnaires (Gp 1=1, Gp 2=1, Gp 3=2); 2 felt they had not 
received treatment (Gp 1=1, Gp 2=1; 1 unknown Gp 3); 
n=429: 
Gp 1 (n=143) male n=36.67%: female n=63.33%, mean age 16.57 
+ 5.0; 
Gp 2 (n=145) male n=25.33%: female n=74.67%, mean age 17.68 
+ 5.53; 
Gp 3 (n=141) male n=40.67%: female n=59.33%, mean age 16.27 
+ 5.02. 
 
Interventions NSAID versus placebo 
Cognitive Behavioural Therapy vs. Ibuprofen (300mg) vs. 
Control (no treatment); 
Gp 1: Cognitive Behavioural Therapy; Immediately after archwire 
placement, structured phone procedure at day 8, 9, 10, 14 and 30. 
Gp 2: Ibuprofen 6hours, 12hours and 24hours after initial archwire 
placement. 
Gp 3: Placebo; routine diet and hygiene. Calls on day 8, 9,10, 14 
and 30 after archwire placement. 
 
Outcomes Primary Outcome: Pain score (Visual Analogue Scale (VAS)) - 
Recorded at 1, 2, 3, 7, 14 and 30 days after initial archwire 
placement. 
Secondary Outcome: Life quality assessed by the SF-36 and 
SAS at baseline and at 30 days. 
 
Notes Conflict of interests/funding: "This study was financially 
supported by the National Natural Science Foundation of China 
(30801304, 81071273, and 31170929) and the Science & 
Technology Department of Sichuan Province (2010SZ0116). The 
author(s) declare no potential conflicts of interest with respect to 
the authorship and/ or publication of this article." 
Adverse events/Harm: Not discussed. 
Data handling by review authors: Data presented for 
characteristics of groups at baseline are prior to drop-out, no data 
available for age after drop-out. 
Study does not allocate intervention to specific group labels. For 
the purposes of this systematic review, Gp 1 has been allocated as 
the CBT arm, Gp 2 as the ibuprofen arm and group 3 as the 
placebo arm. Data from Gp 1 did not contribute to the analyses, 
Gp 2 and 3 data were used for the comparison of pharmacological 
interventions only. 
Unable to calculate standard deviation for Group 2 at 14 days or 
30 days due to scale of graph. No further information available on 
correspondence with the author. 
Other information of note: Additional published information 
available in the study's appendix. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
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Random sequence 
generation (selection 
bias) 
Low risk Quote: "Eligible patients were randomized 
into three groups via a computer 
generated sequence". 
Comment: Appears to be adequate 
randomisation. 
 
Allocation concealment 
(selection bias) 
Low risk Quote: “The randomization sequences 
were stored in opaque envelopes by two 
clinicians who were not involved in the 
enrolment, intervention implementation, or 
outcome assessments." 
Comment: Appears to be adequate 
allocation concealment. 
 
Blinding of participants 
and personnel 
(performance bias) 
High risk Due to the nature of the interventions, it 
was not possible to blind participants or 
personnel to the intervention. 
 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Quote: “The outcome assessors and 
statisticians were blinded to the 
allocation." 
Comment: Appears to be adequate 
blinding. 
 
Incomplete outcome 
data (attrition bias) 
 
Low risk 21/450 drop-outs = 4.67% attrition 
(95.33% completion) 
 
Selective reporting 
(reporting bias) 
Low risk Data for outcomes of this review were 
reported appropriately. 
 
Other bias High risk Large gender variation in Gp 2, could have 
resulted in sampling bias. 
 
 
Yassaei 2012 
Methods Setting: Shahid Sadoughi University, Iran. 
Design: Parallel (2 arms). 
Number of centres: 1. 
Study duration: Not reported. 
 
Participants Inclusion criteria: (1) female patients; (2) age 14-19 years; (3) at 
least 2 months passed from first archwire placement (in first or 
second stage of comprehensive orthodontic treatment but no first 
archwire); (4) upper and lower first premolar extraction cases with 
bialveolar protrusion or crowding; (5) their pain intensity between 
40 and 100 mm (VAS); (6) whom signed the written informed 
consent to participate; (7) no contraindications to the use of 
acetaminophen or calcium such as ventricular fibrillation, renal 
calculi, hypopara-thyroidism and calcium supplement intake. 
Exclusion criteria: None specified. 
Orthodontic intervention: Initial archwire placement. 
Patient Sampling: 
n=40 randomised (although not clear): 
Gp 1 (n=19) male n=0: female n=19, mean age 17.43 + 1.69; 
Gp 2 (n=21) male n=0: female n=21, mean age 16.42 + 1.74. 
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Interventions Paracetamol versus calcium 
Paracetamol (325mg) vs. Calcium (500mg); 
Gp 1: Paracetamol; one tablet nightly until 60 tablets taken. 
Gp 2: Calcium; one tablet nightly until 60 tablets taken. 
 
Outcomes Pain score (Visual Analogue Scale (VAS)) - Recorded at pre-
treatment and 4 days after procedure. 
Pain and anxiety measurements on HAD scale if pain intensity on 
VAS was greater than 40mm. 2, 6, 24 hours and 2, 3 and 7 days 
after separator or initial archwire placement. 
 
Notes Conflict of interests/funding: None reported. 
Adverse events/Harm: Not discussed. 
Data handling by review authors: Study does not allocate 
intervention to specific group labels. For the purposes of this 
systematic review, Gp 1 has been allocated as the paracetamol 
arm and Gp 2 as the calcium arm. 
Time points measured in this study were pre-treatment and 4 days 
later. Therefore, data from this study has not been used for this 
systematic review. 
No information is provided relating to drop-outs, it has been 
assumed that all participants returned questionnaires and 
contributed to the final analysis. 
Other information of note: Although referred to as 
acetaminophen, this group has been referred to as paracetamol for 
the purposes of this review. 
 
Risk of bias 
Bias Authors’ 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk Quote: "On the basis of a systematic 
randomised trial, patients were prescribed 
acetaminophen (325mg) or calcium forte 
(500mg)." 
Comment: Inadequate information 
regarding how randomisation was carried 
out therefore unable to make a judgement 
on appropriateness. 
 
Allocation concealment 
(selection bias) 
Unclear risk Quote: "On the basis of a systematic 
randomised trial, patients were prescribed 
acetaminophen (325mg) or calcium forte 
(500mg)." 
Comment: Inadequate information 
regarding how allocation was carried out 
therefore unable to make a judgement on 
appropriateness. 
 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk Quote: "The patients and the one who did 
the VAS measurements were totally blind 
to the randomization." 
Comment: Appears to be adequate 
blinding however does not specify exactly 
how blinding of participants was achieved. 
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Blinding of outcome 
assessment (detection 
bias) 
Low risk Quote: "The patients and the one who did 
the VAS measurements were totally blind 
to the randomization." 
Comment: Appears to be adequate 
blinding. 
 
Incomplete outcome 
data (attrition bias) 
 
Low risk 0/40 drop-out = 0% attrition (100% 
completion). 
 
Selective reporting 
(reporting bias) 
Unclear risk Unclear outcome assessment and time 
points. 
 
Other bias High risk Only carried out in females but made 
generalisable to all patients therefore 
potential sampling bias. Unclear 
methodology, not repeatable. 
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Appendix 2: Characteristic of excluded studies 
 
Study Reason for exclusion 
Abtahi 2006 Insufficient information to allow inclusion of data. 
Angelopoulou 2013 Systematic Review. 
Arantes 2009 Insufficient information to allow inclusion of data. 
Ashley 2016 Systematic Review. 
Bird 2007 Insufficient information to allow inclusion of data. 
Cherubini 2003 Insufficient information in the abstract record to allow inclusion. 
Eslamian 2016 Insufficient information in the abstract record to allow inclusion. 
Ireland 2016 Not randomised for specific analgesics - potential for crossover 
and confounding of analgesic effect between groups. 
Moradinejad 2014 Insufficient information in the abstract record to allow inclusion. 
Murdock 2010 Not randomised for specific analgesics - potential for crossover 
and confounding of analgesic effect between groups. 
Ngan 1994 Insufficient information to allow inclusion of data. 
Ogata 1999 Insufficient information in the abstract record to allow inclusion. 
Parks 2001 Insufficient information in the abstract record to allow inclusion. 
Patel 2011 Insufficient information to allow inclusion of data. 
Rooke 2012 Insufficient information in the abstract record to allow inclusion. 
Sudhakar 2014 Insufficient information to allow inclusion of data. 
Xiaoting 2010 Systematic Review. 
Young 2006 Insufficient information to allow inclusion of data. 
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Appendix 3: MEDLINE (OVID) search strategy 
#1 Explode ORTHODONTICS(ME) 
#2 orthodontic* 
#3 #1 OR#2 
#4 PAIN (ME) 
#5 FACIAL PAIN (ME) 
#6 HEADACHE (ME) 
#7 NEURALGIA (ME) 
#8 EARACHE (ME) 
#9 TOOTHACHE (ME) 
#10 PAIN-MEASUREMENT (ME) 
#11 pain* OR discomfort OR headache* OR migraine* OR neuralgi* OR earache* OR 
toothache Or odontalgi* OR (pain near (manag* OR relief OR reliev OR control*)) 
#12 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 
#13 Explode ANALGESICS (ME) 
#14 analgesi* 
#15 ANESTHETICS-LOCAL (ME) 
#16 ((local OR topical) AND (anaesthetic* OR analgesi*)) OR ((local OR topical) AND 
(anesthetic* OR analgesi*)) 
#17 ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL (ME) 
#18 “Nonsteroidal Anti-Inflammatory Agent*” OR “Anti Inflammatory Agent*” OR 
“Nonsteroidal Antiinflammatory Agent*” OR “Non Steroidal Antiinflammatory Agent” OR 
“Nonsteroidal Analgesic*” Or “Anti-Inflammatory” OR “Asprin-Like Agent*” or NSAID* 
#19 opioid 
#20 aspirin 
#21 paracetamol 
#22 acetaminophen 
#23 medication* 
#24 #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR 
#23 #25 #3 AND #12 AND #24
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Appendix 4: Title and Abstract Screening 
 
 
Authors NOT an RCT or 
CCT? 
NOT a review 
with relevant 
references? 
NOT 10 to do with 
pain relief during 
ortho Rx 
Studies where pain 
intensity / relief or 
intensity are 
measured 
Notes EXCLUDE 
  Yes No ? Yes No ? Yes No ? Yes No ?  Yes No ? 
1.                   
2.                   
3.                   
4.                   
5.                   
6.  
 
                
7.                   
8.  
 
                
9.  
 
                
10.  
 
                
RCT/CCT – human; prospective; 2 or more interventions; random/quasi- random/haphazard allocation.  
NOT randomly selected; allocation for clinical reasons; participants selected own intervention; intervention & control groups different e.g. sick vs. 
healthy, practice vs. hospital; matched unless matched prior to randomisation
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Appendix 5: Study Eligibility Form 
Factors Assessment Comments 
TYPE OF STUDY 
 
1. Is the study described 
as randomized? 
 
 
Yes         Unclear        No    
 
 
                                
Exclude     
 
PARTICIPANTS 
 
2. Were the participants 
diagnosed as having 
pain? 
 
Yes        Unclear        No   
 
 
                                
Exclude          
 
INTERVENTIONS 
 
3. Did the study contain at 
least two groups receiving 
different route/dose/form 
of pharmacological 
intervention? 
 
 
 
 
Yes         Unclear        No     
 
 
                                
Exclude       
 
 
4. Was the difference in 
pain the only planned 
difference between the 
groups? 
 
Yes        Unclear        No      
 
 
                                
Exclude       
 
OUTCOMES 
 
5. Did the study report 
pain outcomes? 
 
Yes        Unclear        No      
 
 
                                
Exclude       
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Appendix 6: Data Extraction Form 
Study details  
*First Author    *Year of publication    
Number of trials included in this paper      
If more than one, complete separate extraction forms for each and add letters A, B, C etc. to the paper name 
If other papers report further results of this trial, incorporate them onto this form and note 
what has been done here e.g. time points, outcomes. 
________________________________________________________________________
________________________________________________________________________
____________ 
Method 
Setting: Location of trial centre(s) 
Source of participants: Comment 
Method of recruitment: Comment 
Design: Comment 
Study Duration: (Date until Date) (number of months) 
Maximum duration of follow-up: (number of months) 
Follow-up timepoints reported: Comment 
“Detail how measurements were collected” 
Details of Comparisons   Tick if YES 
Analgesic versus Placebo      
Analgesic versus No treatment     
Analgesic versus Active treatment     
Analgesic versus Same analgesic, different dose   
Local anaesthetic versus Placebo     
Other notes on comparisons          
 
Participants 
Selected n=x 
Excluded n=x 
Refused to participate n=x 
Randomised n=x 
Inclusion criteria: (quote/comment) 
Exclusion criteria: (quote/comment) 
Intention to treat analysis: (quote/comment) 
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Details of the interventions 
 Group 1 Group 2 Group 3 Overall 
Group Name (for trial 
ID) 
    
Group randomised)  Yes / No Yes / No Yes / No Yes / No 
Drug / Placebo or No 
Treatment 
    
Route & Dose or 
description of 
Placebo 
    
Time of 
administration of 
drug / placebo 
    
Number recruited     
Number of dropouts     
 
Characteristics of participants 
 Group 1 
 
Group 2 
 
Group 3 
 
Overall/Total 
Age     
Sex     
Ethnicity     
 
Outcomes 
Primary:            
  
Secondary:               
   
 
Notes 
Conflict of interests/funding: Quote/Comment 
 
Adverse events/Harm: Quote/Comment 
 
 
 
141 
Risk of bias assessment 
 
Please CIRCLE / HIGHLIGHT response as appropriate 
Bias Authors' 
judgement 
Support for judgement 
Random sequence 
generation (selection 
bias) 
High/Low/ 
Unclear risk  
Comment:  
Quote: "place corresponding quote here" 
Allocation concealment 
(selection bias) 
High/Low/ 
Unclear risk 
Comment:  
Quote: "place corresponding quote here" 
Blinding of participants 
and personnel 
(performance bias) 
High/Low/ 
Unclear risk 
Comment:  
Quote: "place corresponding quote here" 
Blinding of outcome 
assessment (detection 
bias) 
High/Low/ 
Unclear risk 
Comment:  
Quote: "place corresponding quote here" 
Incomplete outcome data 
(attrition bias) 
High/Low/ 
Unclear risk 
Comment:x/x drop outs = x% attrition (x% 
completion) 
Selective reporting 
(reporting bias) 
High/Low/ 
Unclear risk 
Comment:  
Quote: "place corresponding quote here" 
Other bias High/Low/ 
Unclear risk 
Comment: [If nothing else, state “No 
obvious sources of bias.”] 
 
Results 
Chewing VAS (score/index) 
Results at each time point 
Time point 2hrs 6hrs Bed 24hrs 2d  3d 7d 
CHEWING  SD  SD  SD  SD  SD  SD  SD 
Gp 1  
Drug 
name/placebo 
              
Gp 2  
Drug 
name/placebo 
              
Gp 3  
Drug 
name/placebo 
              
Biting VAS (score/index) 
Results at each time point 
Time point 2hrs 6hrs Bed 24hrs 2d 3d 7d 
CHEWING  SD  SD  SD  SD  SD  SD  SD 
Gp 1  
Drug 
name/placebo 
              
Gp 2  
Drug 
name/placebo 
              
Gp 3  
Drug 
name/placebo 
              
 
Verbal Descriptive Score 
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 Results at each time point 
Time point     
Gp 1 
Drug name/placebo 
    
Gp 2  
Drug name/placebo 
    
Gp 3  
Drug name/placebo 
    
 
Duration of pain 
 Time (days/hours/minutes) 
Gp 1  
Drug name/placebo 
 
Gp 2  
Drug name/placebo 
 
Gp 3  
Drug name/placebo 
 
 
 
 
 
 
Rescue Medication 
 Dose required 
Time point     
Gp 1  
Drug name/placebo 
    
Gp 2  
Drug name/placebo 
    
Gp 3  
Drug name/placebo 
    
 
Comments 
            
            
            
             
 
 
 
 
